drug	genes	question	answer	incorrect_recommendations	concurring_recommendation	llm_answer	oai_embedding_ref_vs_llm	oai_embedding_ref_vs_concurring	oai_embedding_adversarial_vs_llm	oai_embedding_concurring_vs_llm	negation_mpnet_ref_vs_llm	negation_mpnet_ref_vs_concurring	negation_mpnet_adversarial_vs_llm	negation_mpnet_concurring_vs_llm	base_mpnet_ref_vs_llm	base_mpnet_ref_vs_concurring	base_mpnet_adversarial_vs_llm	base_mpnet_concurring_vs_llm	roberta_ref_vs_llm	roberta_ref_vs_concurring	roberta_adversarial_vs_llm	roberta_concurring_vs_llm	gte_ref_vs_llm	gte_ref_vs_concurring	gte_adversarial_vs_llm	gte_concurring_vs_llm	gpt4_ref_vs_llm
abacavir	HLA-B	What would be the clinical guidance for someone who is HLA-B*57:01 positive for HLA-B with regards to taking abacavir? Give a 2-3 sentence summary.	Abacavir is not recommended	['Proceed taking abacavir as normal. There is no recommendation.', 'Take abacavir with a reduced dose.', 'Take abacavir with an increased dose.']	Avoid abacavir. Take an alternate therapy.	Individuals who are HLA-B*57:01 positive should avoid taking abacavir, as they are at an increased risk of developing a severe and potentially life-threatening hypersensitivity reaction to the drug. Prior to initiating abacavir therapy, genetic testing for HLA-B*57:01 is recommended to guide treatment decisions and prevent adverse reactions.	0.6960996441538755	0.7591085217163046	0.7478930202531574	0.6601858882905587	0.6988118	0.7781518	0.6934752	0.58927345	0.6497553	0.83611435	0.7775479	0.60753787	0.51536626	0.81410533	0.7101601	0.49746338	0.6641794	0.8348719	0.68389004	0.6614522	1
abacavir	HLA-B	What would be the clinical guidance for someone who is HLA-B*57:01 negative for HLA-B with regards to taking abacavir? Give a 2-3 sentence summary.	Use abacavir per standard dosing guidelines	['Avoid abacavir. Take an alternate therapy.', 'Take abacavir with a reduced dose.', 'Take abacavir with an increased dose.']	Proceed taking abacavir as normal. There is no recommendation.	For individuals who are HLA-B*57:01 negative, the risk of abacavir hypersensitivity reaction is significantly lower compared to those who are positive. Therefore, for HLA-B*57:01 negative individuals, abacavir can be safely prescribed as part of their HIV treatment regimen without the need for HLA-B*57:01 screening.	0.6034204879676625	0.7425463294048439	0.7393050470573677	0.5755535374288522	0.57604456	0.6159381	0.63718647	0.6110208	0.6695379	0.81842065	0.70092964	0.6543762	0.5228282	0.7709747	0.7008068	0.4340241	0.6389993	0.6778212	0.68626267	0.61492	0
allopurinol	HLA-B	What would be the clinical guidance for someone who is HLA-B*58:01 positive for HLA-B with regards to taking allopurinol? Give a 2-3 sentence summary.	Allopurinol is contraindicated	['Proceed taking allopurinol as normal. There is no recommendation.', 'Take allopurinol with a reduced dose.', 'Take allopurinol with an increased dose.']	Avoid allopurinol. Take an alternate therapy.	For individuals who are HLA-B*58:01 positive, there is an increased risk of developing severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome or toxic epidermal necrolysis when treated with allopurinol. As a result, it is recommended to avoid allopurinol in these individuals if possible, and if needed for uric acid-lowering therapy, alternative medications such as febuxostat may be considered. Consultation with a healthcare provider experienced in pharmacogenomics is recommended to determine the best course of action for personalized treatment.	0.6936137436973813	0.7545144589685137	0.7085670824596689	0.6620353613536984	0.71076906	0.76679975	0.6530146	0.5587314	0.640988	0.8266746	0.66951466	0.6310771	0.46770883	0.70286465	0.5987668	0.5608028	0.65914303	0.6549113	0.6174964	0.7103887	1
allopurinol	HLA-B	What would be the clinical guidance for someone who is HLA-B*58:01 negative for HLA-B with regards to taking allopurinol? Give a 2-3 sentence summary.	Use allopurinol per standard dosing guidelines	['Avoid allopurinol. Take an alternate therapy.', 'Take allopurinol with a reduced dose.', 'Take allopurinol with an increased dose.']	Proceed taking allopurinol as normal. There is no recommendation.	For individuals who are HLA-B*58:01 negative, the risk of allopurinol-induced severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome or toxic epidermal necrolysis is significantly lower. In these cases, allopurinol can typically be prescribed without the need for special precautions related to HLA-B status. However, standard monitoring and precautions for allopurinol use should still be followed as per usual clinical guidelines.	0.6237202441134542	0.7484103453525945	0.7186908948710595	0.5958697909609724	0.5020075	0.6815679	0.65257436	0.575133	0.62433654	0.8328961	0.7034953	0.5875378	0.49684733	0.78210455	0.6806982	0.47261435	0.67003983	0.71530896	0.6425888	0.6466549	1
amikacin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking amikacin as normal. There is no recommendation.', 'Take amikacin with a reduced dose.', 'Take amikacin with an increased dose.']	Avoid amikacin. Take an alternate therapy.	Individuals who carry the MT-RNR1 mutation are at increased risk of aminoglycoside-induced hearing loss, including from amikacin. Before starting amikacin therapy, genetic testing for the MT-RNR1 variant may be considered to identify individuals at higher risk. Close monitoring of hearing function, dosage adjustments, and alternative medication options should be explored in these individuals to minimize the risk of hearing loss associated with aminoglycoside use.	0.6341913739702604	0.5695837331112267	0.4648830871229456	0.44263498858194533	0.57055265	0.60226387	0.47815537	0.496766	0.67940825	0.48981178	0.48967484	0.51264304	0.6635796	0.5031077	0.46382198	0.4561525	0.55612016	0.6614421	0.53816634	0.54258335	0
amikacin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid amikacin. Take an alternate therapy.', 'Take amikacin with a reduced dose.', 'Take amikacin with an increased dose.']	Proceed taking amikacin as normal. There is no recommendation.	For individuals who are at normal risk of aminoglycoside-induced hearing loss due to a variant in MT-RNR1, the clinical guidance would likely be to proceed with caution when considering amikacin therapy. Routine monitoring of hearing function before and during treatment may be recommended to assess for any potential changes in hearing ability. Consultation with a healthcare provider experienced in pharmacogenomics and audiology may be beneficial for personalized treatment decisions.	0.6856575046888626	0.47580446717636815	0.4859188850444213	0.5676704368705818	0.5996455	0.4669419	0.4909214	0.53655696	0.68033165	0.5265164	0.54872555	0.5469837	0.69822896	0.5102065	0.49971142	0.45051673	0.6625771	0.54797655	0.5869781	0.56364936	0
amikacin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid amikacin. Take an alternate therapy.', 'Take amikacin with a reduced dose.', 'Take amikacin with an increased dose.']	Proceed taking amikacin as normal. There is no recommendation.	For individuals with an uncertain risk of aminoglycoside-induced hearing loss related to MT-RNR1 variants, it is recommended to consider proactive monitoring for hearing loss during amikacin therapy. Additionally, alternative antibiotic options with lower risk of ototoxicity may be considered in those with known MT-RNR1 variants associated with aminoglycoside-induced hearing loss. Consulting with a healthcare provider who is knowledgeable in pharmacogenomics can help guide personalized treatment decisions.	0.6657350847517688	0.47580446717636815	0.4859188850444213	0.49902281536692084	0.6069962	0.4669419	0.4909214	0.4807757	0.6615917	0.5265164	0.54872555	0.49473137	0.7300366	0.5102065	0.49971142	0.45998207	0.59774333	0.54797655	0.5869781	0.523059	0
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking aminosalicylic acid? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid aminosalicylic acid. Take an alternate therapy.', 'Take aminosalicylic acid with a reduced dose.', 'Take aminosalicylic acid with an increased dose.']	Proceed taking aminosalicylic acid as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) may be at increased risk of hemolysis when taking aminosalicylic acid. Therefore, it is recommended to exercise caution and closely monitor for signs of hemolysis if aminosalicylic acid therapy is necessary in these individuals. Alternative therapies should be considered when possible to minimize the risk of hemolysis in G6PD deficient individuals.	0.5588980730273829	0.44172620650463	0.32037267961495025	0.5391369696302574	0.5848271	0.57132834	0.38750115	0.62140733	0.5659007	0.48404753	0.32936177	0.6306494	0.51480526	0.42687207	0.34347174	0.5140108	0.5303453	0.48436835	0.38195375	0.49304238	0
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking aminosalicylic acid? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid aminosalicylic acid. Take an alternate therapy.', 'Take aminosalicylic acid with a reduced dose.', 'Take aminosalicylic acid with an increased dose.']	Proceed taking aminosalicylic acid as normal. There is no recommendation.	Individuals who are Indeterminate for G6PD deficiency should exercise caution when taking aminosalicylic acid, as it can potentially trigger hemolytic anemia in individuals with G6PD deficiency. Close monitoring for signs of hemolysis, such as fatigue, pale skin, dark urine, or jaundice, is recommended if aminosalicylic acid therapy is necessary in this population. Consultation with a healthcare provider or a clinical pharmacist specialized in pharmacogenomics is advisable to determine the best course of action based on the individual's clinical status and risk factors.	0.6456234129300841	0.36518252963585807	0.290232986552188	0.5571376733172403	0.5266605	0.27695686	0.3095455	0.63364625	0.67715436	0.35385722	0.31128815	0.6238916	0.5663061	0.2328999	0.22736825	0.5685401	0.52958	0.39969903	0.3975958	0.5382026	0
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking aminosalicylic acid? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid aminosalicylic acid. Take an alternate therapy.', 'Take aminosalicylic acid with a reduced dose.', 'Take aminosalicylic acid with an increased dose.']	Proceed taking aminosalicylic acid as normal. There is no recommendation.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) enzyme activity, it is generally recommended to avoid certain medications, including aminosalicylic acid, as these can trigger hemolysis (breakdown of red blood cells) in individuals with this deficiency. Aminosalicylic acid can potentially worsen hemolysis in individuals with G6PD deficiency, leading to complications such as anemia or other serious health issues. Therefore, individuals with G6PD deficiency should be cautious and consult with their healthcare provider before taking aminosalicylic acid or any other medications known to trigger hemolysis in this population.	0.4746301984222349	0.4006416696819361	0.41775495424629056	0.4778058934364906	0.54837114	0.46784836	0.487771	0.612887	0.5369914	0.4492486	0.45345166	0.58868	0.5240361	0.41248125	0.39447236	0.56854546	0.5141887	0.37057325	0.4644723	0.52673906	0
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking aminosalicylic acid? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid aminosalicylic acid. Take an alternate therapy.', 'Take aminosalicylic acid with a reduced dose.', 'Take aminosalicylic acid with an increased dose.']	Proceed taking aminosalicylic acid as normal. There is no recommendation.	Individuals who are normal for glucose-6-phosphate dehydrogenase (G6PD) deficiency do not have an increased risk of adverse reactions to medications like aminosalicylic acid. Therefore, there is no specific clinical guidance against taking aminosalicylic acid for individuals who are normal for G6PD deficiency. It is still important to consult with a healthcare provider before starting any new medication.	0.6863410826155256	0.3817372014394566	0.25350288918969843	0.5715562203248488	0.54845804	0.39697912	0.20935781	0.6855898	0.51494557	0.27556524	0.16035241	0.6588002	0.43650192	0.17489599	0.10831696	0.59108067	0.5681358	0.4079968	0.2952974	0.63165224	1
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline? Give a 2-3 sentence summary.	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking amitriptyline as normal. There is no recommendation.', 'Take amitriptyline with a reduced dose.', 'Take amitriptyline with an increased dose.']	Avoid amitriptyline. Take an alternate therapy.	For an individual who is an Ultrarapid Metabolizer for CYP2D6 and an Intermediate Metabolizer for CYP2C19, taking amitriptyline may require close monitoring for potential drug interactions and side effects due to the variability in drug metabolism. Dose adjustments may be necessary to optimize therapeutic outcomes and minimize adverse effects. Consulting with a healthcare provider and considering alternative medications or genetic testing guidance may be beneficial in this case.	0.7236502472694173	0.6949423861638112	0.651481370625492	0.626167614685645	0.66785616	0.65050733	0.5732424	0.57414114	0.6619192	0.6533343	0.5974688	0.6997063	0.5570415	0.5631736	0.5388899	0.5589156	0.6516678	0.6366815	0.53334093	0.56035775	0
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline? Give a 2-3 sentence summary.	Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking amitriptyline as normal. There is no recommendation.', 'Take amitriptyline with a reduced dose.', 'Take amitriptyline with an increased dose.']	Avoid amitriptyline. Take an alternate therapy.	For someone who is a Poor Metabolizer for CYP2D6 and an Intermediate Metabolizer for CYP2C19, taking amitriptyline may result in reduced drug metabolism, potentially leading to increased risk of adverse effects and reduced efficacy. Close monitoring for side effects and therapeutic response is recommended, and dose adjustment may be necessary to optimize treatment outcomes while minimizing potential risks associated with altered drug metabolism pathways. Consulting with a healthcare provider or a pharmacogenomics specialist is advised to individualize treatment and ensure the safe and effective use of amitriptyline in this patient population.	0.736988104085577	0.698769571228788	0.6955279047742459	0.6344969738099268	0.70263517	0.6797541	0.6347178	0.6052324	0.69401205	0.72943014	0.6795208	0.6804835	0.6309067	0.6338296	0.6091957	0.57995844	0.6322117	0.64152896	0.546624	0.61406827	0
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	['Proceed taking amitriptyline as normal. There is no recommendation.', 'Take amitriptyline with a reduced dose.', 'Take amitriptyline with an increased dose.']	Avoid amitriptyline. Take an alternate therapy.	For an Ultrarapid Metabolizer with an activity score of ≥4.0 for CYP2D6 and No Result for CYP2C19 taking amitriptyline, caution is advised due to the increased likelihood of rapid metabolism leading to potentially reduced efficacy of amitriptyline. Close monitoring for both efficacy and side effects is recommended, and dose adjustments may be required based on individual response. Consulting with a healthcare provider or a pharmacogenomics expert for personalized dosing recommendations is advisable in this case.	0.6422338834557227	0.5743861857306282	0.5258918246350636	0.5918071652517708	0.734911	0.5125287	0.48056582	0.54297656	0.65900296	0.39688072	0.400237	0.6182744	0.63655376	0.3816344	0.41306093	0.50741905	0.61560005	0.49497038	0.44446456	0.5569946	0
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline? Give a 2-3 sentence summary.	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking amitriptyline as normal. There is no recommendation.', 'Take amitriptyline with a reduced dose.', 'Take amitriptyline with an increased dose.']	Avoid amitriptyline. Take an alternate therapy.	For an individual who is an Ultrarapid Metabolizer for CYP2D6 and a Rapid Metabolizer for CYP2C19, taking amitriptyline may result in faster metabolism of the drug, potentially leading to reduced efficacy. Monitoring for therapeutic efficacy and possible adverse effects is recommended. Adjustments in amitriptyline dosage or alternative treatment options may be considered to achieve optimal therapeutic outcomes in this individual.	0.6967830376166713	0.6949423861638112	0.651481370625492	0.6210013098069166	0.6117839	0.65050733	0.5732424	0.57283497	0.6428167	0.6533343	0.5974688	0.6864144	0.57685137	0.5631736	0.5388899	0.58219266	0.5720708	0.6366815	0.53334093	0.5930588	0
aspirin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking aspirin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid aspirin. Take an alternate therapy.', 'Take aspirin with a reduced dose.', 'Take aspirin with an increased dose.']	Proceed taking aspirin as normal. There is no recommendation.	Individuals who are deficient in Glucose-6-Phosphate Dehydrogenase (G6PD) may be at higher risk of developing hemolysis or breakdown of red blood cells when exposed to certain medications, including aspirin. It is generally advised to avoid aspirin and other drugs that can trigger hemolysis in individuals with G6PD deficiency. It is important for those with G6PD deficiency to consult with a healthcare provider before taking any medications to ensure their safety.	0.6240518050622815	0.4459196450676884	0.3442451989461756	0.37545049567143224	0.53656495	0.50565726	0.29768896	0.48221764	0.58051133	0.3899839	0.20185107	0.4928938	0.5663183	0.30249068	0.20275861	0.333556	0.5193347	0.47129795	0.35572088	0.51265174	0
aspirin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking aspirin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid aspirin. Take an alternate therapy.', 'Take aspirin with a reduced dose.', 'Take aspirin with an increased dose.']	Proceed taking aspirin as normal. There is no recommendation.	Individuals who are indeterminate for glucose-6-phosphate dehydrogenase (G6PD) deficiency should exercise caution when taking aspirin, as aspirin can potentially trigger hemolysis in individuals with G6PD deficiency. Prior to starting aspirin therapy, it is recommended to consult with a healthcare provider or a pharmacist to determine the appropriateness and safety of aspirin use based on the individual's G6PD status and overall health condition.	0.6369503740494262	0.3329144969915283	0.2828750497858906	0.4790115888257509	0.49900684	0.15246582	0.13569383	0.5859764	0.59229577	0.14822075	0.043561343	0.56554514	0.48435193	0.10093915	0.072764836	0.5359858	0.4967818	0.39109543	0.3770856	0.5394488	0
aspirin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking aspirin? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid aspirin. Take an alternate therapy.', 'Take aspirin with a reduced dose.', 'Take aspirin with an increased dose.']	Proceed taking aspirin as normal. There is no recommendation.	Individuals who are deficient in Glucose-6-Phosphate Dehydrogenase (G6PD) should avoid taking aspirin or related medications due to the risk of hemolysis (breakdown of red blood cells). Aspirin can trigger oxidative stress, leading to hemolytic episodes in individuals with G6PD deficiency, especially those with CNSHA (Class I deficiency). It is important for healthcare providers to be aware of a patient's G6PD status before prescribing aspirin or similar medications to prevent potential complications.	0.40890940198931947	0.3629086447441852	0.4316698491535371	0.44434535549198756	0.5727886	0.5096383	0.49232772	0.591713	0.5354093	0.5230757	0.43451044	0.52913445	0.51801234	0.37750256	0.35231495	0.44835413	0.4844002	0.46096954	0.49368557	0.55839044	0
aspirin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking aspirin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid aspirin. Take an alternate therapy.', 'Take aspirin with a reduced dose.', 'Take aspirin with an increased dose.']	Proceed taking aspirin as normal. There is no recommendation.	Individuals who are normal for G6PD can typically safely take aspirin without any increased risk of hemolysis or other adverse effects related to G6PD deficiency. However, it is always important to follow standard dosing guidelines and monitor for any signs of adverse reactions. As with any medication, it is recommended to consult with a healthcare provider before starting aspirin therapy.	0.6451028683692286	0.3801122209271646	0.26357460814829503	0.5626441260896358	0.51123524	0.37381068	0.1668359	0.6712001	0.5186591	0.24273352	0.09404408	0.65235454	0.4167042	0.088122815	0.028731108	0.60697734	0.5560405	0.4127048	0.295844	0.5468058	1
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Normal Metabolizer for UGT1A1 with regards to taking atazanavir? Give a 2-3 sentence summary.	There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).	['Avoid atazanavir. Take an alternate therapy.', 'Take atazanavir with a reduced dose.', 'Take atazanavir with an increased dose.']	Proceed taking atazanavir as normal. There is no recommendation.	For someone who is a Normal Metabolizer for UGT1A1 and is prescribed atazanavir, no dose adjustment is typically required as UGT1A1 plays a minor role in atazanavir metabolism. However, it is still important to monitor for any signs of adverse effects or drug interactions. Overall, standard dosing guidelines for atazanavir can be followed in individuals who are Normal Metabolizers for UGT1A1.	0.7346292399991167	0.5711183341636629	0.5767997077611658	0.6262562649072136	0.6363773	0.6421217	0.52521557	0.5667357	0.64947486	0.6135973	0.54535013	0.6321803	0.5677711	0.45971864	0.41235915	0.4723074	0.6149716	0.4662697	0.5388937	0.55169314	1
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Poor Metabolizer for UGT1A1 with regards to taking atazanavir? Give a 2-3 sentence summary.	Consider an alternative agent particularly where jaundice would be of concern to the patient. If atazanavir is to be prescribed, there is a high likelihood of developing jaundice that will result in atazanavir discontinuation (at least 20% and as high as 60%).	['Proceed taking atazanavir as normal. There is no recommendation.', 'Take atazanavir with a reduced dose.', 'Take atazanavir with an increased dose.']	Avoid atazanavir. Take an alternate therapy.	For someone who is a Poor Metabolizer for UGT1A1 and considering taking atazanavir, caution is advised as they may have an increased risk of adverse effects, particularly hyperbilirubinemia. Close monitoring for side effects and therapeutic drug monitoring may be necessary to mitigate potential complications and ensure the medication is well-tolerated in this individual. Consulting with a healthcare provider or a clinical pharmacist specialized in pharmacogenomics is recommended for personalized treatment recommendations.	0.7253355163815679	0.6557665948866161	0.6045642846820268	0.6614746085334559	0.71996254	0.63117003	0.51049376	0.6209807	0.6547761	0.7025749	0.5682924	0.6641239	0.54610205	0.51187485	0.4455293	0.53459585	0.6147115	0.6169579	0.556464	0.58411497	0
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Indeterminate for UGT1A1 with regards to taking atazanavir? Give a 2-3 sentence summary.	No recommendation	['Avoid atazanavir. Take an alternate therapy.', 'Take atazanavir with a reduced dose.', 'Take atazanavir with an increased dose.']	Proceed taking atazanavir as normal. There is no recommendation.	Individuals who are classified as Indeterminate for UGT1A1 may have a higher risk of developing hyperbilirubinemia when taking atazanavir, a medication primarily metabolized by UGT1A1. Close monitoring for signs of liver toxicity and hyperbilirubinemia is recommended if atazanavir is prescribed to individuals with an Indeterminate genotype for UGT1A1, and alternative medications may be considered based on clinical judgment.	0.2026322222349457	0.48173100566612415	0.23318251202327814	0.518094418769023	0.12569752	0.39350763	0.21344809	0.5005572	0.06797391	0.25891978	0.13633974	0.551566	-0.017140582	0.3284822	0.11475738	0.38897395	0.26158136	0.51323426	0.3697779	0.5223469	0
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Intermediate Metabolizer for UGT1A1 with regards to taking atazanavir? Give a 2-3 sentence summary.	There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).	['Avoid atazanavir. Take an alternate therapy.', 'Take atazanavir with a reduced dose.', 'Take atazanavir with an increased dose.']	Proceed taking atazanavir as normal. There is no recommendation.	As an Intermediate Metabolizer for UGT1A1, individuals may have reduced metabolism of atazanavir, which could lead to higher drug levels and an increased risk of adverse effects such as hyperbilirubinemia. Clinical guidance may include adjusting the dose of atazanavir or considering alternative medications with lower risk of drug accumulation. It is important for healthcare providers to closely monitor for potential side effects and adjust treatment accordingly in this population.	0.732104948193961	0.5711183341636629	0.5767997077611658	0.5692166334603218	0.6690379	0.6421217	0.52521557	0.49690977	0.7588165	0.6135973	0.54535013	0.58388066	0.67203796	0.45971864	0.41235915	0.4741646	0.6503319	0.4662697	0.5388937	0.4830818	0
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking atomoxetine? Give a 2-3 sentence summary.	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	['Proceed taking atomoxetine as normal. There is no recommendation.', 'Avoid atomoxetine. Take an alternate therapy.']	Take atomoxetine with an altered dose.	For individuals who are Normal Metabolizers and have an activity score of 1.25 for CYP2D6, it is recommended to use atomoxetine with standard dosing guidance. Since atomoxetine is primarily metabolized by CYP2D6, having a normal metabolism status suggests that standard dosing should be effective and well-tolerated in this population. Monitoring for therapeutic response and side effects is still recommended as part of routine clinical care.	0.5016977001901752	0.42715668847227034	0.4024412384359093	0.6118761683751048	0.48669028	0.36949787	0.3471994	0.5224803	0.42879206	0.28713918	0.31679457	0.58170354	0.4814028	0.4850908	0.42077208	0.56563604	0.34382334	0.40467218	0.29155576	0.6223208	0
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking atomoxetine? Give a 2-3 sentence summary.	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	['Proceed taking atomoxetine as normal. There is no recommendation.', 'Avoid atomoxetine. Take an alternate therapy.']	Take atomoxetine with an altered dose.	For an individual who is an Ultrarapid Metabolizer with an activity score of ≥3.75 for CYP2D6, they are likely to metabolize atomoxetine rapidly, leading to potential subtherapeutic levels and reduced efficacy. Monitoring for therapeutic effectiveness and potentially adjusting the dosage of atomoxetine may be necessary in this population to ensure optimal treatment outcomes. Consulting with a healthcare provider experienced in pharmacogenomics can help personalize the treatment plan for this individual.	0.5214448133905295	0.42715668847227034	0.4024412384359093	0.6359852867252994	0.4513165	0.36949787	0.3471994	0.5788136	0.26957783	0.28713918	0.31679457	0.5151599	0.39966148	0.4850908	0.42077208	0.4981773	0.40511203	0.40467218	0.29155576	0.6469939	0
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking atomoxetine? Give a 2-3 sentence summary.	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	['Proceed taking atomoxetine as normal. There is no recommendation.', 'Avoid atomoxetine. Take an alternate therapy.']	Take atomoxetine with an altered dose.	Individuals who are Ultrarapid Metabolizers with an activity score of ≥4.0 for CYP2D6 may metabolize atomoxetine, a medication used to treat ADHD, more rapidly than normal. As a result, these individuals may require higher doses of atomoxetine to achieve therapeutic levels, or alternative medications with different metabolic pathways may be considered. Close monitoring of drug efficacy and potential adverse effects is essential to ensure optimal treatment outcomes in Ultrarapid Metabolizers of CYP2D6 taking atomoxetine.	0.48957298954951606	0.42715668847227034	0.4024412384359093	0.6259368477116047	0.36392355	0.36949787	0.3471994	0.5397725	0.31234252	0.28713918	0.31679457	0.4848473	0.39533234	0.4850908	0.42077208	0.54578424	0.37070787	0.40467218	0.29155576	0.6277422	0
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking atomoxetine? Give a 2-3 sentence summary.	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	['Proceed taking atomoxetine as normal. There is no recommendation.', 'Avoid atomoxetine. Take an alternate therapy.']	Take atomoxetine with an altered dose.	In individuals who are normal metabolizers with a CYP2D6 activity score of 1.5, it is recommended to consider dose adjustments of atomoxetine due to potential decreased metabolism of the drug. Close monitoring for both efficacy and potential adverse effects is crucial to optimize treatment outcomes. Consulting with a healthcare provider or a pharmacist experienced in pharmacogenomics can help tailor the atomoxetine dosing regimen based on the individual's CYP2D6 phenotype and activity score.	0.5269358075959982	0.42715668847227034	0.4024412384359093	0.6533121339222834	0.461463	0.36949787	0.3471994	0.600819	0.37002435	0.28713918	0.31679457	0.5663732	0.4311405	0.4850908	0.42077208	0.52626973	0.4564063	0.40467218	0.29155576	0.6663741	0
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking atorvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid atorvastatin. Take an alternate therapy.', 'Take atorvastatin with a reduced dose.', 'Take atorvastatin with an increased dose.']	Proceed taking atorvastatin as normal. There is no recommendation.	Individuals who are Increased Function for SLCO1B1 may metabolize atorvastatin at a faster rate, potentially leading to reduced drug exposure and efficacy. Clinical guidance may include starting at a lower dose of atorvastatin and monitoring for efficacy and adverse effects closely to ensure optimal treatment outcomes. Consulting with a healthcare provider or a pharmacist experienced in pharmacogenomics can help in tailoring the medication regimen for individuals with this genetic variation.	0.3972980944689882	0.3523187039537286	0.36646681329051006	0.5246891468542806	0.54792726	0.27986246	0.3984175	0.5270062	0.44087753	0.47312072	0.35083434	0.57612133	0.39508006	0.37909073	0.32316342	0.5005188	0.57558954	0.5329314	0.59090626	0.5421891	0
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking atorvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid atorvastatin. Take an alternate therapy.', 'Take atorvastatin with a reduced dose.', 'Take atorvastatin with an increased dose.']	Proceed taking atorvastatin as normal. There is no recommendation.	For individuals who are Normal Function for SLCO1B1, typical dosing guidance for atorvastatin can be followed as per standard recommendations. This genetic profile is not associated with increased risk of statin-related myopathy, so no adjustments to atorvastatin dosage are typically needed based on SLCO1B1 status. Monitoring for usual side effects of statin therapy should still be performed regularly.	0.3712890199140848	0.3523187039537286	0.36646681329051006	0.6167300853950842	0.43161902	0.27986246	0.3984175	0.61057365	0.43658686	0.47312072	0.35083434	0.6469031	0.3570328	0.37909073	0.32316342	0.5270854	0.43311378	0.5329314	0.59090626	0.57942855	1
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking atorvastatin? Give a 2-3 sentence summary.	No recommendation	['Avoid atorvastatin. Take an alternate therapy.', 'Take atorvastatin with a reduced dose.', 'Take atorvastatin with an increased dose.']	Proceed taking atorvastatin as normal. There is no recommendation.	Patients who are categorized as Indeterminate for SLCO1B1 genotype may still be at risk for atorvastatin-related adverse effects. In such cases, clinicians may consider starting at a lower dose of atorvastatin and closely monitoring for signs of muscle toxicity. Additionally, alternative statins or lipid-lowering therapies that do not rely on SLCO1B1 for metabolism may be considered based on individual patient characteristics.	0.2320160159573338	0.47622299017767583	0.21799617205276686	0.5252295714498242	0.11503448	0.30401453	0.14507087	0.581484	0.074501306	0.20310934	0.078651264	0.5948753	-0.0012130961	0.27278835	0.06812026	0.5200271	0.27118978	0.5326432	0.41531742	0.517334	0
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking atorvastatin? Give a 2-3 sentence summary.	Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose >40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	['Proceed taking atorvastatin as normal. There is no recommendation.', 'Avoid atorvastatin. Take an alternate therapy.']	Take atorvastatin with an altered dose.	For someone who is categorized as Possible Decreased Function for SLCO1B1 and is prescribed atorvastatin, it is recommended to consider a lower starting dose of atorvastatin and to closely monitor for any signs of statin-related side effects like muscle pain or weakness. This individual may have an increased risk of experiencing myopathy or other adverse effects due to reduced transport of atorvastatin into the liver, potentially leading to higher systemic concentrations. Regular monitoring of liver function tests and creatine kinase levels may also be advisable.	0.7478906017262453	0.6585139763767641	0.6054158908619628	0.6314666622718232	0.70107085	0.6618069	0.59806365	0.59549075	0.6396552	0.6170747	0.6731684	0.57542586	0.5340518	0.5733377	0.54448944	0.53730977	0.58977664	0.66922385	0.5752127	0.62706655	0
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking azathioprine? Give a 2-3 sentence summary.	For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).	['Proceed taking azathioprine as normal. There is no recommendation.', 'Take azathioprine with a reduced dose.', 'Take azathioprine with an increased dose.']	Avoid azathioprine. Take an alternate therapy.	For an individual who is a Normal Metabolizer for TPMT and a Poor Metabolizer for NUDT15, they may have an increased risk of azathioprine toxicity. Close monitoring for adverse effects and adjusting the azathioprine dose based on clinical response and side effects is recommended to optimize therapy and prevent adverse outcomes. Consultation with a healthcare provider experienced in pharmacogenomics may be beneficial to individualize the treatment plan.	0.6315516952545361	0.6419905906519379	0.6083212357836375	0.5516990542445432	0.53157926	0.671346	0.5922713	0.55316347	0.52945	0.6836008	0.5990632	0.5578864	0.51919097	0.63224715	0.58392835	0.56905264	0.57373226	0.6212602	0.57314605	0.60381174	0
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking azathioprine? Give a 2-3 sentence summary.	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	['Proceed taking azathioprine as normal. There is no recommendation.', 'Avoid azathioprine. Take an alternate therapy.']	Take azathioprine with an altered dose.	For an individual who is a Possible Intermediate Metabolizer for TPMT and a Normal Metabolizer for NUDT15, caution and monitoring are recommended when taking azathioprine. Risk of myelosuppression, particularly leukopenia, is increased in individuals with reduced TPMT activity. Close monitoring of blood counts and consideration of dose adjustment may be necessary to reduce the risk of side effects while maintaining therapeutic benefit. Consulting with a healthcare provider experienced in pharmacogenomics is recommended for personalized guidance.	0.6360411932737985	0.6416023522801692	0.5998024512284732	0.5973202795439727	0.5483186	0.5624113	0.47381184	0.54166126	0.6254841	0.59944177	0.65054864	0.5094756	0.5421836	0.5782251	0.5763185	0.5318201	0.61768156	0.60769624	0.53516483	0.6120549	0
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking azathioprine? Give a 2-3 sentence summary.	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	['Proceed taking azathioprine as normal. There is no recommendation.', 'Avoid azathioprine. Take an alternate therapy.']	Take azathioprine with an altered dose.	For an individual who is a Normal Metabolizer for TPMT and an Intermediate Metabolizer for NUDT15, they may have an increased risk of developing myelosuppression when taking azathioprine. Close monitoring of blood counts, particularly during the initiation of therapy, is recommended. Dose adjustments or alternative therapies may be considered based on clinical judgment and response to treatment.	0.6600027064457568	0.6416023522801692	0.5998024512284732	0.6095296136142383	0.6159935	0.5624113	0.47381184	0.58158094	0.6731322	0.59944177	0.65054864	0.5207641	0.5549123	0.5782251	0.5763185	0.5298391	0.69215274	0.60769624	0.53516483	0.5907868	0
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking azathioprine? Give a 2-3 sentence summary.	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	['Proceed taking azathioprine as normal. There is no recommendation.', 'Avoid azathioprine. Take an alternate therapy.']	Take azathioprine with an altered dose.	For individuals who are Intermediate Metabolizers for TPMT and Possible Intermediate Metabolizers for NUDT15, there is an increased risk of developing severe myelosuppression when taking azathioprine. Therefore, it is recommended to consider dose reduction or alternative medications to minimize the risk of adverse effects. Close monitoring of blood cell counts and clinical symptoms is essential to ensure safe and effective use of azathioprine in these individuals.	0.667885249936755	0.6416023522801692	0.5998024512284732	0.6332599976393414	0.5950593	0.5624113	0.47381184	0.5820696	0.65641147	0.59944177	0.65054864	0.51991266	0.54732573	0.5782251	0.5763185	0.54581106	0.60882974	0.60769624	0.53516483	0.60921174	1
capecitabine	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for DPYD with regards to taking capecitabine? Give a 2-3 sentence summary.	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).	['Proceed taking capecitabine as normal. There is no recommendation.', 'Avoid capecitabine. Take an alternate therapy.']	Take capecitabine with an altered dose.	For individuals who are Intermediate Metabolizers with an activity score of 1.5 for DPYD gene and are prescribed capecitabine, it is recommended to consider dose reduction by 50% to minimize the risk of severe toxicity such as diarrhea, stomatitis, and hand-foot syndrome. Close monitoring for adverse reactions and adjusting the dose based on individual tolerability and therapeutic response is crucial to optimize treatment outcomes.	0.5221985407539635	0.47863677882165445	0.40844301278868717	0.6310199425819291	0.67074865	0.42999864	0.33372468	0.5308739	0.5528704	0.40511233	0.3683068	0.52268636	0.48479095	0.4880396	0.39713836	0.5566896	0.59324515	0.6063859	0.4190805	0.715241	1
capecitabine	DPYD	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for DPYD with regards to taking capecitabine? Give a 2-3 sentence summary.	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.	['Proceed taking capecitabine as normal. There is no recommendation.', 'Take capecitabine with a reduced dose.', 'Take capecitabine with an increased dose.']	Avoid capecitabine. Take an alternate therapy.	Given that the individual is a Poor Metabolizer with an activity score of 0.0 for DPYD, they would be at increased risk of severe and life-threatening toxicities when taking capecitabine, which is a medication metabolized by DPYD. Clinical guidance would typically recommend avoiding the use of capecitabine or using alternative medications that do not rely on DPYD metabolism to prevent serious adverse reactions. Consulting with a healthcare provider experienced in pharmacogenomics would be crucial for personalized treatment recommendations.	0.45701505224507727	0.5414726767739763	0.49672553406270065	0.5964852939588433	0.5442103	0.6247767	0.4920834	0.55709493	0.46299228	0.5851306	0.5618895	0.55250555	0.4163878	0.51412904	0.5186717	0.5246947	0.53211296	0.714998	0.6033118	0.6663927	1
capecitabine	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for DPYD with regards to taking capecitabine? Give a 2-3 sentence summary.	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.2846A>T/c.2846A>T genotype may require >50% reduction in starting dose.	['Proceed taking capecitabine as normal. There is no recommendation.', 'Avoid capecitabine. Take an alternate therapy.']	Take capecitabine with an altered dose.	Individuals who are Intermediate Metabolizers with an activity score of 1.0 for DPYD may be at increased risk of severe toxicity when taking capecitabine, a chemotherapy agent metabolized by DPYD. It is recommended to consider dose reduction or alternative therapies to minimize the risk of severe adverse effects. Close monitoring for side effects and individualized treatment plans in consultation with a healthcare provider or a pharmacogenomics specialist are essential.	0.5321217667356533	0.5324344790903448	0.45300515097499244	0.5839635675133438	0.5456988	0.4706911	0.3992529	0.5453476	0.4942408	0.41999757	0.4116537	0.4884949	0.44432363	0.4618656	0.3852155	0.45341644	0.41367236	0.44198045	0.31433272	0.69080174	0
capecitabine	DPYD	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for DPYD with regards to taking capecitabine? Give a 2-3 sentence summary.	Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.	['Avoid capecitabine. Take an alternate therapy.', 'Take capecitabine with a reduced dose.', 'Take capecitabine with an increased dose.']	Proceed taking capecitabine as normal. There is no recommendation.	Patients who are Normal Metabolizers and have an activity score of 2.0 for DPYD are at an increased risk of developing severe fluoropyrimidine-related toxicity when taking capecitabine. Clinical guidance would recommend either dose reduction or alternative treatment options to minimize the risk of adverse reactions. Close monitoring for toxicities and personalized dose adjustments may be necessary to ensure safe and effective treatment.	0.42477811983712277	0.5113245277554628	0.42944674198200233	0.5951469229735104	0.41943198	0.69324726	0.42168808	0.5571905	0.40650585	0.6017656	0.42015585	0.6076671	0.43665788	0.54416347	0.4992672	0.5219396	0.45687822	0.60580325	0.44000736	0.59268945	0
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine? Give a 2-3 sentence summary.	Use carbamazepine per standard dosing guidelines.	['Avoid carbamazepine. Take an alternate therapy.', 'Take carbamazepine with a reduced dose.', 'Take carbamazepine with an increased dose.']	Proceed taking carbamazepine as normal. There is no recommendation.	Individuals who are HLA-A*31:01 negative for HLA-A and HLA-B*15:02 negative for HLA-B have a lower risk of developing severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome or toxic epidermal necrolysis when taking carbamazepine. Given the lower risk, carbamazepine may be considered as a treatment option for these individuals, with appropriate monitoring for other potential adverse effects still recommended based on individual clinical factors.	0.489539230556846	0.7277817176648592	0.7105334996948726	0.49254164976651743	0.40548113	0.7026914	0.746233	0.45702088	0.49682388	0.84202725	0.861857	0.54166037	0.36955526	0.7945945	0.74495906	0.4201819	0.52981853	0.7673427	0.7796819	0.53426754	1
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine? Give a 2-3 sentence summary.	Use carbamazepine per standard dosing guidelines.	['Avoid carbamazepine. Take an alternate therapy.', 'Take carbamazepine with a reduced dose.', 'Take carbamazepine with an increased dose.']	Proceed taking carbamazepine as normal. There is no recommendation.	Individuals who are HLA-A*31:01 negative for HLA-A and HLA-B*15:02 negative for HLA-B have a lower risk of developing severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome or toxic epidermal necrolysis when taking carbamazepine. Given the lower risk, carbamazepine may be considered as a treatment option for these individuals, with appropriate monitoring for other potential adverse effects still recommended based on individual clinical factors.	0.489539230556846	0.7277817176648592	0.7105334996948726	0.49254164976651743	0.40548113	0.7026914	0.746233	0.45702088	0.49682388	0.84202725	0.861857	0.54166037	0.36955526	0.7945945	0.74495906	0.4201819	0.52981853	0.7673427	0.7796819	0.53426754	1
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and No HLA-B Result for HLA-B with regards to taking carbamazepine? Give a 2-3 sentence summary.	Use carbamazepine per standard dosing guidelines.	['Avoid carbamazepine. Take an alternate therapy.', 'Take carbamazepine with a reduced dose.', 'Take carbamazepine with an increased dose.']	Proceed taking carbamazepine as normal. There is no recommendation.	For individuals who are HLA-A*31:01 negative and have no HLA-B result, it is recommended to proceed with caution when considering carbamazepine therapy. While the absence of HLA-A*31:01 decreases the risk of carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis, the absence of an HLA-B result means that a potential risk factor for carbamazepine-induced hypersensitivity reactions has not been fully evaluated. Close monitoring for adverse reactions and personalized risk management strategies should be implemented in these cases.	0.5110389474950554	0.7277817176648592	0.7105334996948726	0.5518411260567048	0.46944535	0.7026914	0.746233	0.64772296	0.54997784	0.84202725	0.861857	0.58811855	0.3990435	0.7945945	0.74495906	0.464038	0.46346524	0.7673427	0.7796819	0.51206785	0
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is No HLA-A Result for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine? Give a 2-3 sentence summary.	Use carbamazepine per standard dosing guidelines.	['Avoid carbamazepine. Take an alternate therapy.', 'Take carbamazepine with a reduced dose.', 'Take carbamazepine with an increased dose.']	Proceed taking carbamazepine as normal. There is no recommendation.	For individuals identified as No HLA-A Result for HLA-A and HLA-B*15:02 negative for HLA-B, there is a lower risk of developing carbamazepine-induced hypersensitivity reactions, particularly Stevens-Johnson syndrome and toxic epidermal necrolysis. However, it is still advisable to monitor for signs of adverse reactions when prescribing carbamazepine and to follow standard clinical guidelines for dosing and monitoring. Overall, the absence of HLA-B*15:02 reduces the risk but does not completely eliminate the potential for adverse reactions with carbamazepine.	0.5330120467527499	0.7277817176648592	0.7105334996948726	0.5406337004444542	0.3968754	0.7026914	0.746233	0.5462679	0.52892184	0.84202725	0.861857	0.5848001	0.3875769	0.7945945	0.74495906	0.439386	0.48558626	0.7673427	0.7796819	0.4954127	1
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking celecoxib? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid celecoxib. Take an alternate therapy.', 'Take celecoxib with a reduced dose.', 'Take celecoxib with an increased dose.']	Proceed taking celecoxib as normal. There is no recommendation.	For an individual who is a Normal Metabolizer with an activity score of 2.0 for CYP2C9, they are expected to metabolize celecoxib at a usual rate. No dose adjustment is typically required based on CYP2C9 genotype alone, but caution and monitoring for adverse effects may be warranted if they experience any side effects or medication interactions while taking celecoxib. It is recommended to consult with a healthcare provider for personalized guidance regarding the use of celecoxib in this individual.	0.3873280459054085	0.40567257225714715	0.42770531724059974	0.6075703419234479	0.38824964	0.38638705	0.39478818	0.5646755	0.43004674	0.45445698	0.36048612	0.69859946	0.37784925	0.37312865	0.36061966	0.5961596	0.40644872	0.46683076	0.45701364	0.6340023	1
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking celecoxib? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid celecoxib. Take an alternate therapy.', 'Take celecoxib with a reduced dose.', 'Take celecoxib with an increased dose.']	Proceed taking celecoxib as normal. There is no recommendation.	For individuals who are Intermediate Metabolizers of CYP2C9 with an activity score of 1.5, it is recommended to consider a lower starting dose and monitor for potential adverse effects when taking celecoxib, a medication primarily metabolized by CYP2C9. Close monitoring for efficacy and side effects is essential to optimize drug therapy in these individuals due to potential variations in drug metabolism. Consulting with a healthcare provider for individualized dosing recommendations is advisable for safety and effectiveness.	0.4802782118136469	0.40567257225714715	0.42770531724059974	0.5675431046010704	0.50297964	0.38638705	0.39478818	0.52527505	0.38161975	0.45445698	0.36048612	0.6121501	0.38540232	0.37312865	0.36061966	0.5689749	0.5494641	0.46683076	0.45701364	0.583228	0
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking celecoxib? Give a 2-3 sentence summary.	No recommendation	['Avoid celecoxib. Take an alternate therapy.', 'Take celecoxib with a reduced dose.', 'Take celecoxib with an increased dose.']	Proceed taking celecoxib as normal. There is no recommendation.	Individuals who are classified as Indeterminate for CYP2C9 may have varying enzyme activity levels, which could impact their metabolism of medications like celecoxib. Clinical guidance for these individuals would typically involve close monitoring for potential side effects or reduced efficacy of celecoxib. Personalized dosing adjustments and consideration of alternative medications may be necessary to optimize therapeutic outcomes.	0.23062150872881076	0.4503348200569034	0.204086610726694	0.5223940660349676	0.097763814	0.30769557	0.16489118	0.5247859	0.044205036	0.16374862	0.082905285	0.5754473	-0.06023192	0.31693703	0.07523396	0.43260446	0.25234362	0.54835063	0.43558237	0.5607675	0
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking celecoxib? Give a 2-3 sentence summary.	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.	['Avoid celecoxib. Take an alternate therapy.', 'Take celecoxib with a reduced dose.', 'Take celecoxib with an increased dose.']	Proceed taking celecoxib as normal. There is no recommendation.	Individuals who are categorized as Intermediate Metabolizers with an activity score of 1.0 for CYP2C9 may metabolize drugs like celecoxib at a slower rate. This may lead to higher drug concentrations in the body and an increased risk of side effects. It is recommended to consider a lower starting dose of celecoxib and monitor for potential side effects closely in these individuals. Consulting with a healthcare provider or a pharmacist for personalized recommendations is advised.	0.4305697502111124	0.3892830671369341	0.4244849987563771	0.5368469851216244	0.47709858	0.5151078	0.4857378	0.5346507	0.4670321	0.4742775	0.36415294	0.6830543	0.40859842	0.37362063	0.35958537	0.60843825	0.43826202	0.37028444	0.40010867	0.60531664	1
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking chloramphenicol? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid chloramphenicol. Take an alternate therapy.', 'Take chloramphenicol with a reduced dose.', 'Take chloramphenicol with an increased dose.']	Proceed taking chloramphenicol as normal. There is no recommendation.	Individuals who are Indeterminate for G6PD (glucose-6-phosphate dehydrogenase) deficiency may have decreased enzyme activity and could potentially be at risk for hemolysis when exposed to oxidative drugs like chloramphenicol. Clinical guidance would recommend caution when using chloramphenicol in these individuals, monitoring for signs of hemolysis, and considering alternative medications when possible to minimize the risk of adverse effects. Discussing with a healthcare provider knowledgeable in pharmacogenomics is essential for personalized treatment decisions.	0.670058027589789	0.39246547575067464	0.3245106801493239	0.49596356765518074	0.5888356	0.19861542	0.20102336	0.47585198	0.6826872	0.2068566	0.117397964	0.41660714	0.6435232	0.21180902	0.17144549	0.44020516	0.5592351	0.45501253	0.41476402	0.56313324	0
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking chloramphenicol? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid chloramphenicol. Take an alternate therapy.', 'Take chloramphenicol with a reduced dose.', 'Take chloramphenicol with an increased dose.']	Proceed taking chloramphenicol as normal. There is no recommendation.	Individuals who are deficient in G6PD (glucose-6-phosphate dehydrogenase) are at risk of hemolysis when exposed to certain medications, including chloramphenicol. For patients with CNSHA (G6PD Canton-Mahidol), which is a severe form of G6PD deficiency, avoidance of chloramphenicol is recommended due to the risk of hemolytic anemia. Clinicians should consider alternative antibiotics that do not pose a risk of hemolysis in these individuals.	0.4440066386395168	0.4178523072839911	0.45615212154559687	0.46648020725926664	0.6079558	0.51649576	0.50096565	0.4330615	0.5854193	0.5041229	0.42528483	0.49367684	0.51978636	0.39991066	0.35830283	0.5150849	0.52588415	0.47981247	0.4969966	0.5407324	0
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking chloramphenicol? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid chloramphenicol. Take an alternate therapy.', 'Take chloramphenicol with a reduced dose.', 'Take chloramphenicol with an increased dose.']	Proceed taking chloramphenicol as normal. There is no recommendation.	For individuals who are Normal for G6PD status, they are not expected to have an increased risk of hemolysis when taking chloramphenicol. Therefore, no specific dose adjustments or monitoring are typically required for individuals who are Normal for G6PD when using chloramphenicol. It is still recommended to follow standard prescribing guidelines and monitor for any signs of adverse reactions.	0.6142727822442408	0.43317725481527186	0.29243096024329013	0.6023082946794605	0.48576796	0.36942506	0.17954536	0.6121426	0.4296376	0.25685412	0.10079092	0.59610707	0.45339486	0.17106257	0.09560957	0.5832862	0.58391535	0.428042	0.3108426	0.5856024	1
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking chloramphenicol? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid chloramphenicol. Take an alternate therapy.', 'Take chloramphenicol with a reduced dose.', 'Take chloramphenicol with an increased dose.']	Proceed taking chloramphenicol as normal. There is no recommendation.	Individuals who are G6PD deficient should avoid chloramphenicol as it can induce hemolysis in these individuals. Chloramphenicol is metabolized by glucuronidation, and G6PD deficiency can impair this metabolic pathway, leading to increased risk of toxicity. Alternative antibiotics should be considered for individuals who are G6PD deficient to avoid potential adverse effects.	0.6249817219525674	0.4898280820656678	0.36499620457823706	0.49121547428981266	0.6327411	0.4934541	0.2918487	0.5937263	0.6232554	0.38766325	0.18482666	0.5277855	0.6443932	0.41142672	0.30628744	0.51834905	0.5919003	0.5183808	0.3895975	0.6132284	0
chloroquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking chloroquine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid chloroquine. Take an alternate therapy.', 'Take chloroquine with a reduced dose.', 'Take chloroquine with an increased dose.']	Proceed taking chloroquine as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) enzyme, especially with the Mediterranean variant like CNSHA, are at an increased risk of hemolytic anemia when exposed to certain drugs like chloroquine. It is generally recommended to avoid the use of chloroquine in individuals with G6PD deficiency, including those with the CNSHA variant, as it may trigger hemolysis. Alternative antimalarial medications should be considered for these individuals to prevent potentially serious complications.	0.4148269275471638	0.37153311495852165	0.4390726087515146	0.46566990216872844	0.5353943	0.48956993	0.48323813	0.5311112	0.4750633	0.459889	0.4264392	0.49225095	0.4593362	0.3573649	0.28844643	0.54247874	0.5487437	0.4705147	0.5014475	0.4660494	0
chloroquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking chloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid chloroquine. Take an alternate therapy.', 'Take chloroquine with a reduced dose.', 'Take chloroquine with an increased dose.']	Proceed taking chloroquine as normal. There is no recommendation.	Individuals who are G6PD Normal can typically take chloroquine without increased risk of hemolysis. However, caution should still be exercised as some rare variants of G6PD deficiency may not be detected by current testing methods. It is advised to monitor for signs of hemolysis and consult with a healthcare provider if any concerning symptoms occur while taking chloroquine.	0.6173335276286043	0.4151865088686798	0.29257253602601274	0.5670003148826629	0.5307974	0.38358575	0.19254194	0.67387575	0.4687886	0.2540765	0.12516873	0.67543304	0.37536228	0.1273699	0.059261054	0.6086304	0.5364023	0.4453672	0.3172803	0.5034125	0
chloroquine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking chloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid chloroquine. Take an alternate therapy.', 'Take chloroquine with a reduced dose.', 'Take chloroquine with an increased dose.']	Proceed taking chloroquine as normal. There is no recommendation.	Individuals who are Variable for G6PD deficiency may be more at risk for hemolysis when taking chloroquine, as chloroquine can induce oxidative stress in red blood cells. Therefore, it is recommended to consider alternative medications for malaria treatment in individuals with G6PD deficiency, or if chloroquine is necessary, to closely monitor for signs of hemolysis and adjust the dosage as needed to reduce the risk of adverse effects.	0.586121557360167	0.46968323126720896	0.36489734562844683	0.4838146007314036	0.5360919	0.5186051	0.31381693	0.51465124	0.5301767	0.4105274	0.23366332	0.56743485	0.4974245	0.3348913	0.21829455	0.5271795	0.52321243	0.50255424	0.3728218	0.49294728	0
chloroquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking chloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid chloroquine. Take an alternate therapy.', 'Take chloroquine with a reduced dose.', 'Take chloroquine with an increased dose.']	Proceed taking chloroquine as normal. There is no recommendation.	Individuals deficient in glucose-6-phosphate dehydrogenase (G6PD) enzyme should avoid taking chloroquine due to the risk of hemolysis (destruction of red blood cells). Chloroquine can trigger hemolysis in individuals with G6PD deficiency, leading to potentially life-threatening complications. Therefore, it is recommended to consider alternative medications for malaria prophylaxis or treatment in individuals with G6PD deficiency.	0.5830438018081475	0.46968323126720896	0.36489734562844683	0.5068488062200444	0.5823702	0.5186051	0.31381693	0.62037945	0.538545	0.4105274	0.23366332	0.5538763	0.51562995	0.3348913	0.21829455	0.51409304	0.5752775	0.50255424	0.3728218	0.5203246	0
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking ciprofloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid ciprofloxacin. Take an alternate therapy.', 'Take ciprofloxacin with a reduced dose.', 'Take ciprofloxacin with an increased dose.']	Proceed taking ciprofloxacin as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) are at an increased risk for hemolysis when exposed to certain medications, including ciprofloxacin. Therefore, it is recommended to avoid ciprofloxacin in individuals with G6PD deficiency or to use it with caution under close monitoring for signs of hemolysis. Alternative antibiotics that do not pose a risk of hemolysis should be considered for these individuals whenever possible.	0.5649138348191816	0.4438475122381718	0.3257868643846184	0.481845518186606	0.6254737	0.49022415	0.29601064	0.5376313	0.58798015	0.35601187	0.17014761	0.55832314	0.5591393	0.4138652	0.28979284	0.5478546	0.5092173	0.48706716	0.3765311	0.5522841	0
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking ciprofloxacin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid ciprofloxacin. Take an alternate therapy.', 'Take ciprofloxacin with a reduced dose.', 'Take ciprofloxacin with an increased dose.']	Proceed taking ciprofloxacin as normal. There is no recommendation.	For individuals who are Indeterminate for G6PD deficiency, caution is advised when taking ciprofloxacin as this antibiotic may cause hemolytic anemia in individuals with G6PD deficiency. Close monitoring for signs of hemolysis, such as dark urine or jaundice, is recommended. Consultation with a healthcare provider or a pharmacist experienced in pharmacogenomics is advised to determine the appropriateness of ciprofloxacin use in this population.	0.5752597279397842	0.3360311875783908	0.25992283892784585	0.5080838814146726	0.5539341	0.1779981	0.18765672	0.5479899	0.62690437	0.19115603	0.08984924	0.5371553	0.51600164	0.21838915	0.17383742	0.534896	0.4694978	0.42345944	0.4001079	0.5232167	0
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking ciprofloxacin? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid ciprofloxacin. Take an alternate therapy.', 'Take ciprofloxacin with a reduced dose.', 'Take ciprofloxacin with an increased dose.']	Proceed taking ciprofloxacin as normal. There is no recommendation.	Individuals who are deficient in G6PD (glucose-6-phosphate dehydrogenase) should exercise caution when taking ciprofloxacin, as this medication has been associated with hemolytic anemia in G6PD-deficient individuals. It is recommended to consider alternative antibiotics that are not associated with hemolysis when treating infections in individuals with G6PD deficiency. Close monitoring for signs of hemolysis is also advised if ciprofloxacin is deemed necessary.	0.4384528760156768	0.38208821088783307	0.42924361795224675	0.49033816108898864	0.58689326	0.5047884	0.5085552	0.5517422	0.54955673	0.50199807	0.40826872	0.575519	0.51131773	0.42412663	0.36324444	0.5354013	0.4841165	0.4018524	0.46376386	0.53143483	0
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking ciprofloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid ciprofloxacin. Take an alternate therapy.', 'Take ciprofloxacin with a reduced dose.', 'Take ciprofloxacin with an increased dose.']	Proceed taking ciprofloxacin as normal. There is no recommendation.	For individuals who are normal for G6PD enzyme function, there is typically no need to modify the dose or monitoring of ciprofloxacin treatment based on G6PD status alone. However, caution should still be exercised as with any medication to monitor for potential adverse effects or drug interactions, especially in those with additional risk factors or comorbidities. Always consult with a healthcare provider for personalized guidance on the use of ciprofloxacin based on individual circumstances.	0.632505555265345	0.38276692008015645	0.25177241089872665	0.5587768336613251	0.5594725	0.37021354	0.19452894	0.5519433	0.51254046	0.22637795	0.10209319	0.5418621	0.4388154	0.14614059	0.068949364	0.59312844	0.5746467	0.42934164	0.32436523	0.6148668	1
citalopram	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking citalopram? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	['Avoid citalopram. Take an alternate therapy.', 'Take citalopram with a reduced dose.', 'Take citalopram with an increased dose.']	Proceed taking citalopram as normal. There is no recommendation.	As a Rapid Metabolizer for CYP2C19, individuals may require higher doses of citalopram to achieve therapeutic levels due to enhanced drug metabolism. Close monitoring for efficacy and potential side effects such as overexposure to the medication is recommended to optimize treatment outcomes. Consulting with a healthcare provider or a pharmacist knowledgeable in pharmacogenomics can help guide personalized medication dosing for optimal response.	0.649510245764847	0.5316032710002577	0.5966979122789285	0.5650089242399438	0.6623779	0.53916734	0.5473874	0.56978923	0.6727183	0.580556	0.46466854	0.6823771	0.59048074	0.5730628	0.5569536	0.5116955	0.7121484	0.5798676	0.6025488	0.5917592	0
citalopram	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking citalopram? Give a 2-3 sentence summary.	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.	['Proceed taking citalopram as normal. There is no recommendation.', 'Take citalopram with a reduced dose.', 'Take citalopram with an increased dose.']	Avoid citalopram. Take an alternate therapy.	For an individual who is a Likely Poor Metabolizer for CYP2C19 and is prescribed citalopram, it is recommended to consider an alternative antidepressant that is not primarily metabolized by CYP2C19. Close monitoring for citalopram-related side effects and efficacy may be necessary due to potential altered drug metabolism in this patient population. Consulting with a healthcare provider or a clinical pharmacist for individualized treatment recommendations is advised.	0.8314172100361957	0.6401034118884491	0.6272478425140092	0.7077814597867913	0.8280158	0.628373	0.54530865	0.6637806	0.8988763	0.64336944	0.5497703	0.683397	0.90702635	0.6504354	0.5842876	0.6779324	0.8278543	0.67197365	0.6417776	0.71766305	0
citalopram	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking citalopram? Give a 2-3 sentence summary.	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.	['Proceed taking citalopram as normal. There is no recommendation.', 'Take citalopram with a reduced dose.', 'Take citalopram with an increased dose.']	Avoid citalopram. Take an alternate therapy.	Individuals who are Ultrarapid Metabolizers for CYP2C19 may potentially metabolize citalopram more quickly, leading to decreased drug levels and potentially reduced efficacy. Monitoring for therapeutic effects and side effects closely is recommended in these individuals to ensure effective treatment outcomes. Dose adjustments may be necessary based on clinical response and tolerability. Consulting with a healthcare provider or a clinical pharmacist for personalized recommendations is advised.	0.6944465190564644	0.6738976936913412	0.6058469264630334	0.6221166913189564	0.66922	0.65306926	0.5437373	0.6101899	0.74460965	0.62100977	0.54659015	0.70159686	0.7246777	0.6746069	0.6136	0.56299424	0.7386105	0.7099127	0.65166336	0.6132235	0
citalopram	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking citalopram? Give a 2-3 sentence summary.	No recommendation	['Avoid citalopram. Take an alternate therapy.', 'Take citalopram with a reduced dose.', 'Take citalopram with an increased dose.']	Proceed taking citalopram as normal. There is no recommendation.	For individuals who are classified as Indeterminate for CYP2C19, it is recommended to use caution and consider personalized dosing adjustments when taking citalopram. Close monitoring for potential side effects or reduced efficacy is important, as the individual's response to the medication may vary. Consulting with a healthcare provider or a pharmacogenomics specialist for personalized recommendations is advised.	0.26223759592573376	0.4305902258140802	0.1971014363581738	0.6212083522090626	0.11344321	0.3139183	0.15235092	0.55412644	0.08851984	0.19333221	0.09381477	0.6386811	-0.0028521046	0.31026813	0.077434786	0.5606389	0.33533067	0.5449865	0.4306178	0.6174044	0
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine? Give a 2-3 sentence summary.	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking clomipramine as normal. There is no recommendation.', 'Take clomipramine with a reduced dose.', 'Take clomipramine with an increased dose.']	Avoid clomipramine. Take an alternate therapy.	For an individual who is an Intermediate Metabolizer for CYP2D6 and a Rapid Metabolizer for CYP2C19, it is essential to consider the potential impact on clomipramine metabolism. Since clomipramine is primarily metabolized by CYP2D6, the individual may have reduced metabolism of clomipramine leading to higher levels of the drug in their system. Monitoring for potential side effects or toxicity of clomipramine is recommended in this case. Consulting with a healthcare provider or pharmacogenomics expert for personalized dosing recommendations may be beneficial.	0.8047457093364491	0.743199199857198	0.6899615499319122	0.6567165803302552	0.68812567	0.6226829	0.5216868	0.50094146	0.82907057	0.6405431	0.53945464	0.64863014	0.79027945	0.638971	0.61448556	0.6074902	0.7492156	0.66807246	0.6294661	0.5765167	0
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine? Give a 2-3 sentence summary.	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking clomipramine as normal. There is no recommendation.', 'Take clomipramine with a reduced dose.', 'Take clomipramine with an increased dose.']	Avoid clomipramine. Take an alternate therapy.	For an individual who is an Intermediate Metabolizer for CYP2D6 and a Poor Metabolizer for CYP2C19, taking clomipramine may result in altered drug metabolism and potentially increased risk of adverse effects. It is recommended to consider dose adjustments, close monitoring for side effects, and potentially choosing alternative medications based on their genetic profile to optimize treatment outcomes and minimize potential risks. Consulting with a healthcare provider or a pharmacist with expertise in pharmacogenomics can help guide personalized treatment decisions.	0.7730882880493094	0.758487090255069	0.723638229420449	0.7067443931125016	0.67137575	0.6844407	0.5856779	0.60154885	0.69541353	0.70384324	0.6105506	0.67564785	0.62638324	0.65684545	0.6160593	0.64662826	0.6123197	0.6555844	0.5484403	0.66813195	0
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine? Give a 2-3 sentence summary.	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking clomipramine as normal. There is no recommendation.', 'Take clomipramine with a reduced dose.', 'Take clomipramine with an increased dose.']	Avoid clomipramine. Take an alternate therapy.	For a person who is classified as No Result for CYP2D6 and Rapid Metabolizer for CYP2C19, there is limited guidance available on how these genetic variations may impact the response to clomipramine. However, it may be prudent to monitor the individual closely for potential drug interactions and adverse effects due to the lack of clear pharmacogenomic guidance for CYP2D6 and the potential increased metabolism of clomipramine in CYP2C19 Rapid Metabolizers. Consulting with a healthcare provider or a pharmacogenomics expert for personalized recommendations is recommended.	0.5849088773962073	0.5670832207503633	0.49539212724239884	0.6245384081320187	0.6483934	0.54132766	0.46458408	0.5119312	0.59416336	0.46163166	0.4087923	0.59213126	0.5167708	0.4565104	0.4474328	0.5894094	0.5649669	0.54319793	0.45833254	0.6275972	0
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine? Give a 2-3 sentence summary.	Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking clomipramine as normal. There is no recommendation.', 'Take clomipramine with a reduced dose.', 'Take clomipramine with an increased dose.']	Avoid clomipramine. Take an alternate therapy.	For an individual who is a Poor Metabolizer for CYP2D6 and a Normal Metabolizer for CYP2C19 taking clomipramine, it is recommended to adjust the dose based on clinical response and tolerance. Monitoring for potential increased side effects or reduced efficacy is important due to altered metabolism of clomipramine in individuals with impaired CYP2D6 metabolism. Further consultation with a healthcare provider or pharmacogenomics specialist is advisable for personalized medication management.	0.7847823782633057	0.7746458766533457	0.7528115651192664	0.6665946128539265	0.69326293	0.7208367	0.6305043	0.54240537	0.71207845	0.75810313	0.6774829	0.66677725	0.54573536	0.70352703	0.6572676	0.57908916	0.63209355	0.69235593	0.59332865	0.62229025	0
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking clopidogrel? Give a 2-3 sentence summary.	No recommendation	['Avoid clopidogrel. Take an alternate therapy.', 'Take clopidogrel with a reduced dose.', 'Take clopidogrel with an increased dose.']	Proceed taking clopidogrel as normal. There is no recommendation.	Individuals who are Ultrarapid Metabolizers for CYP2C19 may have reduced effectiveness of clopidogrel due to increased metabolism of the drug. This may result in decreased antiplatelet effects and potentially lead to poor outcomes, particularly in those undergoing percutaneous coronary interventions. Alternative antiplatelet medications or genetic testing-guided dosing adjustments may be considered to optimize treatment efficacy and safety.	0.19787620959464863	0.45688150306617453	0.21610690458159412	0.5111424844985365	0.10702056	0.31816393	0.17449729	0.4998167	0.0810114	0.21856642	0.11721446	0.53748596	-0.023644423	0.28515077	0.08993647	0.5309173	0.26054487	0.526283	0.40348768	0.58933395	0
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking clopidogrel? Give a 2-3 sentence summary.	No recommendation	['Avoid clopidogrel. Take an alternate therapy.', 'Take clopidogrel with a reduced dose.', 'Take clopidogrel with an increased dose.']	Proceed taking clopidogrel as normal. There is no recommendation.	Individuals who are Ultrarapid Metabolizers for CYP2C19 may have reduced effectiveness of clopidogrel due to increased metabolism of the drug. This may result in decreased antiplatelet effects and potentially lead to poor outcomes, particularly in those undergoing percutaneous coronary interventions. Alternative antiplatelet medications or genetic testing-guided dosing adjustments may be considered to optimize treatment efficacy and safety.	0.19787620959464863	0.45688150306617453	0.21610690458159412	0.5111424844985365	0.10702056	0.31816393	0.17449729	0.4998167	0.0810114	0.21856642	0.11721446	0.53748596	-0.023644423	0.28515077	0.08993647	0.5309173	0.26054487	0.526283	0.40348768	0.58933395	0
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking clopidogrel? Give a 2-3 sentence summary.	If considering clopidogrel, use at standard dose (75 mg/day)	['Avoid clopidogrel. Take an alternate therapy.', 'Take clopidogrel with a reduced dose.', 'Take clopidogrel with an increased dose.']	Proceed taking clopidogrel as normal. There is no recommendation.	Individuals who are Ultrarapid Metabolizers for CYP2C19 may have reduced effectiveness of clopidogrel due to increased metabolism of the drug. This may result in decreased antiplatelet effects and potentially lead to poor outcomes, particularly in those undergoing percutaneous coronary interventions. Alternative antiplatelet medications or genetic testing-guided dosing adjustments may be considered to optimize treatment efficacy and safety.	0.5641663901542765	0.6522205944630053	0.6815597261727898	0.5111424844985365	0.51276153	0.6645943	0.6399111	0.4998167	0.49260986	0.80417114	0.67431617	0.53748596	0.53996074	0.8246283	0.7503503	0.5309173	0.5702271	0.63629496	0.6103577	0.58933395	0
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking clopidogrel? Give a 2-3 sentence summary.	If considering clopidogrel, use at standard dose (75 mg/day)	['Avoid clopidogrel. Take an alternate therapy.', 'Take clopidogrel with a reduced dose.', 'Take clopidogrel with an increased dose.']	Proceed taking clopidogrel as normal. There is no recommendation.	As a Normal Metabolizer for CYP2C19, individuals are expected to have an average response to clopidogrel therapy. They may follow the standard dosing regimen for clopidogrel without requiring dose adjustments based on their CYP2C19 metabolism status. However, it is important to monitor for any signs of inadequate response to treatment and adjust therapy as needed in consultation with a healthcare provider.	0.6390280925105766	0.6522205944630053	0.6815597261727898	0.6149287227213961	0.6356248	0.6645943	0.6399111	0.58234924	0.6173174	0.80417114	0.67431617	0.62613124	0.64861494	0.8246283	0.7503503	0.5705818	0.6286347	0.63629496	0.6103577	0.59126127	1
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking codeine? Give a 2-3 sentence summary.	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	['Proceed taking codeine as normal. There is no recommendation.', 'Take codeine with a reduced dose.', 'Take codeine with an increased dose.']	Avoid codeine. Take an alternate therapy.	Individuals who are CYP2D6 Ultrarapid Metabolizers with an activity score of ≥3.75 may metabolize codeine rapidly into its active metabolite, morphine, leading to potentially higher concentrations of morphine in the blood. This increased metabolization can result in exaggerated pharmacological effects, including higher risk of opioid toxicity. Therefore, alternative pain management strategies or medications should be considered for these individuals to minimize the risk of adverse reactions associated with codeine use.	0.5944687821275678	0.6601620868945094	0.587413750423559	0.5111756749321253	0.5531218	0.68523335	0.6014889	0.41834402	0.6748919	0.70542294	0.6193411	0.5486604	0.6647684	0.6926102	0.6553331	0.5481371	0.6401581	0.7587913	0.6651764	0.6168893	1
codeine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking codeine? Give a 2-3 sentence summary.	Avoid codeine use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-tramadol opioid.	['Proceed taking codeine as normal. There is no recommendation.', 'Take codeine with a reduced dose.', 'Take codeine with an increased dose.']	Avoid codeine. Take an alternate therapy.	Individuals who are Poor Metabolizers (PM) of CYP2D6 and have an activity score of 0.0 would be at increased risk of toxicity when taking codeine as it is converted to its active metabolite, morphine, by CYP2D6. Therefore, alternative pain management strategies should be considered to avoid potential adverse effects associated with codeine use in individuals with this genotype. Consulting with a healthcare provider or a pharmacogenomics expert to discuss personalized options based on the individual's genetic profile is recommended.	0.573499406457	0.6712189997506207	0.6157128084482854	0.552612261004241	0.6521948	0.70070213	0.6140154	0.53367823	0.6139126	0.7190798	0.62698156	0.50847447	0.5843312	0.7003821	0.6592577	0.55019194	0.60841674	0.7284867	0.61820257	0.6406801	0
codeine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking codeine? Give a 2-3 sentence summary.	Use codeine label recommended age- or weight-specific dosing.	['Avoid codeine. Take an alternate therapy.', 'Take codeine with a reduced dose.', 'Take codeine with an increased dose.']	Proceed taking codeine as normal. There is no recommendation.	Individuals who are Normal Metabolizers with an activity score of 1.25 for CYP2D6 may metabolize codeine at a normal rate. They are likely to achieve the intended therapeutic effect of codeine without significant risk of adverse effects related to altered metabolism. However, close monitoring for efficacy and potential adverse effects is still recommended to ensure personalized treatment outcomes.	0.4697804406970499	0.5709305889327287	0.599952295885271	0.536349250810121	0.55978847	0.49087286	0.48797438	0.5721374	0.5519076	0.6813124	0.55925846	0.62557995	0.56552374	0.6714886	0.5974271	0.5226077	0.50388414	0.59692234	0.6480749	0.61203367	0
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking codeine? Give a 2-3 sentence summary.	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	['Proceed taking codeine as normal. There is no recommendation.', 'Take codeine with a reduced dose.', 'Take codeine with an increased dose.']	Avoid codeine. Take an alternate therapy.	For individuals who are Ultrarapid Metabolizers with a CYP2D6 activity score of ≥5.0, they are likely to convert codeine into its active metabolite, morphine, at a faster rate than normal, which can lead to higher levels of morphine in the bloodstream. This can increase the risk of opioid toxicity, such as respiratory depression and overdose. Therefore, alternative pain management strategies or medications that do not rely on CYP2D6 metabolism should be considered to avoid potential adverse effects when taking codeine.	0.6114858209402733	0.6601620868945094	0.587413750423559	0.5546048713363355	0.51536065	0.68523335	0.6014889	0.40818056	0.66490024	0.70542294	0.6193411	0.5705459	0.6661304	0.6926102	0.6553331	0.57040316	0.64037764	0.7587913	0.6651764	0.6009676	1
dapsone	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking dapsone? Give a 2-3 sentence summary.	Avoid use	['Proceed taking dapsone as normal. There is no recommendation.', 'Take dapsone with a reduced dose.', 'Take dapsone with an increased dose.']	Avoid dapsone. Take an alternate therapy.	Individuals deficient in G6PD (glucose-6-phosphate dehydrogenase) with CNSHA (Class II or III) are at an increased risk of hemolytic anemia when exposed to dapsone. Therefore, dapsone use should be avoided in these individuals. Alternative therapies should be considered for conditions that dapsone is typically used to treat to prevent the risk of hemolysis.	0.23964723844515418	0.3185163774677721	0.2651758360971103	0.6019078156173266	0.340993	0.37868088	0.32521656	0.59950525	0.17723784	0.21554653	0.25289652	0.61221534	0.20275861	0.24950446	0.23950267	0.473502	0.50135434	0.5749198	0.47583222	0.6018491	1
dapsone	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking dapsone? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid dapsone. Take an alternate therapy.', 'Take dapsone with a reduced dose.', 'Take dapsone with an increased dose.']	Proceed taking dapsone as normal. There is no recommendation.	Individuals with an indeterminate G6PD status should consider alternatives to dapsone due to the increased risk of hemolytic anemia associated with G6PD deficiency. If dapsone use is necessary, close monitoring for signs of hemolysis is recommended, and consultation with a healthcare provider familiar with pharmacogenomic testing is advisable for personalized dosing guidance.	0.6769619348869254	0.4076634399606662	0.3359090140281565	0.5894078175918598	0.54707235	0.28339827	0.30463564	0.556537	0.6035142	0.35237035	0.29692048	0.66829085	0.6065363	0.23821466	0.19378132	0.4764224	0.5324868	0.41301382	0.40812746	0.52581966	0
dapsone	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking dapsone? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid dapsone. Take an alternate therapy.', 'Take dapsone with a reduced dose.', 'Take dapsone with an increased dose.']	Proceed taking dapsone as normal. There is no recommendation.	For individuals who are Normal for G6PD and are prescribed dapsone, no specific dosage adjustment is recommended. However, it is still important to monitor for any signs of hemolytic anemia, particularly in patients of African or Mediterranean descent. Close monitoring for side effects is recommended during dapsone therapy in these patients.	0.5842754206589357	0.4354732367062862	0.3210860465313764	0.6595667514044068	0.4346102	0.41541058	0.21241479	0.6010497	0.4128267	0.33054855	0.17866246	0.64533335	0.45836544	0.20539324	0.12723547	0.54041326	0.49628654	0.44612318	0.31890652	0.50870883	1
dapsone	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking dapsone? Give a 2-3 sentence summary.	Avoid use	['Proceed taking dapsone as normal. There is no recommendation.', 'Take dapsone with a reduced dose.', 'Take dapsone with an increased dose.']	Avoid dapsone. Take an alternate therapy.	Individuals who are deficient in the G6PD enzyme should avoid taking dapsone, as it can lead to hemolytic anemia due to oxidative stress. Dapsone is a medication that can trigger hemolysis in patients with G6PD deficiency. Before prescribing dapsone, healthcare providers should assess the individual's G6PD status and consider alternative treatments for those who are deficient.	0.2011499588140891	0.3185163774677721	0.2651758360971103	0.6043024083667018	0.3320501	0.37868088	0.32521656	0.6028743	0.19456284	0.21554653	0.25289652	0.6566405	0.17334945	0.24950446	0.23950267	0.4824672	0.44622424	0.5749198	0.47583222	0.6494321	1
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking desflurane? Give a 2-3 sentence summary.	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid desflurane. Take an alternate therapy.', 'Take desflurane with a reduced dose.', 'Take desflurane with an increased dose.']	Proceed taking desflurane as normal. There is no recommendation.	For an individual with Uncertain Susceptibility for RYR1 and No Result for CACNA1S regarding desflurane, caution is advisable due to potential genetic predisposition to malignant hyperthermia (MH). Given the uncertainty in their genetic results, it would be prudent to consider alternative anesthetic agents that do not pose a risk of triggering MH. Consultation with a genetics specialist and anesthesiologist is recommended for personalized risk assessment and anesthesia planning.	0.6969007940681636	0.38577120250986685	0.3307412787379272	0.549469752249247	0.7330968	0.4609391	0.30815086	0.46199265	0.689359	0.3084973	0.28907695	0.42771223	0.58779275	0.3462964	0.27809054	0.49886826	0.7251096	0.42528605	0.3634113	0.53537726	0
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and No Result for CACNA1S with regards to taking desflurane? Give a 2-3 sentence summary.	Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking desflurane as normal. There is no recommendation.', 'Take desflurane with a reduced dose.', 'Take desflurane with an increased dose.']	Avoid desflurane. Take an alternate therapy.	Individuals with Malignant Hyperthermia Susceptibility due to RYR1 gene variants and no results for CACNA1S should avoid desflurane as it is known to trigger malignant hyperthermia in susceptible individuals. Alternative anesthetic agents should be considered that are less likely to induce malignant hyperthermia, such as total intravenous anesthesia (TIVA) or regional anesthesia. It is important for individuals with this genetic predisposition to discuss their specific risks and alternative options with their healthcare provider or a genetic counselor prior to undergoing anesthesia.	0.7609721225221673	0.4877120702202649	0.40759720523702586	0.5316523469475458	0.8502503	0.540203	0.44405654	0.62588274	0.80162495	0.40028316	0.34460056	0.47310883	0.7417976	0.4101717	0.39421642	0.44764668	0.6932616	0.53125346	0.5231835	0.5189211	1
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking desflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking desflurane as normal. There is no recommendation.', 'Take desflurane with a reduced dose.', 'Take desflurane with an increased dose.']	Avoid desflurane. Take an alternate therapy.	For an individual with Malignant Hyperthermia Susceptibility for RYR1 and uncertain susceptibility for CACNA1S regarding desflurane anesthesia, caution is advised due to the increased risk of triggering a malignant hyperthermia (MH) episode. It is recommended to consider alternative anesthetic agents or to proceed with desflurane under close monitoring in a facility equipped to manage MH events promptly. Consultation with a healthcare provider experienced in managing MH is crucial for safe anesthesia management in these individuals.	0.7115853321673795	0.48249697404395686	0.4065796318743214	0.5987888517301528	0.81056434	0.5509429	0.4551545	0.5480401	0.8054545	0.41915092	0.3681922	0.5288257	0.7141635	0.42118034	0.40452838	0.56962883	0.6576518	0.5364594	0.5282536	0.5274593	0
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking desflurane? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid desflurane. Take an alternate therapy.', 'Take desflurane with a reduced dose.', 'Take desflurane with an increased dose.']	Proceed taking desflurane as normal. There is no recommendation.	For an individual with No Result for RYR1 and Uncertain Susceptibility for CACNA1S alleles, there is limited actionable guidance available. It is recommended to consult with a healthcare provider or a pharmacist who is knowledgeable about pharmacogenomics to discuss the potential risks and benefits of desflurane use in this context. Individualized monitoring and selection of alternative anesthesia options may be considered for personalized care.	0.7254855911501658	0.39608846965848793	0.34405547355692284	0.5655130629926932	0.71290284	0.46003866	0.2944893	0.5436702	0.7492385	0.30627367	0.28438205	0.54240036	0.6777647	0.383938	0.31790766	0.44928885	0.74147207	0.4284476	0.36899507	0.56499547	0
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking desipramine? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking desipramine as normal. There is no recommendation.', 'Take desipramine with a reduced dose.', 'Take desipramine with an increased dose.']	Avoid desipramine. Take an alternate therapy.	For someone who is an Ultrarapid Metabolizer of CYP2D6 with an activity score of ≥3.5, taking desipramine may result in rapid metabolism of the drug into potentially ineffective or subtherapeutic levels. This could lead to reduced efficacy or treatment failure. It is recommended to consider alternative medications or adjust the dosage based on therapeutic drug monitoring to optimize treatment outcomes while minimizing the risk of adverse effects.	0.6180210411243657	0.5791451332775236	0.5373567198918817	0.6300544635165333	0.6884596	0.44016337	0.40424857	0.6012541	0.6526805	0.29443657	0.290827	0.6557102	0.6194224	0.4245695	0.42618787	0.6049664	0.60919476	0.4605885	0.41130963	0.62496775	1
desipramine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking desipramine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose	['Avoid desipramine. Take an alternate therapy.', 'Take desipramine with a reduced dose.', 'Take desipramine with an increased dose.']	Proceed taking desipramine as normal. There is no recommendation.	For individuals who are Normal Metabolizers with an activity score of 1.75 for CYP2D6, they are likely to metabolize desipramine at a normal rate. Standard dosing guidelines can be followed, as these individuals are not expected to have significant variations in response to desipramine based on their CYP2D6 genotype. Monitoring for therapeutic efficacy and adverse effects is recommended during treatment.	0.438010159017392	0.4970514938181248	0.49951174077425575	0.6579589610722973	0.3692685	0.3279334	0.33902714	0.51311266	0.34426832	0.3715319	0.26033115	0.6165545	0.3556218	0.3783283	0.36477098	0.56618685	0.38176256	0.5207515	0.5412411	0.589256	1
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking desipramine? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking desipramine as normal. There is no recommendation.', 'Take desipramine with a reduced dose.', 'Take desipramine with an increased dose.']	Avoid desipramine. Take an alternate therapy.	For an individual who is an Ultrarapid Metabolizer of CYP2D6 and has an activity score of 2.75, they may metabolize desipramine too quickly, leading to reduced efficacy or potential for toxicity. Thus, it's recommended to closely monitor for adverse effects and therapeutic response to desipramine and consider dose adjustments or alternative medications if necessary. Consulting with a healthcare provider or a clinical pharmacist with expertise in pharmacogenomics is advised to guide personalized treatment decisions.	0.623542599666582	0.5791451332775236	0.5373567198918817	0.6200825182808098	0.69091535	0.44016337	0.40424857	0.501544	0.6794114	0.29443657	0.290827	0.5665659	0.5952747	0.4245695	0.42618787	0.5852761	0.6127913	0.4605885	0.41130963	0.5941701	0
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking desipramine? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking desipramine as normal. There is no recommendation.', 'Take desipramine with a reduced dose.', 'Take desipramine with an increased dose.']	Avoid desipramine. Take an alternate therapy.	Individuals who are Ultrarapid Metabolizers with an activity score ≥6.0 for CYP2D6 may metabolize desipramine more quickly than expected, potentially leading to reduced efficacy or increased risk of side effects. Clinical guidance would involve monitoring the individual closely for both therapeutic efficacy and adverse effects. Dose adjustments or alternative medication options may be considered to optimize treatment outcomes.	0.6170453021976701	0.5791451332775236	0.5373567198918817	0.6151017236749895	0.66938883	0.44016337	0.40424857	0.58254015	0.6112471	0.29443657	0.290827	0.62304187	0.5991181	0.4245695	0.42618787	0.5915464	0.5947375	0.4605885	0.41130963	0.60288566	0
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking dexlansoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.	['Proceed taking dexlansoprazole as normal. There is no recommendation.', 'Avoid dexlansoprazole. Take an alternate therapy.']	Take dexlansoprazole with an altered dose.	As a Rapid Metabolizer for CYP2C19, individuals may metabolize dexlansoprazole more quickly, potentially leading to reduced drug efficacy in the treatment of acid-related disorders such as gastroesophageal reflux disease (GERD). Monitoring for treatment response and considering dosage adjustments may be necessary to ensure optimal therapeutic outcomes. Consultation with a healthcare provider or a pharmacist knowledgeable in pharmacogenomics is recommended for personalized guidance on dexlansoprazole therapy in Rapid Metabolizers of CYP2C19.	0.4493721993528144	0.4319553597895283	0.42233968245783043	0.6725288773325041	0.49935013	0.5244644	0.4231161	0.57675916	0.39145982	0.45668057	0.45661736	0.45895845	0.32479098	0.3934011	0.36267322	0.5077062	0.40829453	0.5162315	0.40365982	0.6880252	0
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking dexlansoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking dexlansoprazole as normal. There is no recommendation.', 'Avoid dexlansoprazole. Take an alternate therapy.']	Take dexlansoprazole with an altered dose.	For someone who is a Likely Poor Metabolizer for CYP2C19, they may experience increased levels of dexlansoprazole due to decreased metabolism. This can potentially lead to an increased risk of side effects associated with dexlansoprazole, such as prolonged drug effects or toxicity. Close monitoring for adverse effects and dosage adjustments may be necessary in this population to optimize treatment outcomes.	0.3813232687002936	0.42523775097561367	0.42684894270648566	0.6576459353069763	0.32557255	0.44282916	0.42134076	0.5388639	0.3181409	0.41426593	0.4479003	0.5049383	0.31612676	0.40671661	0.422625	0.4812417	0.35527086	0.5007438	0.40314394	0.6280598	0
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking dexlansoprazole? Give a 2-3 sentence summary.	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	['Proceed taking dexlansoprazole as normal. There is no recommendation.', 'Avoid dexlansoprazole. Take an alternate therapy.']	Take dexlansoprazole with an altered dose.	For an Ultrarapid Metabolizer of CYP2C19 taking dexlansoprazole, they may metabolize the medication more quickly than normal, potentially leading to subtherapeutic drug levels. Monitoring for therapeutic efficacy and potential adverse effects is recommended. Adjusting the dosage or considering alternative medications may be necessary based on individual response and clinical judgment.	0.4273619371411401	0.4635054827851051	0.4026219676626276	0.6680931515063708	0.5059864	0.65926266	0.5000261	0.6230762	0.4269943	0.6434663	0.5377309	0.57498723	0.3785441	0.53986955	0.46074867	0.5343708	0.44750798	0.54229647	0.3703695	0.6901498	0
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking dexlansoprazole? Give a 2-3 sentence summary.	No recommendation	['Avoid dexlansoprazole. Take an alternate therapy.', 'Take dexlansoprazole with a reduced dose.', 'Take dexlansoprazole with an increased dose.']	Proceed taking dexlansoprazole as normal. There is no recommendation.	For individuals who are Indeterminate for CYP2C19, which indicates limited genetic information available, it is recommended to consider alternative medications to dexlansoprazole or to monitor for potential drug interactions or adverse effects closely. Consultation with a healthcare provider or pharmacist can help determine the best course of action based on individual factors and additional clinical information.	0.3156079525340222	0.486250059442504	0.24026405407688708	0.6227098666022254	0.24462147	0.31074408	0.17201191	0.57634395	0.14056508	0.20862237	0.104758225	0.63307446	-0.027972564	0.2978906	0.08362041	0.5441969	0.3522516	0.5100925	0.38946712	0.63550377	0
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking dibekacin as normal. There is no recommendation.', 'Take dibekacin with a reduced dose.', 'Take dibekacin with an increased dose.']	Avoid dibekacin. Take an alternate therapy.	Individuals with an increased risk of aminoglycoside-induced hearing loss due to a MT-RNR1 variant may benefit from pharmacogenetic testing before initiating dibekacin therapy. Close monitoring of hearing function and kidney function is recommended during treatment with dibekacin in these individuals. Dose adjustments or alternative treatment options may be considered to minimize the risk of ototoxicity in individuals with MT-RNR1 variants.	0.6040772662341864	0.35741944163104894	0.2734635264132587	0.47271854319750783	0.56318575	0.48581654	0.4086357	0.47108698	0.6035564	0.28585368	0.31050727	0.47456414	0.6096428	0.3569748	0.36481377	0.5008525	0.49150306	0.5829945	0.43764806	0.51383805	0
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid dibekacin. Take an alternate therapy.', 'Take dibekacin with a reduced dose.', 'Take dibekacin with an increased dose.']	Proceed taking dibekacin as normal. There is no recommendation.	For an individual with normal risk of aminoglycoside-induced hearing loss related to MT-RNR1 gene, there may not be a specific guideline to avoid dibekacin based solely on this genetic information. However, close monitoring for ototoxicity symptoms such as hearing loss, ringing in the ears, and dizziness is recommended during dibekacin treatment, with consideration of dose adjustment or alternative medications if ototoxicity occurs. Communication with a healthcare provider experienced in pharmacogenomics may be beneficial for personalized decision-making.	0.5697716172258037	0.27616468966216273	0.3249936539066184	0.4469173411244503	0.48988262	0.44967836	0.4379379	0.58711797	0.58540434	0.46886286	0.39527568	0.5202918	0.6175388	0.43930098	0.41773668	0.51234037	0.49742305	0.42932752	0.4826897	0.48280743	0
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid dibekacin. Take an alternate therapy.', 'Take dibekacin with a reduced dose.', 'Take dibekacin with an increased dose.']	Proceed taking dibekacin as normal. There is no recommendation.	For individuals with uncertain risk of aminoglycoside-induced hearing loss related to MT-RNR1 gene variations when considering dibekacin, it is advisable to monitor closely for signs of ototoxicity such as hearing loss, vertigo, and tinnitus. Regular audiometric evaluations may be recommended to detect early signs of hearing impairment. Consultation with a healthcare provider or a clinical pharmacogenomics expert for personalized guidance and monitoring is recommended to ensure safe use of dibekacin in individuals with this genetic profile.	0.5863918563724849	0.27616468966216273	0.3249936539066184	0.4157494274343725	0.50742525	0.44967836	0.4379379	0.45415407	0.58307165	0.46886286	0.39527568	0.51083595	0.59811354	0.43930098	0.41773668	0.470225	0.6189108	0.42932752	0.4826897	0.46306106	0
dimercaprol	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking dimercaprol? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid dimercaprol. Take an alternate therapy.', 'Take dimercaprol with a reduced dose.', 'Take dimercaprol with an increased dose.']	Proceed taking dimercaprol as normal. There is no recommendation.	For individuals who are normal for G6PD deficiency, dimercaprol can typically be used safely. However, caution should be advised as dimercaprol may cause oxidative stress, potentially placing additional strain on the red blood cells. Monitoring for signs of hemolysis and ensuring adequate hydration are recommended during dimercaprol treatment in individuals with normal G6PD status.	0.6077917950657752	0.4504761207348548	0.31438179236277985	0.6775096703741379	0.5402097	0.43337488	0.25049815	0.639288	0.5480012	0.36993873	0.22432745	0.7152277	0.41616577	0.16816781	0.09049007	0.5800919	0.5760748	0.42321077	0.31795502	0.53048456	1
dimercaprol	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking dimercaprol? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid dimercaprol. Take an alternate therapy.', 'Take dimercaprol with a reduced dose.', 'Take dimercaprol with an increased dose.']	Proceed taking dimercaprol as normal. There is no recommendation.	Individuals who are indeterminate for G6PD deficiency should exercise caution when taking dimercaprol due to the potential increased risk of hemolysis. Close monitoring for signs of hemolysis such as jaundice, dark urine, and fatigue is recommended. It is advisable to consult with a healthcare provider before initiating dimercaprol therapy in individuals with an indeterminate G6PD status.	0.5978738313323951	0.4110698869674558	0.3466776430264691	0.6468144881843572	0.62575054	0.29013315	0.33482385	0.6176332	0.670915	0.40234423	0.33091676	0.6592988	0.5150565	0.20922032	0.1590218	0.565186	0.48651212	0.42118466	0.41460478	0.5275075	0
dimercaprol	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking dimercaprol? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid dimercaprol. Take an alternate therapy.', 'Take dimercaprol with a reduced dose.', 'Take dimercaprol with an increased dose.']	Proceed taking dimercaprol as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) should not receive dimercaprol due to the risk of hemolysis. Dimercaprol can induce oxidative stress in G6PD-deficient individuals, leading to the destruction of red blood cells and potentially life-threatening complications. Alternative therapies should be considered for individuals with G6PD deficiency requiring chelation therapy.	0.4151678132480996	0.4422433961350855	0.47727765551118423	0.5677870402472763	0.522703	0.51419854	0.5208659	0.62382555	0.50436795	0.5395808	0.48958275	0.6332566	0.42968932	0.37105876	0.32608926	0.49029908	0.44213983	0.43311268	0.5046956	0.50771135	0
dimercaprol	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking dimercaprol? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid dimercaprol. Take an alternate therapy.', 'Take dimercaprol with a reduced dose.', 'Take dimercaprol with an increased dose.']	Proceed taking dimercaprol as normal. There is no recommendation.	Individuals deficient in glucose-6-phosphate dehydrogenase (G6PD) should avoid the use of dimercaprol as it can induce hemolysis and worsen the condition. Dimercaprol is known to cause oxidative stress in red blood cells, which can lead to severe hemolytic anemia in individuals with G6PD deficiency. Therefore, an alternative medication should be considered in individuals with G6PD deficiency to prevent this life-threatening adverse reaction.	0.6146421622129652	0.5035624175943788	0.39459110939654013	0.5762327987553606	0.60678065	0.58485574	0.41781464	0.63582754	0.5992851	0.56316566	0.39363757	0.6051798	0.57084215	0.4273458	0.3047075	0.5133551	0.53328735	0.5044765	0.40088812	0.52610004	0
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin? Give a 2-3 sentence summary.	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking doxepin as normal. There is no recommendation.', 'Take doxepin with a reduced dose.', 'Take doxepin with an increased dose.']	Avoid doxepin. Take an alternate therapy.	For an individual who is an Intermediate Metabolizer for CYP2D6 and a Rapid Metabolizer for CYP2C19 taking doxepin, it is important to consider potential drug interactions and adjust dosages accordingly. Monitoring for therapeutic efficacy and toxicity is recommended due to variations in drug metabolism. Consulting with a healthcare provider or a pharmacogenomics expert to individualize the dosing regimen based on the patient's genotype and clinical factors is advised.	0.8247916948300473	0.7151476117280727	0.6841688238371783	0.6396345589219657	0.72226983	0.6404857	0.528271	0.5773224	0.84935784	0.6326013	0.5126578	0.63285714	0.7616876	0.63504755	0.6258844	0.49687535	0.7518779	0.6596959	0.6257886	0.5725143	0
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin? Give a 2-3 sentence summary.	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking doxepin as normal. There is no recommendation.', 'Avoid doxepin. Take an alternate therapy.']	Take doxepin with an altered dose.	For an individual who is an Intermediate Metabolizer for CYP2D6 and a Normal Metabolizer for CYP2C19 taking doxepin, the clinical guidance would be to consider monitoring closely for potential drug interactions and adverse effects. Adjusting the dose of doxepin based on clinical response and monitoring for side effects may be advisable due to the variability in metabolism of doxepin in individuals with different CYP2D6 metabolizer statuses. Consulting with a healthcare provider or pharmacogenomics expert for personalized recommendations may be beneficial in optimizing treatment outcomes.	0.5203603307356011	0.5067308901633374	0.4210325149398224	0.697459722385969	0.42835635	0.316517	0.2795415	0.5311074	0.4292345	0.351068	0.36093313	0.4843273	0.5030144	0.44490945	0.3686589	0.53086734	0.572561	0.69863254	0.5398863	0.66678095	0
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin? Give a 2-3 sentence summary.	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking doxepin as normal. There is no recommendation.', 'Take doxepin with a reduced dose.', 'Take doxepin with an increased dose.']	Avoid doxepin. Take an alternate therapy.	Given the No Result for CYP2D6 and CYP2C19 activity for this individual, it is recommended to monitor doxepin therapy closely for effectiveness and adverse effects due to potential variability in drug metabolism. Consideration of dose adjustments or alternative medications may be necessary based on individual response. Consulting with a healthcare provider or a clinical pharmacist for personalized recommendations is advised.	0.5458723849645146	0.5239138713048924	0.4260355713058504	0.6376606471521488	0.6354354	0.50593096	0.43306768	0.64740777	0.5685174	0.38745186	0.36487615	0.74356943	0.47547674	0.3161475	0.34714463	0.6900723	0.5641278	0.5577876	0.46976265	0.67302257	0
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin? Give a 2-3 sentence summary.	Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking doxepin as normal. There is no recommendation.', 'Take doxepin with a reduced dose.', 'Take doxepin with an increased dose.']	Avoid doxepin. Take an alternate therapy.	Individuals who are Poor Metabolizers (activity score = 0.0) for CYP2D6 are likely to have reduced metabolism of doxepin, which could potentially lead to increased risk of side effects and toxicity. However, being a Normal Metabolizer for CYP2C19 should not significantly impact the metabolism of doxepin. Consideration of a lower starting dose and closer monitoring for efficacy and adverse effects may be warranted for individuals who are Poor Metabolizers for CYP2D6 when taking doxepin.	0.6621455752749035	0.7373097702350665	0.7523437184471442	0.5695329967139359	0.5351276	0.65722984	0.5717569	0.5147129	0.5982988	0.6700948	0.6165454	0.62785095	0.5254831	0.66437507	0.6668616	0.53132	0.5139774	0.7283124	0.64521545	0.58046156	0
doxorubicin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking doxorubicin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid doxorubicin. Take an alternate therapy.', 'Take doxorubicin with a reduced dose.', 'Take doxorubicin with an increased dose.']	Proceed taking doxorubicin as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) should exercise caution when taking doxorubicin, as it can induce oxidative stress and potentially exacerbate the hemolytic effects associated with G6PD deficiency. Close monitoring for signs of hemolysis and regular blood tests may be necessary when administering doxorubicin to individuals with G6PD deficiency to mitigate the risk of severe adverse effects. Consulting with a healthcare provider experienced in managing G6PD deficiency is recommended for personalized guidance.	0.6148102868144796	0.4973267699533063	0.38687022842202695	0.5536192387008261	0.55420977	0.5219781	0.3436304	0.59322864	0.58957434	0.4361492	0.26921847	0.64685947	0.56456697	0.4062026	0.29904422	0.5414941	0.5055392	0.48584712	0.3683913	0.5255248	0
doxorubicin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking doxorubicin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid doxorubicin. Take an alternate therapy.', 'Take doxorubicin with a reduced dose.', 'Take doxorubicin with an increased dose.']	Proceed taking doxorubicin as normal. There is no recommendation.	Individuals with an indeterminate G6PD status may have reduced G6PD enzyme activity, which could increase the risk of hemolytic anemia with certain medications like doxorubicin. Monitoring for signs of hemolysis, such as fatigue, shortness of breath, and dark urine, is recommended if doxorubicin is prescribed to an individual with an indeterminate G6PD status. Close supervision by a healthcare provider is necessary to manage any potential complications that may arise.	0.6768403636625328	0.37680744257423426	0.3029007959726204	0.47448493100575	0.59127265	0.24444607	0.24107237	0.47720072	0.6364851	0.28558215	0.19955266	0.56342524	0.65192187	0.19736032	0.17089064	0.4611349	0.5420174	0.44028217	0.4201783	0.5636435	0
doxorubicin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking doxorubicin? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid doxorubicin. Take an alternate therapy.', 'Take doxorubicin with a reduced dose.', 'Take doxorubicin with an increased dose.']	Proceed taking doxorubicin as normal. There is no recommendation.	Individuals who are deficient in the G6PD enzyme and carry the CNSHA variant may be at an increased risk of experiencing hemolytic anemia when exposed to certain medications, including doxorubicin. Clinical guidance would typically recommend monitoring these individuals closely for signs of hemolysis and considering alternative medications or adjusting the dose of doxorubicin to minimize the risk of adverse effects. Genetic testing for G6PD deficiency may be considered before initiating treatment with doxorubicin in individuals with this genetic predisposition.	0.4416863198493749	0.37513214718029997	0.4063589796439111	0.499304637971532	0.62552726	0.5013409	0.47825193	0.49295086	0.50646687	0.45784482	0.3945907	0.52768594	0.47478324	0.42531055	0.38260412	0.37897313	0.5611221	0.46916938	0.49619785	0.51283485	1
doxorubicin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking doxorubicin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid doxorubicin. Take an alternate therapy.', 'Take doxorubicin with a reduced dose.', 'Take doxorubicin with an increased dose.']	Proceed taking doxorubicin as normal. There is no recommendation.	Individuals who are normal for G6PD enzyme function are not expected to have an increased risk of doxorubicin-induced toxicity compared to the general population. However, it is important for healthcare providers to monitor for signs of cardiotoxicity, myelosuppression, and other potential adverse effects during doxorubicin treatment, regardless of G6PD status. Close monitoring and appropriate dose adjustments based on individual patient factors are recommended.	0.6450795999690201	0.43744437762768595	0.3199766120215332	0.6114407904833767	0.4826747	0.39323217	0.22587413	0.5964349	0.41202015	0.286873	0.17024352	0.59700114	0.42016476	0.13009338	0.061870933	0.50478977	0.5580225	0.4238915	0.30855498	0.5594716	0
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 with regards to taking efavirenz? Give a 2-3 sentence summary.	Initiate efavirenz with standard dosing (600 mg/day)	['Avoid efavirenz. Take an alternate therapy.', 'Take efavirenz with a reduced dose.', 'Take efavirenz with an increased dose.']	Proceed taking efavirenz as normal. There is no recommendation.	Individuals who are Ultrarapid Metabolizers for CYP2B6 may metabolize efavirenz at a faster rate, which could potentially lead to suboptimal drug levels and reduced efficacy. Clinical guidance for these individuals may involve closer monitoring for treatment efficacy and potential side effects, as dose adjustments may be necessary to ensure therapeutic drug levels are achieved. Consultation with a healthcare provider or a clinical pharmacist experienced in pharmacogenomics is recommended for personalized recommendations based on the individual's specific clinical situation.	0.6218107052440451	0.7055012761560941	0.7464661979655807	0.564380334641364	0.6643473	0.6818854	0.714722	0.49853748	0.6164099	0.8309308	0.7367101	0.5704546	0.6105125	0.7354766	0.7257293	0.5487344	0.54315305	0.6453185	0.6786318	0.5240308	0
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 with regards to taking efavirenz? Give a 2-3 sentence summary.	Initiate efavirenz with standard dosing (600 mg/day)	['Avoid efavirenz. Take an alternate therapy.', 'Take efavirenz with a reduced dose.', 'Take efavirenz with an increased dose.']	Proceed taking efavirenz as normal. There is no recommendation.	For individuals who are Rapid Metabolizers for CYP2B6 and are taking efavirenz, it is recommended to monitor for signs of reduced drug efficacy due to increased clearance. Dose adjustments or therapeutic drug monitoring may be necessary to ensure adequate drug levels for optimal treatment outcomes. Consulting with a healthcare provider or a pharmacogenomics specialist for personalized recommendations is advisable.	0.6562211546643123	0.7055012761560941	0.7464661979655807	0.6007712077166774	0.63733476	0.6818854	0.714722	0.48825863	0.6690064	0.8309308	0.7367101	0.6275077	0.6086986	0.7354766	0.7257293	0.54427826	0.59916383	0.6453185	0.6786318	0.5850392	0
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 with regards to taking efavirenz? Give a 2-3 sentence summary.	No recommendation	['Avoid efavirenz. Take an alternate therapy.', 'Take efavirenz with a reduced dose.', 'Take efavirenz with an increased dose.']	Proceed taking efavirenz as normal. There is no recommendation.	For individuals who are Indeterminate for CYP2B6, there is limited guidance available regarding the use of efavirenz. It is recommended to consider alternative medications or closely monitor for adverse drug reactions and therapeutic efficacy. Consultation with a healthcare provider or a pharmacogenomics specialist is advised to tailor the treatment plan based on individual factors and monitoring needs.	0.2740726862755192	0.4569317113924403	0.22062542305999888	0.646800533963891	0.21510679	0.3323083	0.15975553	0.59383965	0.11370881	0.21319598	0.07932254	0.6344732	0.008267132	0.38391602	0.1689954	0.5743199	0.35720778	0.51199925	0.36884865	0.6302606	0
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 with regards to taking efavirenz? Give a 2-3 sentence summary.	Initiate efavirenz with standard dosing (600 mg/day)	['Avoid efavirenz. Take an alternate therapy.', 'Take efavirenz with a reduced dose.', 'Take efavirenz with an increased dose.']	Proceed taking efavirenz as normal. There is no recommendation.	For individuals who are Normal Metabolizers for CYP2B6 when taking efavirenz, the standard dosing regimen can be used as these individuals are expected to metabolize the medication normally. Monitoring for efficacy and adverse effects following standard clinical guidelines is recommended. Adjustments to the efavirenz regimen based on CYP2B6 metabolism are typically not necessary for Normal Metabolizers.	0.6549867434553595	0.7055012761560941	0.7464661979655807	0.6330777457671452	0.699463	0.6818854	0.714722	0.5534945	0.68947613	0.8309308	0.7367101	0.6573599	0.673951	0.7354766	0.7257293	0.59061176	0.6687962	0.6453185	0.6786318	0.6533281	1
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking enflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking enflurane as normal. There is no recommendation.', 'Take enflurane with a reduced dose.', 'Take enflurane with an increased dose.']	Avoid enflurane. Take an alternate therapy.	Individuals who are uncertain susceptibility for RYR1 and have malignant hyperthermia susceptibility for CACNA1S should exercise caution when considering enflurane as an anesthetic agent, as they may have an increased risk of developing malignant hyperthermia (MH) during surgery. It is recommended to consult with a healthcare provider knowledgeable in pharmacogenomics and MH susceptibility prior to administering enflurane to determine the best course of action and potential alternative anesthetics to avoid triggering an MH reaction.	0.6408240969027209	0.46037955059589064	0.37812824480627377	0.5361554009663335	0.7612556	0.54551834	0.44166663	0.5746071	0.7216858	0.4112589	0.35429028	0.5810705	0.6901356	0.47659156	0.4368042	0.54064536	0.643786	0.5346017	0.5189058	0.54280925	0
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking enflurane? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking enflurane as normal. There is no recommendation.', 'Take enflurane with a reduced dose.', 'Take enflurane with an increased dose.']	Avoid enflurane. Take an alternate therapy.	For someone who has a No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S and is considering taking enflurane, caution should be exercised due to the potential risk of experiencing malignant hyperthermia during anesthesia administration. It is recommended to consider alternative anesthesia agents or discuss with healthcare providers the use of appropriate precautions and monitoring during the procedure to prevent malignant hyperthermia reactions.	0.6974258912805025	0.4671850765489417	0.3878358153190092	0.5792190616715143	0.7811579	0.5281074	0.423934	0.6436558	0.74246854	0.39498058	0.33109835	0.6333444	0.7107769	0.4626712	0.4183828	0.5384036	0.6918237	0.52395153	0.51317805	0.5385435	1
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking enflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking enflurane as normal. There is no recommendation.', 'Take enflurane with a reduced dose.', 'Take enflurane with an increased dose.']	Avoid enflurane. Take an alternate therapy.	Individuals with Malignant Hyperthermia Susceptibility for RYR1 and uncertain susceptibility for CACNA1S should avoid using enflurane due to the potential risk of triggering malignant hyperthermia (MH), a life-threatening adverse reaction to certain anesthesia. It is recommended to choose alternative anesthesia agents that do not pose a risk of triggering MH in these individuals, and preoperative genetic testing and close monitoring are advisable to ensure patient safety during anesthesia administration.	0.6743462635730506	0.46037955059589064	0.37812824480627377	0.5457093120568466	0.81263113	0.54551834	0.44166663	0.654656	0.76884	0.4112589	0.35429028	0.5454707	0.7016804	0.47659156	0.4368042	0.50848705	0.6719795	0.5346017	0.5189058	0.5693707	1
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking enflurane? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid enflurane. Take an alternate therapy.', 'Take enflurane with a reduced dose.', 'Take enflurane with an increased dose.']	Proceed taking enflurane as normal. There is no recommendation.	Individuals with No Result for RYR1 and Uncertain Susceptibility for CACNA1S may have a genetic predisposition for malignant hyperthermia (MH) when exposed to enflurane. Given this uncertain genetic profile, caution is recommended when considering the use of enflurane as an anesthetic agent, and alternative agents with a lower risk of triggering MH should be considered. Consultation with a healthcare provider experienced in pharmacogenomics and anesthesia is advised to determine the safest anesthetic option.	0.7174625677474608	0.4147813483935868	0.358039535973299	0.53650703593241	0.666039	0.47012547	0.30272052	0.44351122	0.70286477	0.32209712	0.30513763	0.4632338	0.5630856	0.3831002	0.33377448	0.50300056	0.71191776	0.42923912	0.3765669	0.50335956	0
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking escitalopram? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	['Avoid escitalopram. Take an alternate therapy.', 'Take escitalopram with a reduced dose.', 'Take escitalopram with an increased dose.']	Proceed taking escitalopram as normal. There is no recommendation.	As a Rapid Metabolizer for CYP2C19, individuals may metabolize escitalopram more quickly, potentially leading to decreased drug levels and reduced efficacy. Monitoring for therapeutic response and potential side effects is crucial, and dose adjustments may be necessary based on the individual's clinical response and tolerability. Consulting with a healthcare provider experienced in pharmacogenomics is recommended to personalize treatment and optimize outcomes.	0.588822136007154	0.5075781156939725	0.5583226065780807	0.5534481962484002	0.6189421	0.5094775	0.4746802	0.5262702	0.61204535	0.4981856	0.32803962	0.5219326	0.55737484	0.56714845	0.5543556	0.4963594	0.67600304	0.57716674	0.57637185	0.61766607	0
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking escitalopram? Give a 2-3 sentence summary.	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.	['Proceed taking escitalopram as normal. There is no recommendation.', 'Take escitalopram with a reduced dose.', 'Take escitalopram with an increased dose.']	Avoid escitalopram. Take an alternate therapy.	For an individual who is a Likely Poor Metabolizer for CYP2C19 and is prescribed escitalopram, monitoring for potential adverse effects and considering a lower starting dose may be advisable due to the decreased metabolism of the medication. Close monitoring for efficacy and side effects is recommended, and dosage adjustments may be necessary based on individual response and tolerability. Consulting with a healthcare provider or a clinical pharmacist with expertise in pharmacogenomics can help optimize treatment for this individual.	0.7997125374632011	0.6059810641106896	0.6188451460871146	0.6457957732843449	0.75074756	0.5525944	0.46171078	0.535619	0.77645105	0.50769186	0.3985671	0.5805641	0.78953475	0.654592	0.5856943	0.5928796	0.7608964	0.6138301	0.5987987	0.61118406	0
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking escitalopram? Give a 2-3 sentence summary.	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.	['Proceed taking escitalopram as normal. There is no recommendation.', 'Take escitalopram with a reduced dose.', 'Take escitalopram with an increased dose.']	Avoid escitalopram. Take an alternate therapy.	For someone who is an Ultrarapid Metabolizer for CYP2C19 and is taking escitalopram, it may lead to lower systemic exposure to the medication due to faster metabolism. This could potentially reduce the effectiveness of escitalopram in individuals with this phenotype, leading to suboptimal therapeutic outcomes. Clinical guidance may include closer monitoring for treatment response and potential dose adjustments based on individual response and symptom control. Consulting with a healthcare provider or a pharmacist for personalized recommendations is recommended.	0.692692317381557	0.6528372547404452	0.611068164202671	0.6486262393038443	0.65582925	0.58640766	0.47000778	0.5166719	0.702212	0.50446117	0.40657008	0.6364988	0.7045222	0.6770981	0.6127477	0.57183665	0.7221037	0.66057587	0.61762315	0.60255396	1
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking escitalopram? Give a 2-3 sentence summary.	No recommendation	['Avoid escitalopram. Take an alternate therapy.', 'Take escitalopram with a reduced dose.', 'Take escitalopram with an increased dose.']	Proceed taking escitalopram as normal. There is no recommendation.	For individuals who are categorized as Indeterminate for CYP2C19 metabolism, caution is recommended when taking escitalopram, a medication metabolized by CYP2C19. Close monitoring for potential side effects or reduced efficacy may be warranted due to the uncertainty in predicting how their body will metabolize the medication. Consideration of alternative treatments or dose adjustments may also be needed based on individual response and tolerability.	0.2576702947376096	0.450018056083929	0.2083545670540976	0.6123371345908908	0.1622087	0.3081905	0.13594498	0.5551643	0.061778296	0.16049233	0.043031152	0.5975878	-0.013082501	0.29398826	0.074059986	0.534016	0.35487932	0.53346795	0.42430457	0.6517759	0
fluorouracil	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for DPYD with regards to taking fluorouracil? Give a 2-3 sentence summary.	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).	['Proceed taking fluorouracil as normal. There is no recommendation.', 'Avoid fluorouracil. Take an alternate therapy.']	Take fluorouracil with an altered dose.	For individuals who are Intermediate Metabolizers with an activity score of 1.5 for DPYD and are considering taking fluorouracil, it is recommended to use caution and consider dose reductions or alternative treatments. These individuals are at increased risk of severe toxicity from fluorouracil due to impaired metabolism, so close monitoring for adverse effects is crucial to optimize safety and efficacy of treatment.	0.4641878549825966	0.4710406124520722	0.4086666431197318	0.6289683606564798	0.5275453	0.4059437	0.32531244	0.4482755	0.49650472	0.3628539	0.34309623	0.35062715	0.42163837	0.4564225	0.34486917	0.4509285	0.5019696	0.5977499	0.43774837	0.61615	0
fluorouracil	DPYD	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for DPYD with regards to taking fluorouracil? Give a 2-3 sentence summary.	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.	['Proceed taking fluorouracil as normal. There is no recommendation.', 'Take fluorouracil with a reduced dose.', 'Take fluorouracil with an increased dose.']	Avoid fluorouracil. Take an alternate therapy.	Individuals who are Poor Metabolizers with an activity score of 0.0 for DPYD are at a significantly increased risk of severe toxicities when taking fluorouracil due to impaired drug metabolism. Clinical guidance would typically involve avoiding or strongly reducing the dose of fluorouracil in these individuals to prevent potentially life-threatening adverse reactions. A personalized dosing strategy or alternative treatment options may be considered in consultation with a healthcare provider or a pharmacogenomics expert.	0.5478863529673506	0.6363807078965129	0.6013557767904428	0.5714289186784379	0.5584615	0.64294964	0.54377013	0.47538674	0.61271185	0.7841388	0.6695526	0.5146205	0.5617782	0.7166225	0.68770903	0.5679057	0.60358626	0.82438254	0.7336395	0.65524447	0
fluorouracil	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for DPYD with regards to taking fluorouracil? Give a 2-3 sentence summary.	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.2846A>T/c.2846A>T genotype may require >50% reduction in starting dose.	['Proceed taking fluorouracil as normal. There is no recommendation.', 'Avoid fluorouracil. Take an alternate therapy.']	Take fluorouracil with an altered dose.	Individuals who are Intermediate Metabolizers with an activity score of 1.0 for DPYD may be at an increased risk of developing severe toxicities when taking fluorouracil (5-FU). Clinical guidance may include considering dose reduction, alternative treatment options, or implementing more frequent monitoring for toxicities. It is important for healthcare providers to assess the risks and benefits of 5-FU therapy in these individuals and to personalize treatment approaches to minimize the risk of adverse events.	0.49834530078256906	0.48060659295076996	0.42034116169133706	0.587904142304571	0.55400246	0.43045583	0.38388374	0.46180853	0.48523563	0.3628479	0.38803425	0.39421803	0.34827417	0.4147477	0.32485503	0.512061	0.4229344	0.46764675	0.36165646	0.6125532	0
fluorouracil	DPYD	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for DPYD with regards to taking fluorouracil? Give a 2-3 sentence summary.	Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.	['Avoid fluorouracil. Take an alternate therapy.', 'Take fluorouracil with a reduced dose.', 'Take fluorouracil with an increased dose.']	Proceed taking fluorouracil as normal. There is no recommendation.	Individuals classified as Normal Metabolizers with an activity score of 2.0 for DPYD are typically considered at average risk for fluorouracil toxicity. However, caution should still be exercised when initiating treatment with fluorouracil. Clinicians should consider factors such as age, comorbidities, concomitant medications, and other genetic variations that may impact drug response before prescribing fluorouracil. Close monitoring for potential adverse effects during treatment is recommended.	0.3931055783254229	0.4782238902673939	0.3833564023397967	0.596516671237158	0.4437152	0.6445161	0.3959833	0.47975093	0.47605494	0.5520111	0.3715272	0.5100439	0.42941567	0.50641716	0.44197294	0.50952905	0.47117135	0.61629343	0.4629691	0.6365425	0
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking flurbiprofen? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid flurbiprofen. Take an alternate therapy.', 'Take flurbiprofen with a reduced dose.', 'Take flurbiprofen with an increased dose.']	Proceed taking flurbiprofen as normal. There is no recommendation.	Based on the CYP2C9 genotype of Normal Metabolizer and an activity score of 2.0, it indicates normal activity of the CYP2C9 enzyme. For flurbiprofen, which is metabolized primarily by CYP2C9, standard dosing recommendations would likely apply. However, monitoring for potential adverse effects and therapeutic response may still be warranted due to individual variations in drug metabolism and response.	0.3784647303233782	0.39321415262206366	0.4285082952552643	0.6008902562417285	0.35868344	0.3423517	0.33949637	0.40431017	0.30856133	0.39875072	0.27121535	0.41574866	0.26941568	0.36041084	0.34209514	0.5287741	0.41069517	0.47378537	0.46098462	0.68448323	1
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking flurbiprofen? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid flurbiprofen. Take an alternate therapy.', 'Take flurbiprofen with a reduced dose.', 'Take flurbiprofen with an increased dose.']	Proceed taking flurbiprofen as normal. There is no recommendation.	For an individual who is an Intermediate Metabolizer with an activity score of 1.5 for CYP2C9 and is prescribed flurbiprofen, caution should be exercised as there may be an increased risk of adverse effects due to reduced metabolism of the drug. Close monitoring for potential side effects and adjustments to the dose of flurbiprofen may be necessary to ensure safety and effectiveness in this individual. Consulting with a healthcare provider or a clinical pharmacogenomics expert for personalized guidance is recommended.	0.41106817229616366	0.39321415262206366	0.4285082952552643	0.6227551102648441	0.3849853	0.3423517	0.33949637	0.44844547	0.3629414	0.39875072	0.27121535	0.47326672	0.34418786	0.36041084	0.34209514	0.52740675	0.4399635	0.47378537	0.46098462	0.58706594	0
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking flurbiprofen? Give a 2-3 sentence summary.	No recommendation	['Avoid flurbiprofen. Take an alternate therapy.', 'Take flurbiprofen with a reduced dose.', 'Take flurbiprofen with an increased dose.']	Proceed taking flurbiprofen as normal. There is no recommendation.	Individuals who are classified as Indeterminate for CYP2C9 may have altered metabolism of medications such as flurbiprofen. Due to the potential for variability in drug response, personalized dosing based on clinical monitoring of therapeutic response and potential adverse effects may be necessary. Close monitoring for efficacy and side effects of flurbiprofen is recommended in individuals with an Indeterminate CYP2C9 phenotype. Consulting with a healthcare provider or a pharmacist experienced in pharmacogenomics can help optimize the treatment plan for these individuals.	0.23848110318806123	0.44451550026558473	0.22525894588730652	0.5612895350409449	0.13992701	0.2772925	0.14221925	0.45624936	0.054100156	0.13851252	0.051738933	0.3747161	-0.025524758	0.294111	0.100122064	0.42282784	0.32437283	0.5312631	0.39120016	0.6212953	0
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking flurbiprofen? Give a 2-3 sentence summary.	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.	['Avoid flurbiprofen. Take an alternate therapy.', 'Take flurbiprofen with a reduced dose.', 'Take flurbiprofen with an increased dose.']	Proceed taking flurbiprofen as normal. There is no recommendation.	Individuals who are Intermediate Metabolizers with an activity score of 1.0 for CYP2C9 may have reduced metabolism of medications like flurbiprofen, potentially leading to increased drug levels and a higher risk of side effects. It is recommended to consider a lower starting dose of flurbiprofen and close monitoring for efficacy and adverse effects to optimize treatment outcomes in this population. Consulting with a healthcare provider or a pharmacist for personalized dosing recommendations is advisable.	0.45872626964856483	0.3798003381723816	0.4327170944504029	0.5766150593122228	0.4541994	0.43295488	0.37236837	0.43644574	0.42055783	0.37317118	0.23944336	0.5008578	0.43294716	0.34830803	0.33611223	0.54150486	0.4735124	0.3862069	0.4123571	0.640721	1
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin? Give a 2-3 sentence summary.	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 phenotype could not be assigned based on genotyping.	['Avoid fluvastatin. Take an alternate therapy.', 'Take fluvastatin with a reduced dose.', 'Take fluvastatin with an increased dose.']	Proceed taking fluvastatin as normal. There is no recommendation.	For someone who is Indeterminate for CYP2C9 and Possible Decreased Function for SLCO1B1 and considering fluvastatin, caution and individualized dosing may be warranted due to potential variability in drug metabolism and transport. Close monitoring for adverse effects such as myopathy or liver toxicity is advised, and adjustments in dosage may be needed based on clinical response and side effects. Consulting with a healthcare provider or a pharmacogenomics specialist for personalized recommendations is recommended.	0.8382946014886516	0.6064781273496315	0.6521096009458823	0.5962524735313184	0.8115568	0.5956504	0.5552284	0.48807877	0.8874547	0.6790964	0.539539	0.6317573	0.8025074	0.54763275	0.51577735	0.51226777	0.81432766	0.6026437	0.6182136	0.59545803	1
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2C9 and Indeterminate for SLCO1B1 with regards to taking fluvastatin? Give a 2-3 sentence summary.	n/a	['Avoid fluvastatin. Take an alternate therapy.', 'Take fluvastatin with a reduced dose.', 'Take fluvastatin with an increased dose.']	Proceed taking fluvastatin as normal. There is no recommendation.	For an individual with No Result for CYP2C9 and Indeterminate for SLCO1B1 when considering fluvastatin therapy, caution is advised. Fluvastatin is primarily metabolized by CYP2C9, and alterations in SLCO1B1 may affect its pharmacokinetics. Due to the uncertainty in predicting the response to fluvastatin in this case, close monitoring for potential adverse effects or inadequate response is recommended. Consultation with a healthcare provider or a clinical pharmacogenomics expert may be beneficial for personalized recommendations.	0.1364630707585184	0.20474682946536557	0.10894521055019962	0.5792521176124413	0.15135193	0.12301877	0.092413835	0.5870732	0.02421183	0.038634017	0.042194594	0.586123	-0.03929675	0.016649766	-0.006094717	0.52920943	0.33027175	0.3559772	0.37700883	0.6004633	0
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and Decreased Function for SLCO1B1 with regards to taking fluvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day.	['Avoid fluvastatin. Take an alternate therapy.', 'Take fluvastatin with a reduced dose.', 'Take fluvastatin with an increased dose.']	Proceed taking fluvastatin as normal. There is no recommendation.	For someone who is a Normal Metabolizer with an activity score of 2.0 for CYP2C9 and has Decreased Function for SLCO1B1, they may have an increased risk of statin-related adverse effects with fluvastatin. Monitoring for side effects such as myopathy or liver toxicity is recommended, and dose adjustments or alternative statin medications may be considered based on individual response and tolerance. Close monitoring by a healthcare provider is advised to ensure safety and efficacy during treatment with fluvastatin.	0.6972877081729312	0.6367757620343362	0.6899546755355092	0.6177115993289647	0.64367324	0.50806934	0.53615195	0.53380066	0.575454	0.6572926	0.4876262	0.63856953	0.5094369	0.52920747	0.515023	0.5361658	0.64722526	0.5800475	0.60205317	0.61411846	0
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin? Give a 2-3 sentence summary.	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 genotype result is not available.	['Avoid fluvastatin. Take an alternate therapy.', 'Take fluvastatin with a reduced dose.', 'Take fluvastatin with an increased dose.']	Proceed taking fluvastatin as normal. There is no recommendation.	For an individual with No Result for CYP2C9 and activity score, and Possible Decreased Function for SLCO1B1 gene status, caution is advised when starting fluvastatin. These genetic variations may impact the metabolism and transport of fluvastatin, potentially leading to altered drug response or increased risk of side effects. Close monitoring, dose adjustments, and consideration of alternative statin options may be necessary to optimize treatment outcomes while minimizing the risk of adverse events.	0.8201210385133985	0.6176859495097352	0.6645208434567201	0.5932058870363941	0.80853736	0.59110093	0.5367722	0.5745782	0.8288158	0.67734224	0.52115065	0.6266862	0.72885364	0.5533289	0.521245	0.57046944	0.7678078	0.61240405	0.623084	0.59280056	0
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking fluvoxamine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid fluvoxamine. Take an alternate therapy.', 'Take fluvoxamine with a reduced dose.', 'Take fluvoxamine with an increased dose.']	Proceed taking fluvoxamine as normal. There is no recommendation.	As an Intermediate Metabolizer with an activity score of 0.5 for CYP2D6, the individual may experience higher-than-expected levels of fluvoxamine, a CYP2D6 substrate. Monitoring for potential side effects or reduced efficacy of fluvoxamine is recommended. Dose adjustments or alternative medications may be considered based on clinical response and tolerability. Consulting with a healthcare provider or a pharmacist specialized in pharmacogenomics can be helpful in optimizing treatment for individuals with this genotype.	0.4024869846617868	0.4769947583084961	0.49449161103990885	0.6240353812208702	0.43105134	0.39972264	0.4494815	0.52373075	0.3622652	0.5182947	0.4310929	0.5454532	0.40099737	0.48154306	0.4874611	0.43519917	0.51186705	0.51965314	0.5779416	0.66173345	0
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking fluvoxamine? Give a 2-3 sentence summary.	No recommendation due to lack of evidence	['Avoid fluvoxamine. Take an alternate therapy.', 'Take fluvoxamine with a reduced dose.', 'Take fluvoxamine with an increased dose.']	Proceed taking fluvoxamine as normal. There is no recommendation.	For individuals who are Ultrarapid Metabolizers with a CYP2D6 activity score of 4.0, there is a potential for decreased efficacy of fluvoxamine due to rapid metabolism of the drug. Monitoring for therapeutic response and potential side effects is important, as dose adjustments may be necessary to achieve optimal treatment outcomes. Consultation with a healthcare provider or a pharmacist specializing in pharmacogenomics is recommended to personalize treatment and maximize benefits while minimizing risks.	0.25271894009530455	0.4218766925953058	0.2753222920876771	0.5821753271165011	0.25214377	0.36573133	0.21147163	0.51382595	0.21085124	0.32147405	0.16616675	0.5920627	0.04939328	0.26190105	0.08319646	0.43664244	0.30305162	0.53878886	0.36661777	0.63569885	0
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking fluvoxamine? Give a 2-3 sentence summary.	No recommendation due to lack of evidence	['Avoid fluvoxamine. Take an alternate therapy.', 'Take fluvoxamine with a reduced dose.', 'Take fluvoxamine with an increased dose.']	Proceed taking fluvoxamine as normal. There is no recommendation.	For an individual who is an Ultrarapid Metabolizer with an activity score of ≥3.75 for CYP2D6, caution is advised when taking fluvoxamine, as this medication is a strong inhibitor of CYP2D6. The individual may metabolize fluvoxamine too rapidly, potentially leading to reduced efficacy or increased risk of side effects. Close monitoring for therapeutic response and adverse effects is recommended, and dosage adjustments may be necessary based on individual response.	0.2522173526122034	0.4218766925953058	0.2753222920876771	0.620443848497014	0.25184998	0.36573133	0.21147163	0.5994569	0.25486678	0.32147405	0.16616675	0.63423854	0.08848759	0.26190105	0.08319646	0.5207457	0.31657055	0.53878886	0.36661777	0.6103451	0
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking fluvoxamine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid fluvoxamine. Take an alternate therapy.', 'Take fluvoxamine with a reduced dose.', 'Take fluvoxamine with an increased dose.']	Proceed taking fluvoxamine as normal. There is no recommendation.	Individuals who are classified as Intermediate Metabolizers (IMs) with an activity score of 0.25 for CYP2D6 may experience reduced metabolism of drugs like fluvoxamine, potentially leading to increased drug concentrations and risk of adverse effects. Clinical guidance would typically recommend starting fluvoxamine at a lower dosage and closely monitoring for side effects or toxicity to ensure safe and effective treatment. Consulting with a healthcare provider or a clinical pharmacist for personalized dosing recommendations is recommended for individuals with this genotype.	0.42707730069072053	0.4769947583084961	0.49449161103990885	0.6008936206567494	0.38156062	0.39972264	0.4494815	0.54908985	0.3973481	0.5182947	0.4310929	0.62965155	0.5081201	0.48154306	0.4874611	0.47776428	0.47402334	0.51965314	0.5779416	0.62173104	0
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin? Give a 2-3 sentence summary.	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	['Proceed taking fosphenytoin as normal. There is no recommendation.', 'Take fosphenytoin with a reduced dose.', 'Take fosphenytoin with an increased dose.']	Avoid fosphenytoin. Take an alternate therapy.	Individuals who are HLA-B*15:02 positive have an increased risk of developing severe cutaneous adverse reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, when treated with fosphenytoin. Therefore, it is strongly recommended to avoid fosphenytoin in patients who test positive for HLA-B*15:02 to prevent these dangerous reactions. Alternative medications should be considered for the management of seizures in these individuals.	0.5630675425481082	0.6702755159184737	0.6107443987024547	0.602045787119937	0.5417694	0.59464526	0.4982821	0.5817047	0.5486763	0.57391894	0.5386757	0.5493513	0.5197032	0.7290294	0.6978836	0.5819543	0.5815709	0.66946775	0.5832608	0.616751	1
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin? Give a 2-3 sentence summary.	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	['Proceed taking fosphenytoin as normal. There is no recommendation.', 'Avoid fosphenytoin. Take an alternate therapy.']	Take fosphenytoin with an altered dose.	For individuals without an HLA-B result, it is recommended to exercise caution when considering fosphenytoin therapy due to the potential risk of developing serious skin reactions, such as Stevens-Johnson syndrome or toxic epidermal necrolysis. Close monitoring for any signs of adverse skin reactions is advised, and the decision to initiate fosphenytoin should be carefully weighed against the potential risks for each individual patient.	0.6049339475962804	0.501226012451486	0.5279686776720288	0.5748380579305423	0.55588776	0.52785814	0.52631456	0.44498226	0.5478977	0.46483022	0.49385822	0.43080953	0.5830749	0.493664	0.46575844	0.53665155	0.6335418	0.53713393	0.49919698	0.5792585	0
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin? Give a 2-3 sentence summary.	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	['Proceed taking fosphenytoin as normal. There is no recommendation.', 'Avoid fosphenytoin. Take an alternate therapy.']	Take fosphenytoin with an altered dose.	For individuals without an HLA-B result, it is recommended to exercise caution when considering fosphenytoin therapy due to the potential risk of developing serious skin reactions, such as Stevens-Johnson syndrome or toxic epidermal necrolysis. Close monitoring for any signs of adverse skin reactions is advised, and the decision to initiate fosphenytoin should be carefully weighed against the potential risks for each individual patient.	0.6049339475962804	0.501226012451486	0.5279686776720288	0.5748380579305423	0.55588776	0.52785814	0.52631456	0.44498226	0.5478977	0.46483022	0.49385822	0.43080953	0.5830749	0.493664	0.46575844	0.53665155	0.6335418	0.53713393	0.49919698	0.5792585	0
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin? Give a 2-3 sentence summary.	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	['Avoid fosphenytoin. Take an alternate therapy.', 'Take fosphenytoin with a reduced dose.', 'Take fosphenytoin with an increased dose.']	Proceed taking fosphenytoin as normal. There is no recommendation.	Individuals who are HLA-B*15:02 positive have an increased risk of developing severe cutaneous adverse reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, when treated with fosphenytoin. Therefore, it is strongly recommended to avoid fosphenytoin in patients who test positive for HLA-B*15:02 to prevent these dangerous reactions. Alternative medications should be considered for the management of seizures in these individuals.	0.555875364696496	0.48824529050027937	0.47294060571268814	0.5596325280781067	0.46910605	0.50990474	0.45730594	0.58842385	0.42517483	0.46680757	0.40350342	0.5393005	0.43559664	0.45731217	0.45889673	0.48886594	0.40078452	0.45130447	0.46494862	0.5796155	0
furazolidone	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking furazolidone? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid furazolidone. Take an alternate therapy.', 'Take furazolidone with a reduced dose.', 'Take furazolidone with an increased dose.']	Proceed taking furazolidone as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) are at an increased risk of hemolysis when exposed to certain medications, including furazolidone. Therefore, it is recommended to avoid the use of furazolidone in individuals with G6PD deficiency to prevent the risk of severe side effects such as hemolytic anemia. Alternative treatment options should be considered in these individuals.	0.5916785768881501	0.47913669049993196	0.35253250497545424	0.5188230030841777	0.5839277	0.48758852	0.25889498	0.5933362	0.5709606	0.3791599	0.16561508	0.5561673	0.5285525	0.3970475	0.26155618	0.51881576	0.54008037	0.5409147	0.41668686	0.58350474	0
furazolidone	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking furazolidone? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid furazolidone. Take an alternate therapy.', 'Take furazolidone with a reduced dose.', 'Take furazolidone with an increased dose.']	Proceed taking furazolidone as normal. There is no recommendation.	Individuals who are classified as Indeterminate for G6PD deficiency may have reduced enzyme activity levels, which can increase the risk of hemolysis when exposed to medications like furazolidone. Therefore, it is advisable to exercise caution and consider alternative medications or closely monitor for signs of hemolysis if furazolidone therapy is deemed necessary in such individuals. Consulting with a healthcare provider or a pharmacogenomics specialist to discuss the potential risks and benefits of furazolidone in this specific case is recommended.	0.5955950406476088	0.3773792634833346	0.30732528260765085	0.561290728453734	0.5691741	0.21883878	0.229263	0.5228006	0.67182857	0.25067353	0.14510423	0.5444256	0.63271	0.21878554	0.16820498	0.47109672	0.5485867	0.46202555	0.42795384	0.5760881	0
furazolidone	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking furazolidone? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid furazolidone. Take an alternate therapy.', 'Take furazolidone with a reduced dose.', 'Take furazolidone with an increased dose.']	Proceed taking furazolidone as normal. There is no recommendation.	Individuals who are deficient in G6PD enzyme activity may be at risk for hemolytic anemia when exposed to furazolidone, an antibiotic and antiprotozoal agent. Due to the potential for severe side effects, including hemolysis, it is recommended to avoid the use of furazolidone in individuals with G6PD deficiency. Alternative treatment options should be considered in this population to prevent potential harm.	0.3835432493671568	0.35920067335988476	0.36998925309527014	0.5463034562825808	0.5814534	0.4745068	0.42660522	0.5314128	0.53259265	0.4559514	0.34154233	0.5049286	0.48020148	0.4212205	0.35976788	0.516955	0.5006234	0.41092572	0.46192658	0.5649238	0
furazolidone	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking furazolidone? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid furazolidone. Take an alternate therapy.', 'Take furazolidone with a reduced dose.', 'Take furazolidone with an increased dose.']	Proceed taking furazolidone as normal. There is no recommendation.	For individuals who are normal for G6PD deficiency, there is typically no contraindication to using furazolidone. However, given that furazolidone can cause hemolysis in individuals with G6PD deficiency, caution should still be exercised. Monitoring for potential signs of hemolysis, such as jaundice or dark urine, is recommended if furazolidone therapy is initiated.	0.6022134886819163	0.40583018558805406	0.2756435379268424	0.6209659807944123	0.47326833	0.3701698	0.14049484	0.59752357	0.45982215	0.2350072	0.06022823	0.6095356	0.40178418	0.1464956	0.059222415	0.48951396	0.48743019	0.4469264	0.32621247	0.53581023	0
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking gentamicin as normal. There is no recommendation.', 'Take gentamicin with a reduced dose.', 'Take gentamicin with an increased dose.']	Avoid gentamicin. Take an alternate therapy.	Individuals with a known increased risk of aminoglycoside-induced hearing loss due to an MT-RNR1 mutation should be closely monitored and alternative non-aminoglycoside antibiotics should be considered whenever possible to minimize the risk of hearing damage. If gentamicin must be used in this population, personalized dosing based on therapeutic drug monitoring and renal function should be considered to minimize the risk of adverse effects.	0.7357217147014955	0.5727240540413857	0.4999290832437488	0.5527467042952253	0.68586695	0.5789478	0.4776456	0.5667197	0.75651085	0.5039189	0.48770854	0.5637783	0.7745045	0.4621089	0.43198887	0.5176582	0.67007744	0.64363265	0.561553	0.61590916	0
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid gentamicin. Take an alternate therapy.', 'Take gentamicin with a reduced dose.', 'Take gentamicin with an increased dose.']	Proceed taking gentamicin as normal. There is no recommendation.	For individuals with normal risk of aminoglycoside-induced hearing loss associated with MT-RNR1 gene variants, the usual clinical guidance would recommend gentamicin use with caution and close monitoring for any signs of ototoxicity. Consideration may be given to using alternative antibiotics if possible, especially for prolonged or high-dose regimens. Consultation with a healthcare provider or a pharmacogenomics expert would be advisable to determine the most appropriate approach for gentamicin therapy in these individuals.	0.6881248087781829	0.490414452354216	0.5102863961167895	0.6083933303422822	0.6582818	0.51108366	0.50961554	0.5700709	0.7313997	0.5786553	0.54718715	0.5651947	0.7270567	0.4842328	0.4831772	0.55178255	0.6612906	0.57890636	0.6105881	0.58885	0
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid gentamicin. Take an alternate therapy.', 'Take gentamicin with a reduced dose.', 'Take gentamicin with an increased dose.']	Proceed taking gentamicin as normal. There is no recommendation.	Individuals with uncertain risk of aminoglycoside-induced hearing loss due to MT-RNR1 variants should undergo pharmacogenetic testing to assess their genetic predisposition. Based on the test results, clinicians can determine the appropriateness of using gentamicin or consider alternative treatment options to minimize the risk of ototoxicity. Close monitoring of hearing function and kidney function is also recommended during gentamicin therapy for patients with this genetic variation.	0.623035728803737	0.490414452354216	0.5102863961167895	0.544641223897638	0.53491753	0.51108366	0.50961554	0.4185348	0.61572087	0.5786553	0.54718715	0.45415395	0.619474	0.4842328	0.4831772	0.4473416	0.65418017	0.57890636	0.6105881	0.52113646	0
glyburide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking glyburide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid glyburide. Take an alternate therapy.', 'Take glyburide with a reduced dose.', 'Take glyburide with an increased dose.']	Proceed taking glyburide as normal. There is no recommendation.	Individuals who are deficient in Glucose-6-Phosphate Dehydrogenase (G6PD) may be at increased risk of hemolysis when taking glyburide due to the potential oxidative stress caused by the medication. It is generally recommended to avoid glyburide in individuals with G6PD deficiency and to consider alternative medications that do not pose a similar risk of hemolysis. Close monitoring for signs of hemolytic anemia is also important if glyburide is used in these individuals.	0.6035650960537701	0.5059322248389749	0.38436230227362467	0.5244760656425697	0.6059896	0.63096577	0.44991803	0.61833054	0.63383937	0.58356655	0.41665685	0.6557786	0.6073046	0.55687624	0.45458207	0.6048238	0.5808816	0.5694796	0.4480128	0.5171899	0
glyburide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking glyburide? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid glyburide. Take an alternate therapy.', 'Take glyburide with a reduced dose.', 'Take glyburide with an increased dose.']	Proceed taking glyburide as normal. There is no recommendation.	Individuals who are indeterminate for G6PD deficiency may still carry a variant that could impact enzyme function. In the case of glyburide, which is metabolized by various enzymes including CYP2C9, individuals with G6PD variants could potentially experience increased sensitivity to the medication due to altered metabolism. Therefore, close monitoring for drug efficacy and adverse effects is recommended when prescribing glyburide to individuals with an indeterminate G6PD status.	0.674607140815321	0.3998292587178428	0.33707966123279814	0.5169886940304015	0.6791396	0.33047724	0.33726558	0.47975954	0.7239764	0.40882063	0.3365035	0.53870404	0.7556567	0.3728444	0.3463533	0.5512921	0.6084921	0.46678153	0.45682272	0.50095636	0
glyburide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking glyburide? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid glyburide. Take an alternate therapy.', 'Take glyburide with a reduced dose.', 'Take glyburide with an increased dose.']	Proceed taking glyburide as normal. There is no recommendation.	Individuals with G6PD deficiency may have an increased risk of hemolysis when taking medications like glyburide due to oxidative stress. Clinical guidance would recommend monitoring for signs of hemolysis such as pale skin, jaundice, or dark urine, and considering alternative medications that do not pose a risk to individuals with G6PD deficiency. Consultation with a healthcare provider experienced in pharmacogenomics is recommended to determine the most appropriate course of action for the individual.	0.4865883258420595	0.36733386981728566	0.3981281133812886	0.4738136432350568	0.6101893	0.48771554	0.4872537	0.51046246	0.54361105	0.4324181	0.42766428	0.5459828	0.5227006	0.42212665	0.39028063	0.5158472	0.5385193	0.38036668	0.46689287	0.46998602	0
glyburide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking glyburide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid glyburide. Take an alternate therapy.', 'Take glyburide with a reduced dose.', 'Take glyburide with an increased dose.']	Proceed taking glyburide as normal. There is no recommendation.	Individuals who are normal for G6PD enzyme activity are not expected to have any specific pharmacogenomic considerations related to glyburide use. However, other factors such as renal function, liver function, and overall health should be taken into account when prescribing and monitoring glyburide therapy. It is important for healthcare providers to individualize treatment based on the patient's overall clinical status.	0.6589825279988195	0.44756236119760623	0.32030727867000786	0.5877814826700413	0.48000196	0.45541766	0.2555867	0.6120627	0.4563985	0.3578021	0.21604638	0.6388023	0.4261992	0.2883242	0.21600156	0.5523091	0.51918286	0.49520373	0.36960807	0.5492379	1
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking halothane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking halothane as normal. There is no recommendation.', 'Take halothane with a reduced dose.', 'Take halothane with an increased dose.']	Avoid halothane. Take an alternate therapy.	Individuals who are Malignant Hyperthermia Susceptibility (MHS) positive for RYR1 gene and uncertain for CACNA1S should avoid halothane due to the potential risk of triggering malignant hyperthermia (MH) in susceptible individuals. Halothane is a known trigger of MH, a potentially life-threatening condition associated with certain genetic variants. It is crucial for these individuals to inform their healthcare providers about their genetic status to ensure safe anesthesia management.	0.6687589431325262	0.5125833701259792	0.436373501116472	0.47015129068502	0.72951937	0.6434366	0.5418251	0.5818874	0.7584359	0.5877565	0.4985808	0.56481767	0.6883355	0.47715402	0.41892657	0.52873784	0.67248964	0.593848	0.5662722	0.5415095	0
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking halothane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking halothane as normal. There is no recommendation.', 'Take halothane with a reduced dose.', 'Take halothane with an increased dose.']	Avoid halothane. Take an alternate therapy.	Individuals who are Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S are at high risk for developing malignant hyperthermia (MH) when exposed to trigger agents like halothane during anesthesia. Clinical guidance would recommend avoiding the use of halothane and opting for alternative anesthetics in individuals with these genetic susceptibilities to reduce the risk of MH crisis and associated complications during surgical procedures. It is essential to inform healthcare providers about these genetic vulnerabilities to ensure safe anesthesia management.	0.6859286169283111	0.5125833701259792	0.436373501116472	0.4793585493421809	0.8206262	0.6434366	0.5418251	0.6325773	0.79458696	0.5877565	0.4985808	0.536007	0.727772	0.47715402	0.41892657	0.4681581	0.6517331	0.593848	0.5662722	0.50149626	1
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking halothane? Give a 2-3 sentence summary.	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid halothane. Take an alternate therapy.', 'Take halothane with a reduced dose.', 'Take halothane with an increased dose.']	Proceed taking halothane as normal. There is no recommendation.	Individuals with uncertain susceptibility for RYR1 and no result for CACNA1S should exercise caution when considering the use of halothane due to the potential risk of malignant hyperthermia (MH), a serious adverse reaction associated with these genetic variants. Precautionary measures such as using alternative anesthetic agents or performing MH testing prior to administration of halothane may be considered. Consultation with a genetic counselor or a healthcare provider with expertise in pharmacogenomics is recommended to guide clinical decision-making.	0.7164868078416566	0.43087132781590964	0.37226282698796437	0.5607954282426454	0.7188937	0.5207521	0.37978888	0.5590277	0.7849885	0.39891043	0.40849724	0.5490268	0.59143794	0.3723084	0.32514384	0.5031039	0.72595286	0.4512371	0.41108957	0.54919773	0
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking halothane? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking halothane as normal. There is no recommendation.', 'Take halothane with a reduced dose.', 'Take halothane with an increased dose.']	Avoid halothane. Take an alternate therapy.	For individuals who are No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S, caution should be exercised when considering the use of halothane, a known trigger for malignant hyperthermia (MH). Given the inconclusive genetic testing results, it is recommended to consider alternative anesthetics that do not pose a risk of triggering MH in individuals with unknown genetic susceptibility to the condition. Consulting with a healthcare provider or a pharmacogenomics specialist for personalized recommendations is advisable.	0.7302231081739301	0.5192424969053808	0.4447830076105678	0.5270444221872068	0.8184364	0.6295587	0.53317004	0.63250065	0.8358469	0.5611591	0.46712592	0.5920049	0.79338866	0.45054677	0.39339378	0.51499724	0.73140574	0.57862145	0.5561028	0.534467	0
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking hydrocodone? Give a 2-3 sentence summary.	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	['Avoid hydrocodone. Take an alternate therapy.', 'Take hydrocodone with a reduced dose.', 'Take hydrocodone with an increased dose.']	Proceed taking hydrocodone as normal. There is no recommendation.	Individuals who are Ultrarapid Metabolizers (UMs) with an activity score of ≥5 for CYP2D6 may metabolize hydrocodone rapidly, potentially leading to subtherapeutic levels and reduced effectiveness. Providers may consider alternative pain management strategies or adjusting the dose and closely monitoring for efficacy and adverse effects when prescribing hydrocodone to UMs with high CYP2D6 activity scores.	0.4870990493129289	0.6161507282885375	0.5686107654364894	0.49861178999456823	0.39223084	0.58620346	0.42646375	0.4989807	0.6469775	0.7300503	0.63213	0.57269007	0.5922527	0.7018526	0.6028943	0.53454226	0.5041174	0.798659	0.62215155	0.5420503	0
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking hydrocodone? Give a 2-3 sentence summary.	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	['Avoid hydrocodone. Take an alternate therapy.', 'Take hydrocodone with a reduced dose.', 'Take hydrocodone with an increased dose.']	Proceed taking hydrocodone as normal. There is no recommendation.	Individuals who are Ultrarapid Metabolizers (UMs) for CYP2D6, like in the case with an activity score of 2.5, may metabolize drugs, such as hydrocodone, at a faster rate than normal. This can potentially lead to subtherapeutic levels of the medication, resulting in reduced efficacy. Close monitoring for efficacy and potential adverse effects is recommended to ensure appropriate dosing and treatment outcomes.	0.3627825903622182	0.6161507282885375	0.5686107654364894	0.4017349432040361	0.33046734	0.58620346	0.42646375	0.44103384	0.55642265	0.7300503	0.63213	0.50180143	0.43654904	0.7018526	0.6028943	0.44843143	0.4930827	0.798659	0.62215155	0.5549703	0
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking hydrocodone? Give a 2-3 sentence summary.	Use hydrocodone label recommended age- or weight-specific dosing.	['Avoid hydrocodone. Take an alternate therapy.', 'Take hydrocodone with a reduced dose.', 'Take hydrocodone with an increased dose.']	Proceed taking hydrocodone as normal. There is no recommendation.	For a Normal Metabolizer with an activity score of 1.5 for CYP2D6 taking hydrocodone, they are expected to metabolize hydrocodone at a normal rate. This individual may achieve the expected therapeutic effect and toxicity profile with standard dosing of hydrocodone, although careful monitoring for efficacy and side effects is always recommended. It is important to consider other factors that may influence drug response, such as drug-drug interactions and individual patient characteristics.	0.5251122290495764	0.6090451225031737	0.6433887561233885	0.5774645085916946	0.51465	0.47603956	0.54207224	0.47331378	0.52191	0.66232723	0.63483906	0.55704784	0.50813437	0.7024995	0.5987571	0.5343997	0.50242287	0.67024654	0.6824866	0.591559	1
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking hydrocodone? Give a 2-3 sentence summary.	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	['Avoid hydrocodone. Take an alternate therapy.', 'Take hydrocodone with a reduced dose.', 'Take hydrocodone with an increased dose.']	Proceed taking hydrocodone as normal. There is no recommendation.	Individuals who are Ultrarapid Metabolizers with a CYP2D6 activity score of ≥6.0 may metabolize hydrocodone more rapidly than normal, potentially leading to reduced efficacy or inadequate pain relief. Clinicians should consider alternative pain management strategies, including monitoring for efficacy and potential adverse effects, adjusting dosage if necessary, or opting for a different medication with a more predictable response in individuals with this pharmacogenomic profile.	0.5071650201806801	0.6161507282885375	0.5686107654364894	0.5137084647208682	0.42098963	0.58620346	0.42646375	0.5132597	0.61634123	0.7300503	0.63213	0.5258886	0.6095658	0.7018526	0.6028943	0.52966845	0.58901864	0.798659	0.62215155	0.62697357	0
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking hydroxychloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid hydroxychloroquine. Take an alternate therapy.', 'Take hydroxychloroquine with a reduced dose.', 'Take hydroxychloroquine with an increased dose.']	Proceed taking hydroxychloroquine as normal. There is no recommendation.	Individuals who are Variable for G6PD (Glucose-6-Phosphate Dehydrogenase) may be at an increased risk of hemolytic anemia when taking medications like hydroxychloroquine that can induce oxidative stress. Monitoring for signs of hemolysis, such as fatigue, pale skin, and dark-colored urine, is recommended if hydroxychloroquine is prescribed to someone with G6PD deficiency. Consulting with a healthcare provider or a clinical pharmacist before initiating treatment is crucial to weigh the potential benefits versus risks and consider alternative treatments if needed.	0.614882879288506	0.45205065480352546	0.3323417258016147	0.4562708299436522	0.4823366	0.5309878	0.31695506	0.43522802	0.5319402	0.42106065	0.23939104	0.55991787	0.58665407	0.38040987	0.23393212	0.49739283	0.51437914	0.52370197	0.3827801	0.47634572	0
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking hydroxychloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid hydroxychloroquine. Take an alternate therapy.', 'Take hydroxychloroquine with a reduced dose.', 'Take hydroxychloroquine with an increased dose.']	Proceed taking hydroxychloroquine as normal. There is no recommendation.	For individuals who are normal for G6PD (glucose-6-phosphate dehydrogenase) and require treatment with hydroxychloroquine, there is generally no increased risk of hemolysis or other adverse effects associated with the medication. However, it is still recommended to monitor for any signs of drug-related toxicity while on hydroxychloroquine therapy, as per standard clinical practice. Close monitoring and adherence to standard dosing guidelines are important to ensure the safe and effective use of hydroxychloroquine in individuals normal for G6PD.	0.5711729528482247	0.3887950861137486	0.25870312161007675	0.5909967190293627	0.524713	0.39236608	0.19392107	0.6491766	0.46367487	0.257026	0.12544477	0.6427363	0.41621408	0.14875	0.05898493	0.62097144	0.63071495	0.46030128	0.32393625	0.54442567	1
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking hydroxychloroquine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid hydroxychloroquine. Take an alternate therapy.', 'Take hydroxychloroquine with a reduced dose.', 'Take hydroxychloroquine with an increased dose.']	Proceed taking hydroxychloroquine as normal. There is no recommendation.	For individuals who are indeterminate for G6PD deficiency, caution should be exercised when considering the use of hydroxychloroquine, as this medication has the potential to cause hemolysis in individuals with G6PD deficiency. Close monitoring for signs and symptoms of hemolysis should be implemented if hydroxychloroquine is prescribed, and alternative treatment options may be considered based on individual risk assessment. Consulting with a healthcare provider knowledgeable in pharmacogenomics is recommended to make an informed decision regarding the use of hydroxychloroquine in this population.	0.6169242717809585	0.3572291636238882	0.2946983749619397	0.5198076278532576	0.4929275	0.24435943	0.266636	0.61094767	0.6325054	0.2771159	0.21064825	0.6066081	0.5308862	0.20778732	0.14779188	0.5830343	0.5762225	0.45534867	0.41669604	0.5174932	0
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking hydroxychloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid hydroxychloroquine. Take an alternate therapy.', 'Take hydroxychloroquine with a reduced dose.', 'Take hydroxychloroquine with an increased dose.']	Proceed taking hydroxychloroquine as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) may be at an increased risk of hemolysis when taking hydroxychloroquine. It is important to consider alternative treatments or closely monitor for signs of hemolysis if hydroxychloroquine is necessary. Consultation with a healthcare provider, such as a pharmacist or genetic counselor, can help guide clinical decision-making for individuals with G6PD deficiency considering hydroxychloroquine therapy.	0.5698259157224737	0.45205065480352546	0.3323417258016147	0.4897830362321996	0.53150874	0.5309878	0.31695506	0.6054378	0.5315824	0.42106065	0.23939104	0.6190545	0.48933133	0.38040987	0.23393212	0.5691087	0.47829798	0.52370197	0.3827801	0.4962618	0
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking ibuprofen? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid ibuprofen. Take an alternate therapy.', 'Take ibuprofen with a reduced dose.', 'Take ibuprofen with an increased dose.']	Proceed taking ibuprofen as normal. There is no recommendation.	For individuals who are Normal Metabolizers with an activity score of 2.0 for CYP2C9, they are expected to metabolize ibuprofen at a normal rate. This suggests that standard dosing of ibuprofen should be effective and well-tolerated in this population, without a need for dose adjustments based on CYP2C9 metabolism status. It is still important to monitor for potential side effects and drug interactions, as with any medication.	0.39494124575692	0.4006584357188238	0.4396917121283619	0.5495472520789918	0.39018667	0.32480732	0.31108817	0.44956303	0.34843683	0.35875928	0.24688198	0.44514093	0.37136897	0.33359322	0.30585048	0.4933519	0.39278948	0.4845922	0.44641066	0.56442314	1
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking ibuprofen? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid ibuprofen. Take an alternate therapy.', 'Take ibuprofen with a reduced dose.', 'Take ibuprofen with an increased dose.']	Proceed taking ibuprofen as normal. There is no recommendation.	For individuals who are Intermediate Metabolizers with an activity score of 1.5 for CYP2C9, they may be at an increased risk of experiencing adverse reactions to medications metabolized by this enzyme, such as ibuprofen. It is recommended to consider alternative pain relievers with different metabolic pathways or adjust the dosage of ibuprofen based on individual factors and monitoring for potential side effects. Consulting with a healthcare provider or a pharmacogenomics expert can help personalize the treatment plan for optimal safety and efficacy.	0.3956267124675435	0.4006584357188238	0.4396917121283619	0.4558536954704732	0.2767073	0.32480732	0.31108817	0.40970874	0.31590074	0.35875928	0.24688198	0.45609817	0.28717846	0.33359322	0.30585048	0.4836943	0.42375785	0.4845922	0.44641066	0.5891333	0
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking ibuprofen? Give a 2-3 sentence summary.	No recommendation	['Avoid ibuprofen. Take an alternate therapy.', 'Take ibuprofen with a reduced dose.', 'Take ibuprofen with an increased dose.']	Proceed taking ibuprofen as normal. There is no recommendation.	Individuals who are classified as Indeterminate for CYP2C9 may have variable responses to drugs metabolized by this enzyme, such as ibuprofen. Therefore, it is recommended to consider personalized dosing based on individual response and potential drug interactions. Close monitoring for side effects or reduced efficacy of ibuprofen may be necessary in these individuals. Consulting with a healthcare provider or a clinical pharmacist for personalized guidance is advisable.	0.25802765653552223	0.48599801094480516	0.2182767175546251	0.44289918806509043	0.12096729	0.23385403	0.100331865	0.41192865	0.057477616	0.09324747	0.015746238	0.4392571	-0.007547713	0.27112207	0.069338076	0.43406272	0.33004135	0.5637174	0.40936735	0.5919316	0
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking ibuprofen? Give a 2-3 sentence summary.	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.	['Avoid ibuprofen. Take an alternate therapy.', 'Take ibuprofen with a reduced dose.', 'Take ibuprofen with an increased dose.']	Proceed taking ibuprofen as normal. There is no recommendation.	Individuals who are Intermediate Metabolizers of CYP2C9 may have a reduced ability to metabolize drugs such as ibuprofen. In this case, it is recommended to consider reducing the dose of ibuprofen to avoid potential adverse effects related to drug accumulation. Close monitoring for signs of toxicity or reduced efficacy may also be necessary.	0.4379973223066389	0.39285660678716616	0.4442933924759782	0.443607567129835	0.4762643	0.4101101	0.34259138	0.4630426	0.34201774	0.3405758	0.22255297	0.46131918	0.3612772	0.3271477	0.30738145	0.4599115	0.40695792	0.39364275	0.39321008	0.5381141	0
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine? Give a 2-3 sentence summary.	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking imipramine as normal. There is no recommendation.', 'Take imipramine with a reduced dose.', 'Take imipramine with an increased dose.']	Avoid imipramine. Take an alternate therapy.	For an individual who is an Ultrarapid Metabolizer for CYP2D6 and an Intermediate Metabolizer for CYP2C19, taking imipramine may require closer monitoring and potential dosage adjustments. The increased metabolism of imipramine due to CYP2D6 Ultrarapid Metabolism may necessitate higher dosages to achieve therapeutic effects, while the Intermediate Metabolism of CYP2C19 may influence the drug's metabolism and efficacy. Consulting with a healthcare provider or a pharmacogenomics expert for personalized dosing recommendations is advisable to optimize treatment outcomes and minimize potential adverse effects.	0.730118236722374	0.7450422613076159	0.7134930859317925	0.6137186511040953	0.59689766	0.64964586	0.5529227	0.4742053	0.6203137	0.65750116	0.5660723	0.5678037	0.49235854	0.56931394	0.53625494	0.50858593	0.5915652	0.6534099	0.5688579	0.51810074	0
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid imipramine. Take an alternate therapy.', 'Take imipramine with a reduced dose.', 'Take imipramine with an increased dose.']	Proceed taking imipramine as normal. There is no recommendation.	For a person who is a Normal Metabolizer for CYP2D6 and an Intermediate Metabolizer for CYP2C19, when considering taking imipramine, caution is advised as both enzymes are involved in imipramine metabolism. Close monitoring for potential adverse effects or reduced efficacy may be warranted, and dosage adjustments may be needed based on individual response to avoid therapeutic failure or toxicity. Consulting with a healthcare provider with expertise in pharmacogenomics is recommended to personalize the treatment plan.	0.40178911665367967	0.4908741748286966	0.5123352083304534	0.6515846426411326	0.35334656	0.38066065	0.41784343	0.5169967	0.31659785	0.5019479	0.3961862	0.5912373	0.31146553	0.4548648	0.47493827	0.53993094	0.5154525	0.5462582	0.5904767	0.63713616	0
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	['Proceed taking imipramine as normal. There is no recommendation.', 'Take imipramine with a reduced dose.', 'Take imipramine with an increased dose.']	Avoid imipramine. Take an alternate therapy.	Individuals who are Ultrarapid Metabolizers with an activity score of ≥4.0 for CYP2D6 are likely to metabolize imipramine faster than normal, potentially leading to lower drug levels and reduced therapeutic effectiveness. Given the lack of CYP2C19 genotyping results, caution should be exercised as variations in metabolism could impact imipramine's efficacy and safety. Consulting with healthcare providers for personalized dosing and monitoring is recommended to optimize treatment outcomes.	0.5882473870931288	0.5578426613906001	0.5193132654916947	0.5898056762078356	0.61645424	0.44053555	0.40628043	0.47741795	0.6135002	0.32613507	0.3218074	0.5253662	0.5680187	0.40993163	0.41416633	0.53987044	0.549835	0.4719266	0.4182336	0.60033685	0
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	['Proceed taking imipramine as normal. There is no recommendation.', 'Take imipramine with a reduced dose.', 'Take imipramine with an increased dose.']	Avoid imipramine. Take an alternate therapy.	For an individual who is an Ultrarapid Metabolizer for CYP2D6 with an activity score of 3.0 and Indeterminate for CYP2C19, caution is advised when taking imipramine. Ultrarapid Metabolizers may metabolize imipramine more quickly, potentially leading to reduced drug efficacy or increased risk of side effects. Close monitoring for therapeutic response and adverse effects is recommended, with possible dosage adjustments based on individual response and tolerability. Consulting with a healthcare provider or a pharmacist experienced in pharmacogenomics can help tailor the treatment plan for this individual.	0.6097621530007554	0.5578426613906001	0.5193132654916947	0.6272757006943539	0.70461327	0.44053555	0.40628043	0.50981647	0.6732171	0.32613507	0.3218074	0.5557811	0.6511139	0.40993163	0.41416633	0.5475673	0.59095806	0.4719266	0.4182336	0.55357814	0
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking isoflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking isoflurane as normal. There is no recommendation.', 'Take isoflurane with a reduced dose.', 'Take isoflurane with an increased dose.']	Avoid isoflurane. Take an alternate therapy.	For someone with uncertain susceptibility for RYR1 and malignant hyperthermia susceptibility for CACNA1S, caution should be exercised when considering the use of isoflurane due to the risk of triggering malignant hyperthermia (MH) in susceptible individuals. Close monitoring for signs of MH, such as unexplained fever, muscle rigidity, and acidosis, is essential during anesthesia with isoflurane in this population. It is recommended to consult with a healthcare provider knowledgeable in pharmacogenomics and MH susceptibility before proceeding with isoflurane administration.	0.6445134411084827	0.4495130904628476	0.3617350067114547	0.5552544940363056	0.69019574	0.53825134	0.442722	0.60717106	0.7390254	0.4140642	0.36374617	0.62887526	0.63836616	0.37577188	0.38502988	0.530835	0.6189969	0.5462868	0.524697	0.5269715	0
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking isoflurane? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking isoflurane as normal. There is no recommendation.', 'Take isoflurane with a reduced dose.', 'Take isoflurane with an increased dose.']	Avoid isoflurane. Take an alternate therapy.	For individuals with a No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S, there is insufficient genetic information to definitively predict their risk of malignant hyperthermia (MH) during exposure to isoflurane. In such cases, it is recommended to closely monitor for signs and symptoms of MH and consider alternative anesthetic agents or approaches in consultation with a healthcare provider familiar with MH management. Additionally, proper anesthesia precautions and protocols should be followed for all patients regardless of genetic testing results to mitigate the risk of adverse events during anesthesia.	0.6788657868317021	0.45614978682644847	0.37056933441858364	0.47144769367350875	0.61270386	0.5214989	0.43131432	0.46829325	0.73484486	0.3956143	0.33795953	0.5246324	0.7589537	0.3587199	0.36191645	0.5213366	0.65054846	0.5345819	0.5182881	0.54092544	0
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking isoflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking isoflurane as normal. There is no recommendation.', 'Take isoflurane with a reduced dose.', 'Take isoflurane with an increased dose.']	Avoid isoflurane. Take an alternate therapy.	For an individual who is a Malignant Hyperthermia Susceptibility (MHS) for RYR1 and uncertain for CACNA1S, caution is advised when considering the use of isoflurane due to the potential risk of triggering a malignant hyperthermia (MH) crisis. It is recommended to select alternative anesthetics or employ protective measures such as preoperative genetic testing and monitoring for early signs of MH when isoflurane is needed. Consultation with a specialized anesthesia team familiar with managing MH is also recommended when planning anesthesia for individuals with MHS.	0.7058409334137309	0.4495130904628476	0.3617350067114547	0.570232898419972	0.80747956	0.53825134	0.442722	0.6369234	0.80281466	0.4140642	0.36374617	0.572013	0.7285695	0.37577188	0.38502988	0.5518113	0.652721	0.5462868	0.524697	0.5700798	0
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking isoflurane? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid isoflurane. Take an alternate therapy.', 'Take isoflurane with a reduced dose.', 'Take isoflurane with an increased dose.']	Proceed taking isoflurane as normal. There is no recommendation.	For a patient who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S genes with regards to taking isoflurane, it is recommended to consider alternative anesthetic agents or consult with a healthcare provider specializing in pharmacogenomics. The uncertain findings in CACNA1S may indicate potential variability in response to isoflurane due to individual genetic factors, necessitating personalized dosing or monitoring during anesthesia administration.	0.7402977972045909	0.40895507371181516	0.3593131329637432	0.5576147241960577	0.7229203	0.47162196	0.31851384	0.506574	0.77861834	0.30084196	0.31226307	0.5513187	0.69125307	0.38888192	0.3407664	0.42990473	0.7865936	0.4430562	0.40123078	0.552312	0
ivacaftor	CFTR	What would be the clinical guidance for someone who is ivacaftor responsive in CF patients for CFTR with regards to taking ivacaftor? Give a 2-3 sentence summary.	Use ivacaftor according to the product label	['Avoid ivacaftor. Take an alternate therapy.', 'Take ivacaftor with a reduced dose.', 'Take ivacaftor with an increased dose.']	Proceed taking ivacaftor as normal. There is no recommendation.	There is strong evidence to support the use of ivacaftor in cystic fibrosis (CF) patients who are responsive to it based on their CFTR gene mutation. Clinical guidance suggests regular monitoring of lung function, weight, and symptoms to assess treatment response and potential side effects. Additionally, genetic testing should be performed prior to starting ivacaftor to confirm the presence of responsive mutations.	0.6044610726371296	0.7318675888562056	0.7403879963197788	0.5754589903396974	0.54599	0.6627078	0.682622	0.47221676	0.50723046	0.7752967	0.7427501	0.57263786	0.3979421	0.48500445	0.42284766	0.51660395	0.61257434	0.6062356	0.7029137	0.4604538	0
ivacaftor	CFTR	What would be the clinical guidance for someone who is ivacaftor non-responsive in CF patients for CFTR with regards to taking ivacaftor? Give a 2-3 sentence summary.	Ivacaftor is not recommended	['Proceed taking ivacaftor as normal. There is no recommendation.', 'Take ivacaftor with a reduced dose.', 'Take ivacaftor with an increased dose.']	Avoid ivacaftor. Take an alternate therapy.	For individuals with cystic fibrosis who do not respond to ivacaftor due to specific CFTR mutations, alternative treatment options should be considered based on the patient's genotype and overall health status. Clinical guidance may involve exploring other CFTR modulators or supportive therapies to manage symptoms and improve quality of life in these individuals. It is crucial to work closely with a healthcare provider specializing in cystic fibrosis to determine the most appropriate treatment strategy for each patient.	0.5277382764342312	0.6982744309840512	0.72880598182411	0.569738628252065	0.4463074	0.72865677	0.6260349	0.53507227	0.45908117	0.7701304	0.64781475	0.49789378	0.36488965	0.57497895	0.5446182	0.5210608	0.5509197	0.8849492	0.6666561	0.60069364	0
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking kanamycin as normal. There is no recommendation.', 'Take kanamycin with a reduced dose.', 'Take kanamycin with an increased dose.']	Avoid kanamycin. Take an alternate therapy.	Individuals with increased risk of aminoglycoside-induced hearing loss due to specific variants in the MT-RNR1 gene may benefit from alternative antibiotic options or personalized dosing strategies for kanamycin to minimize the risk of ototoxicity. It is recommended to consider pharmacogenetic testing to identify these high-risk individuals prior to initiating treatment with aminoglycosides like kanamycin and to closely monitor for signs of hearing impairment during treatment. Collaborating with a healthcare provider experienced in pharmacogenomics can help guide treatment decisions for individuals with actionable genetic variants.	0.6687162429200414	0.49411530553905875	0.4267016598194589	0.5551803446895807	0.63737607	0.6088733	0.48264697	0.5376553	0.6834276	0.51080847	0.47089657	0.5220483	0.6619788	0.42772728	0.41820803	0.42217803	0.5731581	0.6533365	0.5447252	0.66497064	0
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid kanamycin. Take an alternate therapy.', 'Take kanamycin with a reduced dose.', 'Take kanamycin with an increased dose.']	Proceed taking kanamycin as normal. There is no recommendation.	For individuals with normal risk of aminoglycoside-induced hearing loss due to MT-RNR1 variations, close monitoring of hearing function is recommended when taking kanamycin. Regular monitoring of renal function is also advised, as dose adjustments may be necessary based on kidney function to minimize the risk of toxicity. If signs of hearing loss develop, prompt discontinuation of kanamycin is crucial to prevent irreversible damage.	0.6337938590222708	0.4442617705364379	0.42469025246809405	0.5677854947813484	0.65088993	0.45152903	0.4905007	0.5780566	0.6733653	0.510667	0.52820104	0.6638255	0.69187415	0.46866763	0.48679948	0.5104989	0.63762826	0.51939267	0.57403207	0.5807088	0
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid kanamycin. Take an alternate therapy.', 'Take kanamycin with a reduced dose.', 'Take kanamycin with an increased dose.']	Proceed taking kanamycin as normal. There is no recommendation.	Individuals with a variation in the MT-RNR1 gene may have an uncertain risk of aminoglycoside-induced hearing loss, particularly when taking medications like kanamycin. Clinical guidance would recommend considering alternative medications or closely monitoring for signs of hearing loss when using aminoglycosides in individuals with this genetic variant to mitigate the potential risk. Genetic testing may also be beneficial to guide treatment decisions.	0.5782640287130222	0.4442617705364379	0.42469025246809405	0.4750339484627865	0.48070693	0.45152903	0.4905007	0.4698949	0.5745305	0.510667	0.52820104	0.4911068	0.6451037	0.46866763	0.48679948	0.33682647	0.6029893	0.51939267	0.57403207	0.515683	0
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking lansoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.	['Proceed taking lansoprazole as normal. There is no recommendation.', 'Avoid lansoprazole. Take an alternate therapy.']	Take lansoprazole with an altered dose.	As a Rapid Metabolizer for CYP2C19, individuals may metabolize lansoprazole more quickly, leading to potentially reduced drug levels in the body and decreased therapeutic efficacy. Clinical guidance may include the need for higher lansoprazole doses or monitoring for treatment response to ensure adequate acid suppression in individuals with this metabolizer phenotype. Consulting a healthcare provider or a pharmacist for personalized dosing recommendations is recommended for individuals who are Rapid Metabolizers for CYP2C19 and are taking lansoprazole.	0.417242014717425	0.4618732254591509	0.4340223530824725	0.6747506726268018	0.46397775	0.5101036	0.40146247	0.60737205	0.48692012	0.43865693	0.4294069	0.5769083	0.36053482	0.39795923	0.36851606	0.5738644	0.36869112	0.52924126	0.40537262	0.6401551	1
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking lansoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking lansoprazole as normal. There is no recommendation.', 'Avoid lansoprazole. Take an alternate therapy.']	Take lansoprazole with an altered dose.	For someone who is a Likely Poor Metabolizer for CYP2C19, they are at an increased risk of having higher levels of lansoprazole in their body due to slower metabolism. It is recommended to reduce the dose of lansoprazole and monitor for potential side effects or toxicity. Consulting with a healthcare provider or a pharmacist for individualized dosing recommendations based on pharmacogenomic results is advised to optimize therapy and avoid adverse effects.	0.4036975546153578	0.4415692772456328	0.4177318595080739	0.683294828377872	0.3779296	0.4223595	0.40915698	0.5673959	0.42408502	0.3880214	0.42315438	0.5647142	0.39772284	0.3922678	0.41773152	0.5447131	0.45280525	0.49732292	0.37711364	0.6852224	0
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking lansoprazole? Give a 2-3 sentence summary.	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	['Proceed taking lansoprazole as normal. There is no recommendation.', 'Avoid lansoprazole. Take an alternate therapy.']	Take lansoprazole with an altered dose.	As an Ultrarapid Metabolizer for CYP2C19, individuals may metabolize lansoprazole more quickly than usual, potentially leading to reduced efficacy of the drug. It is advisable to monitor for therapeutic response and adjust the dosage accordingly to ensure adequate acid suppression. Consultation with a healthcare provider or a pharmacist knowledgeable in pharmacogenomics is recommended for personalized dosing recommendations.	0.39424672516027276	0.45711498228336384	0.38184739094618025	0.6936460383831777	0.540568	0.6346298	0.48931384	0.687007	0.47773862	0.6092481	0.51846784	0.61828893	0.3621786	0.5226105	0.4483411	0.51648843	0.48320213	0.5466819	0.34637892	0.7417719	0
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking lansoprazole? Give a 2-3 sentence summary.	No recommendation	['Avoid lansoprazole. Take an alternate therapy.', 'Take lansoprazole with a reduced dose.', 'Take lansoprazole with an increased dose.']	Proceed taking lansoprazole as normal. There is no recommendation.	Individuals who are classified as Indeterminate for CYP2C19 metabolism may have unpredictable response to medications metabolized by this enzyme, such as lansoprazole. It is recommended to consider alternative medications or adjust the dosage based on other factors, like clinical response and potential side effects, in consultation with a healthcare provider to optimize therapy effectiveness and minimize adverse reactions.	0.2666474710827412	0.4679618523456921	0.23704759217871807	0.5419866801231057	0.15348154	0.315339	0.15860732	0.5683525	0.0802179	0.196159	0.08397603	0.5944221	-0.04236966	0.29971334	0.08771375	0.5206385	0.33957836	0.53281885	0.3946633	0.5852604	0
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking lornoxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid lornoxicam. Take an alternate therapy.', 'Take lornoxicam with a reduced dose.', 'Take lornoxicam with an increased dose.']	Proceed taking lornoxicam as normal. There is no recommendation.	For someone classified as a Normal Metabolizer with an activity score of 2.0 for CYP2C9, they are likely to have normal metabolism of lornoxicam. It is recommended to follow standard dosing guidelines for lornoxicam in this individual as no dose adjustments are typically necessary based on CYP2C9 metabolism status in Normal Metabolizers.	0.34827642445717916	0.41373041902339813	0.4277075831363146	0.6552356268429892	0.4319959	0.38846064	0.346195	0.6070306	0.4136731	0.47035366	0.31686828	0.6062095	0.32713854	0.3714915	0.39143813	0.5133095	0.32474047	0.443077	0.45283318	0.59435874	1
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking lornoxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid lornoxicam. Take an alternate therapy.', 'Take lornoxicam with a reduced dose.', 'Take lornoxicam with an increased dose.']	Proceed taking lornoxicam as normal. There is no recommendation.	For an individual who is an Intermediate Metabolizer of CYP2C9 with an activity score of 1.5 and considering taking lornoxicam, caution is advised. Lornoxicam is primarily metabolized by CYP2C9, and reduced enzyme activity may lead to higher drug levels and an increased risk of adverse effects. Close monitoring for side effects and potentially adjusting the dose under medical supervision may be necessary to ensure safe and effective use of lornoxicam in individuals with this genotype.	0.361851749716535	0.41373041902339813	0.4277075831363146	0.6284611851773552	0.35933802	0.38846064	0.346195	0.60967267	0.35950413	0.47035366	0.31686828	0.65119755	0.33251318	0.3714915	0.39143813	0.507889	0.3369564	0.443077	0.45283318	0.57921994	0
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking lornoxicam? Give a 2-3 sentence summary.	No recommendation	['Avoid lornoxicam. Take an alternate therapy.', 'Take lornoxicam with a reduced dose.', 'Take lornoxicam with an increased dose.']	Proceed taking lornoxicam as normal. There is no recommendation.	For individuals who are Indeterminate for CYP2C9 genotype and considering taking lornoxicam, it is recommended to start with a lower dose and monitor for signs of drug efficacy and toxicity. Close clinical monitoring and dose adjustments based on individual response may be necessary to optimize therapeutic outcomes and minimize potential adverse effects, as there may be variability in drug metabolism in individuals with Indeterminate CYP2C9 status. Consulting with a healthcare provider or a pharmacist knowledgeable in pharmacogenomics can help guide personalized treatment decisions.	0.2716260749495284	0.47006597786454063	0.24039404793535188	0.6391092254780583	0.20678578	0.39879048	0.2583364	0.6191008	0.13344166	0.29928493	0.2044519	0.655579	0.009345565	0.3430517	0.12544459	0.5441114	0.27568	0.49462235	0.3532696	0.6225723	0
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking lornoxicam? Give a 2-3 sentence summary.	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.	['Avoid lornoxicam. Take an alternate therapy.', 'Take lornoxicam with a reduced dose.', 'Take lornoxicam with an increased dose.']	Proceed taking lornoxicam as normal. There is no recommendation.	Individuals who are Intermediate Metabolizers with an activity score of 1.0 for CYP2C9 may require a dosage adjustment or closer monitoring when taking lornoxicam. This is because lornoxicam is primarily metabolized by CYP2C9, and reduced enzyme activity may lead to increased drug levels and potential risk of adverse effects. Healthcare providers may consider starting with a lower dose of lornoxicam and titrating based on clinical response and tolerance in this population.	0.4331616138022991	0.4080056542722781	0.4421674292264462	0.6167968899515393	0.5129421	0.52421063	0.45007896	0.5512733	0.51095295	0.5286274	0.3690702	0.6224471	0.52430785	0.3636173	0.38535556	0.48596603	0.46194908	0.3587416	0.42705807	0.5604449	0
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking lovastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid lovastatin. Take an alternate therapy.', 'Take lovastatin with a reduced dose.', 'Take lovastatin with an increased dose.']	Proceed taking lovastatin as normal. There is no recommendation.	For individuals who are categorized as Normal Function for SLCO1B1, it is generally safe to take lovastatin at standard doses without a need for dose adjustments. However, regular monitoring for adverse effects and lipid-lowering efficacy is recommended due to individual variability in response to statin therapy. It is important to consult with a healthcare provider for personalized guidance on lovastatin therapy based on individual health considerations and concurrent medications.	0.3939738536163174	0.3680136707653139	0.3441995673652946	0.6707974300289528	0.51631886	0.28405085	0.38512143	0.6288981	0.4608158	0.46173477	0.34138277	0.7766434	0.38778293	0.30372772	0.26445478	0.6751486	0.54039	0.52720636	0.58332014	0.65972817	1
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking lovastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid lovastatin. Take an alternate therapy.', 'Take lovastatin with a reduced dose.', 'Take lovastatin with an increased dose.']	Proceed taking lovastatin as normal. There is no recommendation.	Individuals with increased function for SLCO1B1 may be at an increased risk of experiencing statin-induced myopathy when taking lovastatin. Lower initial doses and close monitoring for muscle symptoms are recommended in these individuals. Consideration of alternative statins with lower risk of myopathy may be appropriate based on individual patient characteristics.	0.30101582657310105	0.3680136707653139	0.3441995673652946	0.5481973285451103	0.36486512	0.28405085	0.38512143	0.54691315	0.31196764	0.46173477	0.34138277	0.61131257	0.25753596	0.30372772	0.26445478	0.541933	0.34900072	0.52720636	0.58332014	0.5427467	0
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking lovastatin? Give a 2-3 sentence summary.	No recommendation	['Avoid lovastatin. Take an alternate therapy.', 'Take lovastatin with a reduced dose.', 'Take lovastatin with an increased dose.']	Proceed taking lovastatin as normal. There is no recommendation.	For individuals who are indeterminate for SLCO1B1, there is a moderate risk of potential adverse effects when taking lovastatin. Clinical guidance may suggest considering alternative statin medications or starting lovastatin at a lower dose with close monitoring for any signs of muscle-related side effects. Personalized healthcare decisions should be made in consultation with a healthcare provider knowledgeable in pharmacogenomics.	0.2403032970284965	0.4506944890612066	0.200337886496929	0.6146353292398372	0.2052217	0.3070175	0.15847011	0.64810693	0.08381704	0.21312553	0.09796449	0.68326825	0.04056453	0.3272289	0.11403362	0.6250979	0.28191426	0.5263305	0.41636434	0.59432393	0
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking lovastatin? Give a 2-3 sentence summary.	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.	['Proceed taking lovastatin as normal. There is no recommendation.', 'Take lovastatin with a reduced dose.', 'Take lovastatin with an increased dose.']	Avoid lovastatin. Take an alternate therapy.	Individuals who are categorized as Possible Decreased Function for SLCO1B1 may be at an increased risk of experiencing statin-related myopathy when taking lovastatin. It is recommended to consider a lower starting dose of lovastatin and closely monitor for signs of muscle pain or weakness. Additionally, alternative statins with lower risk of myopathy such as pravastatin or rosuvastatin may be considered based on individual patient factors.	0.6659807859329792	0.7213938761137982	0.6558009763906334	0.6049880810085353	0.6911738	0.716754	0.6497324	0.64335763	0.71084356	0.79426247	0.76160735	0.68673867	0.57556856	0.56785214	0.59017074	0.5429943	0.5553496	0.6932387	0.6043497	0.59790695	0
mafenide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking mafenide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid mafenide. Take an alternate therapy.', 'Take mafenide with a reduced dose.', 'Take mafenide with an increased dose.']	Proceed taking mafenide as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) should avoid taking mafenide, a medication used for treating burns, as it can lead to hemolytic anemia in this population. Mafenide is known to cause oxidative stress on red blood cells, which can exacerbate hemolysis in individuals with G6PD deficiency. Therefore, it is important to consider alternative treatments for individuals with this genetic condition.	0.5621109240052322	0.48647954638521407	0.3775819350714695	0.49495987849727224	0.52546376	0.5759992	0.37785307	0.5495059	0.5269276	0.47978303	0.2654313	0.4458081	0.51575226	0.46378386	0.3401513	0.50520533	0.5289204	0.4833471	0.3955594	0.47887763	0
mafenide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking mafenide? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid mafenide. Take an alternate therapy.', 'Take mafenide with a reduced dose.', 'Take mafenide with an increased dose.']	Proceed taking mafenide as normal. There is no recommendation.	For individuals who are Indeterminate for G6PD deficiency, caution should be taken when considering the use of mafenide, a sulfonamide antibiotic. Regular monitoring for signs of hemolysis and laboratory testing for G6PD activity may be recommended before and during treatment with mafenide to ensure safe use in this population. Close collaboration with healthcare providers experienced in managing G6PD-related adverse events is essential to mitigate potential risks while optimizing therapeutic benefits.	0.6360803990948385	0.3795899424179429	0.3146545293281255	0.5794831710184107	0.5909846	0.21448557	0.221178	0.60631907	0.6216648	0.24836834	0.124411665	0.61949044	0.5969567	0.24246366	0.1924832	0.5350517	0.6412049	0.38702694	0.39681974	0.45422786	0
mafenide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking mafenide? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid mafenide. Take an alternate therapy.', 'Take mafenide with a reduced dose.', 'Take mafenide with an increased dose.']	Proceed taking mafenide as normal. There is no recommendation.	Individuals who are deficient in the enzyme glucose-6-phosphate dehydrogenase (G6PD) are at risk of hemolytic anemia when exposed to certain medications, including mafenide. Mafenide may trigger hemolysis in individuals with G6PD deficiency, and therefore alternative medications should be considered for this population to avoid complications. Consultation with a healthcare provider or pharmacist is recommended to discuss safer alternatives for individuals with G6PD deficiency.	0.40670262968206083	0.369260778890445	0.41209268652720676	0.49797194030468717	0.5917486	0.49657178	0.5036514	0.513018	0.57497346	0.48548	0.40020892	0.53108424	0.4414469	0.39984766	0.34765235	0.53123605	0.46596697	0.30615044	0.40768027	0.46942922	0
mafenide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking mafenide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid mafenide. Take an alternate therapy.', 'Take mafenide with a reduced dose.', 'Take mafenide with an increased dose.']	Proceed taking mafenide as normal. There is no recommendation.	For individuals who are normal for G6PD (Glucose-6-Phosphate Dehydrogenase), there is generally no specific contraindication for taking mafenide, an antibiotic commonly used to prevent or treat infections in burns. However, it is always important to consult with a healthcare provider before starting any new medication to ensure it is safe and appropriate based on individual health considerations and potential drug interactions.	0.5673985648003219	0.43123714569734845	0.2997913890209301	0.6403770881212347	0.46688816	0.4481534	0.23981701	0.59867704	0.42041	0.34508458	0.16066018	0.68998545	0.3352267	0.20597138	0.12792923	0.6121419	0.4687488	0.40791816	0.30661854	0.5707973	1
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking meloxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid meloxicam. Take an alternate therapy.', 'Take meloxicam with a reduced dose.', 'Take meloxicam with an increased dose.']	Proceed taking meloxicam as normal. There is no recommendation.	For an individual who is a Normal Metabolizer and has a CYP2C9 activity score of 2.0, they are likely to metabolize meloxicam at a normal rate. However, monitoring for potential side effects or altered response to meloxicam may be necessary due to the variability in CYP2C9 activity even among Normal Metabolizers. Close monitoring for both efficacy and toxicity of meloxicam is recommended based on individual response and clinical symptoms.	0.3337720113494669	0.4093567670951658	0.40235702608687696	0.5937091690711734	0.27541372	0.36293304	0.34451762	0.47931114	0.31988811	0.44117254	0.2936089	0.58163655	0.32126704	0.36278895	0.37953636	0.59220016	0.3113736	0.4726547	0.45383415	0.64404213	1
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking meloxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid meloxicam. Take an alternate therapy.', 'Take meloxicam with a reduced dose.', 'Take meloxicam with an increased dose.']	Proceed taking meloxicam as normal. There is no recommendation.	For an individual who is an Intermediate Metabolizer with an activity score of 1.5 for CYP2C9 and considering taking meloxicam, caution is advised. Due to reduced enzyme activity, this individual may metabolize meloxicam at a slower rate, leading to potential accumulation of the drug in the body and increased risk of adverse effects. Close monitoring for drug efficacy and side effects is recommended, and dose adjustments may be necessary to optimize therapy and minimize the risk of adverse events.	0.6785475304256153	0.6241105076865281	0.6760802183669804	0.5845858734075939	0.48278958	0.4756466	0.45348	0.55185354	0.5397632	0.6375218	0.4730623	0.5992241	0.56738424	0.61261976	0.6238072	0.57777375	0.5474182	0.6139773	0.5632675	0.57371205	0
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking meloxicam? Give a 2-3 sentence summary.	No recommendation	['Avoid meloxicam. Take an alternate therapy.', 'Take meloxicam with a reduced dose.', 'Take meloxicam with an increased dose.']	Proceed taking meloxicam as normal. There is no recommendation.	Individuals who are classified as Indeterminate for CYP2C9 metabolism may have a variable response to meloxicam. Close monitoring for drug efficacy and side effects is recommended when initiating meloxicam therapy. Consideration of alternate pain management options or dosing adjustments may be necessary based on individual response and clinical outcomes.	0.24390994874211153	0.45395168083906384	0.21922545101477975	0.5887911644718065	0.14171907	0.27544275	0.12379988	0.5001866	0.064867206	0.1511889	0.061338622	0.5436543	0.008900896	0.36191893	0.13929836	0.54322755	0.28233743	0.53668666	0.4205043	0.55562025	0
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking meloxicam? Give a 2-3 sentence summary.	Initiate therapy with 50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 7 days). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	['Proceed taking meloxicam as normal. There is no recommendation.', 'Avoid meloxicam. Take an alternate therapy.']	Take meloxicam with an altered dose.	Based on being an Intermediate Metabolizer with an activity score of 1.0 for CYP2C9, the individual may require a lower meloxicam dosage to reduce the risk of potential side effects such as increased drug concentrations and adverse events due to slower metabolism. Monitoring for drug efficacy and adverse effects is recommended, and consulting with a healthcare provider or a pharmacist for personalized dosing adjustments is advised.	0.7699147749234118	0.6420754538166199	0.6438447299175116	0.6613802824547944	0.68008727	0.5590076	0.53591454	0.4988922	0.8087223	0.53969234	0.6209737	0.48816723	0.7678807	0.5727233	0.5665212	0.53428805	0.7544327	0.6676766	0.5732453	0.69583255	0
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking mercaptopurine? Give a 2-3 sentence summary.	For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).	['Proceed taking mercaptopurine as normal. There is no recommendation.', 'Avoid mercaptopurine. Take an alternate therapy.']	Take mercaptopurine with an altered dose.	Individuals who are Normal Metabolizers for TPMT and Poor Metabolizers for NUDT15 are at increased risk of mercaptopurine toxicity. Clinical guidance would typically recommend alternative treatments or substantial dose reductions of mercaptopurine to minimize the risk of severe adverse reactions. Close monitoring for signs of toxicity and adjusting the medication regimen accordingly is also essential in this scenario.	0.6631894344009657	0.656033861424704	0.6531215378731485	0.6577590240812392	0.52635473	0.54011464	0.50656897	0.5696655	0.56753516	0.5443496	0.617	0.50126994	0.42534384	0.53400606	0.49136633	0.48020238	0.55061305	0.6409073	0.50744545	0.67605495	0
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine? Give a 2-3 sentence summary.	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.	['Proceed taking mercaptopurine as normal. There is no recommendation.', 'Avoid mercaptopurine. Take an alternate therapy.']	Take mercaptopurine with an altered dose.	For individuals who are Intermediate Metabolizers for both TPMT and NUDT15 and are considering taking mercaptopurine, it is recommended to exercise caution and closely monitor for potential adverse effects such as myelosuppression. Consideration should be given to reducing the starting dose of mercaptopurine and adjusting based on clinical response and side effects to optimize therapeutic outcomes while minimizing the risk of toxicity. Consulting with a healthcare provider experienced in pharmacogenomics is advisable for personalized treatment recommendations.	0.754035097434931	0.6875104304921226	0.6657776061987652	0.6745364707205416	0.5467541	0.5255369	0.47550333	0.5403739	0.67903054	0.5455124	0.6310689	0.47496384	0.6675684	0.63834155	0.6251917	0.5728984	0.60698175	0.5916299	0.47121668	0.6869032	0
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking mercaptopurine? Give a 2-3 sentence summary.	For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).	['Proceed taking mercaptopurine as normal. There is no recommendation.', 'Avoid mercaptopurine. Take an alternate therapy.']	Take mercaptopurine with an altered dose.	For an individual who is a Possible Intermediate Metabolizer for TPMT and a Poor Metabolizer for NUDT15, there is a significant risk of severe toxicity when taking mercaptopurine. Clinical guidance would typically involve avoiding or significantly reducing the dose of mercaptopurine due to the increased risk of adverse reactions. Close monitoring for signs of toxicity and considering alternative treatments may be necessary to optimize therapeutic outcomes and minimize harm.	0.6930058335137851	0.656033861424704	0.6531215378731485	0.6812258965600204	0.47727585	0.54011464	0.50656897	0.51286244	0.566155	0.5443496	0.617	0.4949962	0.45221686	0.53400606	0.49136633	0.5477383	0.526618	0.6409073	0.50744545	0.6641766	0
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking mercaptopurine? Give a 2-3 sentence summary.	For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).	['Proceed taking mercaptopurine as normal. There is no recommendation.', 'Avoid mercaptopurine. Take an alternate therapy.']	Take mercaptopurine with an altered dose.	For an individual who is a Poor Metabolizer for TPMT and a Normal Metabolizer for NUDT15, the clinical guidance for taking mercaptopurine would involve reducing the initial dose of mercaptopurine to minimize the risk of severe myelosuppression. Close monitoring for signs of toxicity and adjusting the dose based on tolerance and efficacy is crucial in this case to optimize the therapeutic outcome while minimizing adverse effects. Consulting with a healthcare provider experienced in pharmacogenomics is recommended to personalize the treatment plan for this individual.	0.7531146563203462	0.6824092340964264	0.678523228009069	0.6875390634131073	0.71835935	0.52621776	0.4666165	0.5637148	0.6716119	0.56850994	0.64690125	0.46844572	0.6584611	0.5993989	0.56710446	0.5603016	0.6268218	0.673325	0.5324691	0.6694277	0
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking methoxyflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking methoxyflurane as normal. There is no recommendation.', 'Take methoxyflurane with a reduced dose.', 'Take methoxyflurane with an increased dose.']	Avoid methoxyflurane. Take an alternate therapy.	For an individual with Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S, caution is advised when considering the use of methoxyflurane due to the potential risk of malignant hyperthermia (MH) reaction. Before administering methoxyflurane, it is recommended to consult with a healthcare provider experienced in managing MH susceptibility to assess the potential risks and benefits for the individual.	0.6514571371532051	0.4832833750282811	0.44367088102211133	0.5874707340944902	0.70784646	0.52831686	0.4143478	0.60199505	0.6826159	0.3992715	0.32240808	0.62577873	0.6194758	0.45769954	0.41020012	0.55898017	0.6508423	0.58519626	0.5607931	0.58276266	0
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking methoxyflurane? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking methoxyflurane as normal. There is no recommendation.', 'Take methoxyflurane with a reduced dose.', 'Take methoxyflurane with an increased dose.']	Avoid methoxyflurane. Take an alternate therapy.	Individuals who are No Result for both RYR1 and CACNA1S genes for Malignant Hyperthermia Susceptibility are typically considered to have a normal response to methoxyflurane, a volatile anesthetic. However, it is important to consider individual patient factors and consult with a healthcare provider to determine the most appropriate anesthesia regimen for each patient, taking into account their medical history and specific risk factors.	0.6802749486907528	0.4839318504817565	0.44415626595215296	0.5178631762362791	0.7388793	0.5184895	0.4119039	0.48386532	0.78655654	0.3746874	0.2927024	0.5016136	0.7325678	0.42452854	0.3807415	0.46822935	0.69941586	0.56964153	0.5502052	0.5323574	0
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking methoxyflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking methoxyflurane as normal. There is no recommendation.', 'Take methoxyflurane with a reduced dose.', 'Take methoxyflurane with an increased dose.']	Avoid methoxyflurane. Take an alternate therapy.	Individuals who are Malignant Hyperthermia Susceptibility (MHS) positive for RYR1 gene are advised to avoid methoxyflurane, as it has been implicated as a trigger for malignant hyperthermia in susceptible individuals. Since their susceptibility for CACNA1S is uncertain, caution is advised and alternative medications should be considered to avoid potential adverse events associated with methoxyflurane use in individuals with Malignant Hyperthermia Susceptibility. Always consult with a healthcare provider or a genetics specialist for personalized recommendations.	0.6822302010941204	0.4832833750282811	0.44367088102211133	0.5191996580562291	0.6933266	0.52831686	0.4143478	0.56775457	0.63164824	0.3992715	0.32240808	0.5113724	0.6106682	0.45769954	0.41020012	0.5029906	0.6780119	0.58519626	0.5607931	0.62433475	0
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking methoxyflurane? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid methoxyflurane. Take an alternate therapy.', 'Take methoxyflurane with a reduced dose.', 'Take methoxyflurane with an increased dose.']	Proceed taking methoxyflurane as normal. There is no recommendation.	Individuals who are No Result for RYR1 and have Uncertain Susceptibility for CACNA1S should exercise caution when taking methoxyflurane due to potential risks associated with these genetic variations. It is important to consult with a healthcare provider or a pharmacogenomics expert to assess the potential impact on drug response and determine the most appropriate course of action, which may include monitoring for adverse effects or considering alternative treatment options.	0.7308902029765904	0.44254844715601316	0.3755510898875167	0.5656596004107068	0.68848044	0.45844546	0.28589624	0.5819379	0.67753756	0.24951358	0.24346183	0.5915974	0.6514911	0.39962572	0.34295952	0.5241064	0.72758406	0.44583112	0.39463902	0.60950214	0
methylene blue	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking methylene blue? Give a 2-3 sentence summary.	Avoid use	['Proceed taking methylene blue as normal. There is no recommendation.', 'Take methylene blue with a reduced dose.', 'Take methylene blue with an increased dose.']	Avoid methylene blue. Take an alternate therapy.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) may be at increased risk of hemolysis (breakdown of red blood cells) when exposed to drugs such as methylene blue. Therefore, caution is advised when considering the use of methylene blue in individuals with G6PD deficiency. Close monitoring for signs of hemolysis and consultation with a healthcare provider is recommended if methylene blue is necessary for treatment.	0.20177596606339337	0.29396252494959985	0.2635735545962334	0.5552261209988745	0.2593239	0.40431276	0.3338392	0.586314	0.147007	0.21889381	0.2300791	0.60410464	0.16829246	0.18944	0.18988742	0.66224647	0.39974895	0.6267883	0.5424116	0.64033824	0
methylene blue	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking methylene blue? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid methylene blue. Take an alternate therapy.', 'Take methylene blue with a reduced dose.', 'Take methylene blue with an increased dose.']	Proceed taking methylene blue as normal. There is no recommendation.	Individuals with an indeterminate status for G6PD are recommended to exercise caution when taking medications that can potentially cause hemolysis, such as methylene blue, due to the risk of exacerbating underlying G6PD deficiency. In these cases, careful monitoring for signs of hemolysis should be implemented, and alternative treatment options should be considered if available to minimize potential adverse effects. Consulting with a healthcare provider or a pharmacogenomics expert is advisable to ensure safe and effective treatment outcomes.	0.6799217130265482	0.39926667705511604	0.34025789233989445	0.5291033611144277	0.56785315	0.25596574	0.2768521	0.5839293	0.63955605	0.2835732	0.24537903	0.56847686	0.5911777	0.19279297	0.19199747	0.5384605	0.5420415	0.41993737	0.42208827	0.56303185	0
methylene blue	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking methylene blue? Give a 2-3 sentence summary.	Avoid use	['Proceed taking methylene blue as normal. There is no recommendation.', 'Take methylene blue with a reduced dose.', 'Take methylene blue with an increased dose.']	Avoid methylene blue. Take an alternate therapy.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) enzyme should avoid taking methylene blue due to the risk of causing severe hemolysis (breakdown of red blood cells). Hemolytic reactions can lead to serious health complications such as anemia and jaundice. Therefore, individuals with G6PD deficiency should inform their healthcare provider about their condition before considering methylene blue treatment.	0.1957400978985526	0.29396252494959985	0.2635735545962334	0.5636417947569885	0.34522578	0.40431276	0.3338392	0.6407398	0.20836045	0.21889381	0.2300791	0.6075501	0.18272616	0.18944	0.18988742	0.70113784	0.4649755	0.6267883	0.5424116	0.69864243	1
methylene blue	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking methylene blue? Give a 2-3 sentence summary.	No reason to avoid ased on G6PD status	['Avoid methylene blue. Take an alternate therapy.', 'Take methylene blue with a reduced dose.', 'Take methylene blue with an increased dose.']	Proceed taking methylene blue as normal. There is no recommendation.	Individuals who are normal for G6PD enzyme activity are usually able to metabolize methylene blue safely. However, caution should still be exercised as high doses of methylene blue may still cause hemolytic anemia in some individuals. It is recommended to monitor for any signs of hemolysis such as jaundice, dark urine, and fatigue while taking methylene blue.	0.5969110337318129	0.4094021002240724	0.28886343401229864	0.5839832943492731	0.36143407	0.33019596	0.17593654	0.64424026	0.29505253	0.2158015	0.122321494	0.6999907	0.23548028	0.14012602	0.09004671	0.7059111	0.3640243	0.38158786	0.30839118	0.6152234	0
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking nalidixic acid? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid nalidixic acid. Take an alternate therapy.', 'Take nalidixic acid with a reduced dose.', 'Take nalidixic acid with an increased dose.']	Proceed taking nalidixic acid as normal. There is no recommendation.	Individuals who are deficient in the enzyme glucose-6-phosphate dehydrogenase (G6PD) are at increased risk of hemolytic anemia when exposed to certain medications, including nalidixic acid. Clinical guidance for individuals deficient in G6PD would typically involve avoiding medications known to trigger hemolysis, such as nalidixic acid, to prevent serious complications. It is important for individuals with G6PD deficiency to inform their healthcare providers about their condition to ensure safe medication choices.	0.6410398439668312	0.5102963233087527	0.3995030814456959	0.44314313357345136	0.557103	0.5367552	0.33543587	0.5072433	0.57800806	0.43464684	0.25055793	0.48051	0.5647896	0.44526783	0.3288478	0.5080762	0.5532462	0.5274701	0.41685203	0.57232505	0
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking nalidixic acid? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid nalidixic acid. Take an alternate therapy.', 'Take nalidixic acid with a reduced dose.', 'Take nalidixic acid with an increased dose.']	Proceed taking nalidixic acid as normal. There is no recommendation.	Individuals who are classified as Indeterminate for G6PD deficiency may have decreased enzyme activity, increasing their risk of hemolysis when exposed to medications like nalidixic acid. In this case, it is recommended to consider alternative antibiotics that do not pose a risk of hemolysis in individuals with G6PD deficiency or closely monitor for signs of hemolysis if nalidixic acid must be used, while also considering individual factors such as the severity of the deficiency and the need for the medication.	0.6479761237863524	0.41028201602843883	0.34138512113866976	0.5213391739137604	0.51058215	0.25943494	0.27332565	0.583909	0.5995021	0.31100872	0.2369225	0.596866	0.6088551	0.22788674	0.19734377	0.52887416	0.5352247	0.4442517	0.42799935	0.5630049	0
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking nalidixic acid? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid nalidixic acid. Take an alternate therapy.', 'Take nalidixic acid with a reduced dose.', 'Take nalidixic acid with an increased dose.']	Proceed taking nalidixic acid as normal. There is no recommendation.	Individuals who are deficient in G6PD (glucose-6-phosphate dehydrogenase) should avoid taking nalidixic acid due to the risk of hemolytic anemia. Nalidixic acid can induce oxidative stress on red blood cells in individuals with G6PD deficiency, leading to the destruction of red blood cells and severe complications. It is important for healthcare providers to be aware of a patient’s G6PD status before prescribing medications like nalidixic acid to prevent adverse effects.	0.4149591390384104	0.41934796179015893	0.4490871397025546	0.5284762506040918	0.48286587	0.4938284	0.4958153	0.6387753	0.46480116	0.4820026	0.45384482	0.6361923	0.4194604	0.39614537	0.36586258	0.52841896	0.40352198	0.3824438	0.4566885	0.6256851	0
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking nalidixic acid? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid nalidixic acid. Take an alternate therapy.', 'Take nalidixic acid with a reduced dose.', 'Take nalidixic acid with an increased dose.']	Proceed taking nalidixic acid as normal. There is no recommendation.	Individuals who are normal for G6PD are generally not at increased risk for hemolysis when taking nalidixic acid. However, it is still important to monitor for any signs of hemolytic anemia such as fatigue, pallor, and jaundice. Close monitoring and prompt intervention if any symptoms occur is recommended.	0.6387134025033774	0.44993205836648464	0.32019268583958693	0.5814633657411806	0.43388334	0.38517892	0.1905008	0.62125736	0.3840513	0.25284716	0.1232888	0.64665174	0.3455562	0.16881055	0.08779632	0.60247284	0.4963239	0.45205277	0.34309897	0.538731	0
neomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking neomycin as normal. There is no recommendation.', 'Take neomycin with a reduced dose.', 'Take neomycin with an increased dose.']	Avoid neomycin. Take an alternate therapy.	Individuals who are at an increased risk of aminoglycoside-induced hearing loss due to a variant in the MT-RNR1 gene may benefit from an alternative antibiotic to neomycin if possible. If neomycin must be used, close monitoring of kidney function and therapeutic drug monitoring to ensure optimal dosing while minimizing risk of toxicity is recommended. Additionally, patients should be counseled on the signs and symptoms of hearing loss and advised to report any changes promptly for further evaluation.	0.7158419356168234	0.5170128410934319	0.43902898045025657	0.5810008040999702	0.67726594	0.60293967	0.48924625	0.62422675	0.7691772	0.5176673	0.5016423	0.6213931	0.75971204	0.4763912	0.44747832	0.5616167	0.64242905	0.6149113	0.50945026	0.6501548	0
neomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid neomycin. Take an alternate therapy.', 'Take neomycin with a reduced dose.', 'Take neomycin with an increased dose.']	Proceed taking neomycin as normal. There is no recommendation.	Individuals with normal risk of aminoglycoside-induced hearing loss for the MT-RNR1 gene may still be at risk for this adverse effect with neomycin use. Therefore, caution should be exercised, and close monitoring of hearing function is recommended when initiating neomycin therapy. Consideration of alternative antibiotics with a lower risk of ototoxicity may be considered, especially if the individual is known to have mutations in the MT-RNR1 gene.	0.6128803498135506	0.436805259352131	0.45868538317550017	0.5581641458753914	0.5932634	0.4583342	0.48983455	0.5828667	0.6951294	0.52771825	0.55508214	0.58320427	0.6912633	0.50227654	0.50675625	0.48084176	0.54429936	0.4940156	0.5422487	0.51759934	0
neomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid neomycin. Take an alternate therapy.', 'Take neomycin with a reduced dose.', 'Take neomycin with an increased dose.']	Proceed taking neomycin as normal. There is no recommendation.	Individuals with MT-RNR1 variants have an increased risk of aminoglycoside-induced hearing loss such as with neomycin. Clinical guidance would involve performing genetic testing to identify these variants before prescribing neomycin. If a MT-RNR1 variant is present, alternative medications should be considered to avoid potential hearing loss risk associated with aminoglycosides.	0.5738455118668855	0.436805259352131	0.45868538317550017	0.46718084899529105	0.49982044	0.4583342	0.48983455	0.4253067	0.55090934	0.52771825	0.55508214	0.47915044	0.62568533	0.50227654	0.50675625	0.40430462	0.51983625	0.4940156	0.5422487	0.46304142	0
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking netilmicin as normal. There is no recommendation.', 'Take netilmicin with a reduced dose.', 'Take netilmicin with an increased dose.']	Avoid netilmicin. Take an alternate therapy.	Individuals with a variant in the MT-RNR1 gene that is associated with increased risk of aminoglycoside-induced hearing loss may benefit from alternative antibiotics or dosage adjustments when prescribed netilmicin. It is recommended to consult with a healthcare provider or a clinical pharmacist experienced in pharmacogenomics to determine the most appropriate course of action to minimize the risk of adverse effects while ensuring effective treatment. Close monitoring of hearing function during netilmicin therapy is also advisable.	0.658088645928821	0.5081800664560344	0.43533232783108206	0.5778684964005585	0.62568974	0.57104945	0.4572886	0.5697041	0.73091686	0.4305896	0.41669762	0.6085143	0.66705865	0.405359	0.39526176	0.5678052	0.5771581	0.59560007	0.4809334	0.6305375	0
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid netilmicin. Take an alternate therapy.', 'Take netilmicin with a reduced dose.', 'Take netilmicin with an increased dose.']	Proceed taking netilmicin as normal. There is no recommendation.	Individuals with normal risk of aminoglycoside-induced hearing loss for MT-RNR1 may still benefit from monitoring for signs of ototoxicity when taking netilmicin. It is important to assess their hearing function at baseline and at regular intervals during treatment. If signs of hearing loss develop, dosage adjustments or discontinuation of netilmicin may be necessary to prevent further damage.	0.6250596029544058	0.4284412123096973	0.41428631836409213	0.5789166160189773	0.5785493	0.45805687	0.45130825	0.549091	0.62418437	0.4630871	0.47007787	0.5967738	0.63834786	0.46881813	0.46443865	0.47871268	0.60823154	0.45471826	0.5047259	0.47373483	0
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid netilmicin. Take an alternate therapy.', 'Take netilmicin with a reduced dose.', 'Take netilmicin with an increased dose.']	Proceed taking netilmicin as normal. There is no recommendation.	For individuals with the MT-RNR1 variant associated with aminoglycoside-induced hearing loss uncertainty, it is recommended to consider alternative antibiotics to netilmicin if possible, particularly in cases where the benefits of aminoglycoside therapy do not clearly outweigh the potential risk of hearing loss. Close monitoring for signs of ototoxicity, such as hearing loss or tinnitus, is essential during treatment with netilmicin in these individuals. Consulting with a healthcare provider or a clinical pharmacist experienced in pharmacogenomics can help guide personalized treatment decisions.	0.6277482243111586	0.4284412123096973	0.41428631836409213	0.5667754693225852	0.5671872	0.45805687	0.45130825	0.5100912	0.6656549	0.4630871	0.47007787	0.5247375	0.7204204	0.46881813	0.46443865	0.49698317	0.61034465	0.45471826	0.5047259	0.49857265	0
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking nitrofurantoin? Give a 2-3 sentence summary.	Use at standard doses with caution and with close monitoring for anemia	['Avoid nitrofurantoin. Take an alternate therapy.', 'Take nitrofurantoin with a reduced dose.', 'Take nitrofurantoin with an increased dose.']	Proceed taking nitrofurantoin as normal. There is no recommendation.	Individuals deficient in G6PD may be at increased risk of hemolysis when taking nitrofurantoin, as the drug has been associated with causing hemolytic anemia in these patients. Therefore, it is generally recommended to avoid using nitrofurantoin in individuals with G6PD deficiency to prevent the risk of serious complications such as hemolysis. Alternative antibiotics should be considered for these individuals.	0.33129962264206647	0.387101450133549	0.4052466910355325	0.5616811425894264	0.49653167	0.522519	0.46297336	0.64584434	0.5100233	0.5286387	0.4036254	0.67023903	0.45597467	0.40946662	0.3082297	0.5693739	0.4517853	0.40740108	0.44536152	0.57001734	0
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking nitrofurantoin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid nitrofurantoin. Take an alternate therapy.', 'Take nitrofurantoin with a reduced dose.', 'Take nitrofurantoin with an increased dose.']	Proceed taking nitrofurantoin as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, caution is advised when considering the use of nitrofurantoin, as it may lead to an increased risk of hemolysis. It is recommended to consult with a healthcare provider or a clinical pharmacist to weigh the benefits versus risks of using nitrofurantoin in this population and to consider alternative medications if necessary. Close monitoring for signs of hemolysis may be warranted if nitrofurantoin is prescribed.	0.5456490467936566	0.34926333492144146	0.28611565102392605	0.6335660745367904	0.5049563	0.2725551	0.28808877	0.6415771	0.57760406	0.33166814	0.27097312	0.6917454	0.4874205	0.2132039	0.17746516	0.6022349	0.5199133	0.40906742	0.38126978	0.58246017	0
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking nitrofurantoin? Give a 2-3 sentence summary.	Avoid	['Proceed taking nitrofurantoin as normal. There is no recommendation.', 'Take nitrofurantoin with a reduced dose.', 'Take nitrofurantoin with an increased dose.']	Avoid nitrofurantoin. Take an alternate therapy.	Individuals who are deficient in G6PD (glucose-6-phosphate dehydrogenase) and are treated with nitrofurantoin, a commonly used antibiotic, may be at higher risk of developing hemolytic anemia. It is recommended to avoid nitrofurantoin in individuals with G6PD deficiency to prevent this serious adverse reaction. Alternative antibiotics should be considered for those with G6PD deficiency to avoid potential harm.	0.1710362022906057	0.3005691797852066	0.2357660913345824	0.6022228809044622	0.23928964	0.37423956	0.32493457	0.59193254	0.13593642	0.22473016	0.2399553	0.61368835	0.10361143	0.26494846	0.24695277	0.5892612	0.34536442	0.51067966	0.43996444	0.648036	1
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking nitrofurantoin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid nitrofurantoin. Take an alternate therapy.', 'Take nitrofurantoin with a reduced dose.', 'Take nitrofurantoin with an increased dose.']	Proceed taking nitrofurantoin as normal. There is no recommendation.	For individuals who are Normal for G6PD enzyme activity, there is typically no increased risk of hemolysis when taking nitrofurantoin. Clinical guidance suggests that these individuals can safely take nitrofurantoin without the need for dose adjustments or additional monitoring related to G6PD status. However, as with any medication, it is important to follow healthcare provider recommendations and watch for any signs of adverse reactions while taking nitrofurantoin.	0.5424207700708308	0.36693159426412836	0.2457900146282421	0.6789878148256517	0.5383766	0.44078693	0.269966	0.71434265	0.50342387	0.33738163	0.21715666	0.7049031	0.39911065	0.1798882	0.100993395	0.60776216	0.5816714	0.4436887	0.32732594	0.6206834	1
norfloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking norfloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid norfloxacin. Take an alternate therapy.', 'Take norfloxacin with a reduced dose.', 'Take norfloxacin with an increased dose.']	Proceed taking norfloxacin as normal. There is no recommendation.	Individuals deficient in glucose-6-phosphate dehydrogenase (G6PD) are at an increased risk of developing hemolytic anemia when exposed to certain medications, including norfloxacin. Clinical guidance for individuals deficient in G6PD is to avoid medications known to cause hemolysis, such as norfloxacin, and to consider alternative antibiotic therapies that are safer for individuals with this deficiency. It is recommended to consult with a healthcare provider or pharmacist for appropriate antibiotic selection in individuals deficient in G6PD.	0.6300386522690822	0.41963863061013507	0.32170793635523803	0.46947552314605395	0.53986335	0.46382824	0.25206774	0.41438684	0.55810946	0.31267026	0.12702455	0.41116944	0.51024437	0.3985021	0.28740144	0.4901861	0.52801204	0.46547198	0.35617176	0.56982	0
norfloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking norfloxacin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid norfloxacin. Take an alternate therapy.', 'Take norfloxacin with a reduced dose.', 'Take norfloxacin with an increased dose.']	Proceed taking norfloxacin as normal. There is no recommendation.	For an individual who is Indeterminate for G6PD deficiency and needs to take norfloxacin, it is recommended to consider alternative antibiotics that do not carry a risk of inducing hemolysis in G6PD deficient individuals. Monitoring for signs of hemolytic anemia such as fatigue, pallor, or dark urine should be performed if norfloxacin is used, and immediate medical attention sought if these symptoms occur.	0.5525065624064971	0.3099475422170956	0.24670080838918584	0.61003164595406	0.5087851	0.13171333	0.12475675	0.5251823	0.57704467	0.111671075	0.031879365	0.5209302	0.5261042	0.1869118	0.15330034	0.5259097	0.4653677	0.40342304	0.38039103	0.5722037	0
norfloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking norfloxacin? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid norfloxacin. Take an alternate therapy.', 'Take norfloxacin with a reduced dose.', 'Take norfloxacin with an increased dose.']	Proceed taking norfloxacin as normal. There is no recommendation.	Individuals deficient in glucose-6-phosphate dehydrogenase (G6PD) enzyme activity, such as those with the CNSHA variant, are at an increased risk of hemolysis when exposed to certain drugs like norfloxacin. It is recommended to avoid the use of norfloxacin in patients with G6PD deficiency unless the benefits clearly outweigh the risks. Close monitoring for signs of hemolysis such as dark urine, shortness of breath, or jaundice is essential if norfloxacin is prescribed in this population.	0.4453765495026465	0.34606818928904154	0.3893772566465747	0.4678125972352773	0.57158256	0.47659543	0.46238354	0.47860008	0.5378242	0.44834954	0.35976207	0.4331008	0.5431068	0.41963315	0.3625772	0.54071105	0.53365815	0.42166263	0.47665906	0.56827223	0
norfloxacin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking norfloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid norfloxacin. Take an alternate therapy.', 'Take norfloxacin with a reduced dose.', 'Take norfloxacin with an increased dose.']	Proceed taking norfloxacin as normal. There is no recommendation.	For individuals who are Normal for G6PD, there is typically no known increased risk of hemolysis associated with taking norfloxacin, an antibiotic. Monitoring for any signs or symptoms of hematologic adverse effects is recommended as a general precaution when starting any antibiotic therapy, but specific precautions related to G6PD status are not typically necessary in Normal individuals.	0.5825578174062839	0.3663251993408382	0.2497966719033872	0.6104681969877982	0.5549449	0.34096554	0.16035789	0.6348608	0.44391567	0.19446607	0.06388267	0.6119787	0.350142	0.139765	0.08049331	0.6122614	0.5058255	0.4030785	0.3007896	0.60538965	1
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking nortriptyline? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking nortriptyline as normal. There is no recommendation.', 'Take nortriptyline with a reduced dose.', 'Take nortriptyline with an increased dose.']	Avoid nortriptyline. Take an alternate therapy.	For individuals who are Ultrarapid Metabolizers with an activity score of ≥3.75 for CYP2D6, caution is advised when taking nortriptyline. Due to the rapid metabolism of nortriptyline in these individuals, higher drug concentrations and increased risk of side effects may occur. Monitoring for adverse effects and adjusting the dosage based on individual response and tolerance may be necessary to optimize treatment outcomes.	0.6257673792591246	0.5539332337773649	0.5185643014818234	0.613468882427558	0.72566414	0.59421337	0.53958297	0.51516503	0.68779564	0.50010276	0.4762896	0.6286873	0.653296	0.48090205	0.46487388	0.4846529	0.6415055	0.5963231	0.5515143	0.6101043	0
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking nortriptyline? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose	['Avoid nortriptyline. Take an alternate therapy.', 'Take nortriptyline with a reduced dose.', 'Take nortriptyline with an increased dose.']	Proceed taking nortriptyline as normal. There is no recommendation.	Patients who are Normal Metabolizers with a CYP2D6 activity score of 1.75 may have a normal response to nortriptyline therapy. Standard dosing guidelines for nortriptyline can be followed, with careful monitoring for both efficacy and side effects, as individual variability in drug response may still occur. Consulting with a healthcare provider or a pharmacist for personalized dosing recommendations based on the patient's specific clinical factors is advisable.	0.4401941958494854	0.48586007244775986	0.47727313192606696	0.6743805595875704	0.43104246	0.3388268	0.41150093	0.56079274	0.42391688	0.43394366	0.35340515	0.69936097	0.42057467	0.36809278	0.34603143	0.58147	0.42371428	0.51391894	0.5276429	0.6092013	0
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking nortriptyline? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking nortriptyline as normal. There is no recommendation.', 'Take nortriptyline with a reduced dose.', 'Take nortriptyline with an increased dose.']	Avoid nortriptyline. Take an alternate therapy.	Individuals who are classified as Ultrarapid Metabolizers for CYP2D6 may metabolize nortriptyline more quickly than normal, potentially leading to decreased drug levels and reduced efficacy. This may necessitate higher doses or alternative medications to achieve desired therapeutic effects. Close monitoring of nortriptyline levels and clinical response is recommended to ensure optimal treatment outcomes in Ultrarapid Metabolizers with an activity score of 2.75 for CYP2D6.	0.6454287745487519	0.5539332337773649	0.5185643014818234	0.6348062263691131	0.72652626	0.59421337	0.53958297	0.5829802	0.7062052	0.50010276	0.4762896	0.59613687	0.64501524	0.48090205	0.46487388	0.4854361	0.6232662	0.5963231	0.5515143	0.58464384	1
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking nortriptyline? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking nortriptyline as normal. There is no recommendation.', 'Take nortriptyline with a reduced dose.', 'Take nortriptyline with an increased dose.']	Avoid nortriptyline. Take an alternate therapy.	For an individual who is an Ultrarapid Metabolizer with an activity score of ≥4.0 for CYP2D6 and is taking nortriptyline, cautious monitoring is recommended due to the potential for increased metabolism of nortriptyline leading to reduced efficacy or suboptimal drug levels. Close clinical supervision, dose adjustment, and consideration of alternative medications or genetic testing-guided dosing may be necessary to optimize treatment outcomes and minimize adverse effects in this population.	0.6525095644497576	0.5539332337773649	0.5185643014818234	0.6314530465623407	0.72427934	0.59421337	0.53958297	0.5583803	0.694043	0.50010276	0.4762896	0.6151822	0.6324177	0.48090205	0.46487388	0.47403	0.6136698	0.5963231	0.5515143	0.5572748	0
ofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking ofloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid ofloxacin. Take an alternate therapy.', 'Take ofloxacin with a reduced dose.', 'Take ofloxacin with an increased dose.']	Proceed taking ofloxacin as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) may be at an increased risk of hemolysis when taking certain medications like ofloxacin, as the drug can trigger oxidative stress leading to hemolysis in these individuals. Clinical guidance would typically recommend avoiding the use of ofloxacin in individuals with G6PD deficiency, or monitoring closely for signs of hemolysis if the medication is deemed necessary, under the supervision of healthcare professionals.	0.536411470966773	0.4073082038427261	0.2968745737750878	0.4767495426304031	0.53618914	0.52439594	0.32061028	0.571837	0.54429567	0.40802163	0.2311114	0.5691446	0.540174	0.38465032	0.27130282	0.48541665	0.47436923	0.43098566	0.33088526	0.5156167	0
ofloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking ofloxacin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid ofloxacin. Take an alternate therapy.', 'Take ofloxacin with a reduced dose.', 'Take ofloxacin with an increased dose.']	Proceed taking ofloxacin as normal. There is no recommendation.	For individuals who are classified as Indeterminate for G6PD deficiency, caution is advised when taking medications such as ofloxacin that can induce oxidative stress on red blood cells. Close monitoring for signs of hemolysis (breakdown of red blood cells) is recommended, and the decision to use ofloxacin should be made after considering the potential risks and benefits based on the individual's clinical situation. Consulting a healthcare provider or a pharmacist who is knowledgeable about pharmacogenomics is important for personalized guidance.	0.5533166652861097	0.3015775796198828	0.2275060579392735	0.5596639707670497	0.57641894	0.23022361	0.23508711	0.5583798	0.6481316	0.23781705	0.14877336	0.5631293	0.5756728	0.19479704	0.16254325	0.5303065	0.57912725	0.39192256	0.39242938	0.5531263	0
ofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking ofloxacin? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid ofloxacin. Take an alternate therapy.', 'Take ofloxacin with a reduced dose.', 'Take ofloxacin with an increased dose.']	Proceed taking ofloxacin as normal. There is no recommendation.	Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, especially those with class III variants such as CNSHA, are at an increased risk of hemolysis when exposed to certain medications like ofloxacin. Therefore, caution is advised when considering the use of ofloxacin in this population. Monitoring for signs of hemolysis and considering alternative antibiotics may be necessary in individuals with G6PD deficiency, including those with the CNSHA variant.	0.46987147222397213	0.3722279232955478	0.39823882251465387	0.459728225222572	0.6063699	0.47258347	0.47498977	0.51208335	0.4845187	0.43115827	0.40081966	0.5835783	0.5690504	0.4406681	0.4035031	0.49970612	0.526961	0.41272187	0.49330425	0.47121584	1
ofloxacin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking ofloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid ofloxacin. Take an alternate therapy.', 'Take ofloxacin with a reduced dose.', 'Take ofloxacin with an increased dose.']	Proceed taking ofloxacin as normal. There is no recommendation.	For individuals who are Normal for G6PD status, there is no specific contraindication for taking ofloxacin. However, as with any medication, it is important to follow healthcare provider guidance and monitor for any signs of adverse effects while taking ofloxacin. If experiencing any unusual symptoms while on this medication, it is recommended to seek medical advice promptly.	0.5408068079504998	0.3386573415241505	0.22096623346335686	0.6840128237457667	0.5281701	0.4036585	0.21641771	0.7338197	0.5014316	0.26453057	0.14745688	0.74255717	0.40430164	0.1290781	0.05306213	0.59795046	0.5144039	0.38018796	0.26939926	0.5740866	1
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking omeprazole? Give a 2-3 sentence summary.	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	['Proceed taking omeprazole as normal. There is no recommendation.', 'Avoid omeprazole. Take an alternate therapy.']	Take omeprazole with an altered dose.	Individuals who are Ultrarapid Metabolizers for CYP2C19 may metabolize omeprazole faster than normal, leading to potentially reduced efficacy of the drug. In such cases, higher doses or alternative medications may be considered for optimal therapeutic outcome. It is recommended to consult with a healthcare provider or a pharmacogenomics specialist to determine the most appropriate treatment strategy based on individual genetic makeup.	0.35639730697255767	0.4454323819857296	0.36912897080624996	0.6282273656667539	0.44007882	0.63719136	0.47588378	0.61019236	0.3751197	0.6020922	0.49424553	0.5559739	0.35786173	0.52940774	0.453827	0.51094294	0.3702189	0.5606365	0.34522527	0.67431986	0
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking omeprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking omeprazole as normal. There is no recommendation.', 'Avoid omeprazole. Take an alternate therapy.']	Take omeprazole with an altered dose.	For individuals who are Likely Poor Metabolizers for CYP2C19, omeprazole may accumulate in the body leading to increased risk of side effects like elevated drug concentrations and potential toxicity. Clinical guidance may involve using alternative medications that are not significantly metabolized by CYP2C19 or adjust the omeprazole dosage based on therapeutic drug monitoring to minimize the risk of adverse events. Consulting with a healthcare provider or a pharmacist for personalized recommendations is essential for individuals with this genotype.	0.36783875697041174	0.431118623473782	0.41026860792589404	0.6458480557211682	0.33772272	0.42749757	0.3863197	0.6004162	0.34071717	0.39290285	0.40172052	0.56257534	0.33749256	0.40408832	0.42602524	0.5470047	0.39524674	0.51069117	0.39541352	0.6437357	0
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking omeprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking omeprazole as normal. There is no recommendation.', 'Avoid omeprazole. Take an alternate therapy.']	Take omeprazole with an altered dose.	For someone who is a Likely Intermediate Metabolizer for CYP2C19, they may require a lower dose of omeprazole compared to normal metabolizers to achieve the desired therapeutic effect and minimize the risk of side effects. Close monitoring for efficacy and adherence to the prescribed dose is recommended to ensure optimal treatment outcomes. Consulting with a healthcare provider or a pharmacist who is knowledgeable about pharmacogenomics may help in determining the appropriate dosage adjustment based on their CYP2C19 metabolizer status.	0.46088680929395687	0.431118623473782	0.41026860792589404	0.6538358351589478	0.50774056	0.42749757	0.3863197	0.59930634	0.4190354	0.39290285	0.40172052	0.5674336	0.47893745	0.40408832	0.42602524	0.537268	0.5073853	0.51069117	0.39541352	0.6404819	0
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking omeprazole? Give a 2-3 sentence summary.	No recommendation	['Avoid omeprazole. Take an alternate therapy.', 'Take omeprazole with a reduced dose.', 'Take omeprazole with an increased dose.']	Proceed taking omeprazole as normal. There is no recommendation.	For individuals who are classified as Indeterminate for CYP2C19, there is uncertainty in predicting their response to medications metabolized by this enzyme, such as omeprazole. It is recommended to consider alternative medications or dose adjustments based on the individual's clinical response or potential for drug-drug interactions to optimize therapy and minimize the risk of adverse effects. Consulting with a healthcare provider or a pharmacist who is knowledgeable in pharmacogenomics can help guide treatment decisions for these individuals.	0.25905165935775304	0.4505783381963025	0.19287095045098726	0.5343042184967958	0.14262736	0.34948722	0.17491753	0.49489725	0.08083067	0.2224891	0.094694875	0.5157996	-0.039727956	0.28686637	0.06165957	0.4915459	0.37309903	0.55088276	0.41253772	0.58189714	0
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking ondansetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking ondansetron as normal. There is no recommendation.', 'Take ondansetron with a reduced dose.', 'Take ondansetron with an increased dose.']	Avoid ondansetron. Take an alternate therapy.	Individuals who are Ultrarapid Metabolizers (UMs) with an activity score of ≥6.0 for CYP2D6 may experience decreased effectiveness or potential toxicity of drugs metabolized by this enzyme, such as ondansetron. Clinical guidance may include monitoring for efficacy and potential adverse effects of ondansetron, adjusting the dose if necessary, and considering alternative medications or therapeutic strategies to ensure optimal treatment outcomes. Consulting a healthcare provider or a clinical pharmacist for personalized recommendations is advisable.	0.495474156214057	0.6064120937930781	0.4734419763492406	0.552348643916057	0.55457145	0.5319944	0.47772932	0.5318268	0.75096667	0.41769275	0.39910686	0.5610214	0.6796258	0.5270997	0.5287408	0.529357	0.54421496	0.5799418	0.52722955	0.5845138	0
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking ondansetron? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid ondansetron. Take an alternate therapy.', 'Take ondansetron with a reduced dose.', 'Take ondansetron with an increased dose.']	Proceed taking ondansetron as normal. There is no recommendation.	For an individual who is a Normal Metabolizer with an activity score of 1.75 for CYP2D6, they are unlikely to experience significant drug interactions or variations in metabolism when taking ondansetron. Normal Metabolizers typically have a normal response to medications metabolized by CYP2D6, so standard dosing guidelines for ondansetron can be followed without the need for dose adjustments.	0.3306328558925438	0.4896730095819196	0.5304752031389409	0.568137679484027	0.3398098	0.40120316	0.525737	0.5522204	0.34925202	0.51873624	0.524869	0.5947576	0.26579195	0.45777196	0.49198285	0.546145	0.32219562	0.5024893	0.5728647	0.56740546	1
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking ondansetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking ondansetron as normal. There is no recommendation.', 'Take ondansetron with a reduced dose.', 'Take ondansetron with an increased dose.']	Avoid ondansetron. Take an alternate therapy.	Individuals who are ultrarapid metabolizers with an activity score of 2.75 for CYP2D6 may metabolize ondansetron more quickly, potentially leading to reduced efficacy or increased risk of side effects. Clinicians may consider adjusting the dosage or selecting an alternate antiemetic medication with a different metabolic pathway or monitoring closely for efficacy and adverse effects. Personalized dosing and monitoring are important to optimize treatment outcomes in this population.	0.5280679447770013	0.6064120937930781	0.4734419763492406	0.601885833767503	0.49358377	0.5319944	0.47772932	0.54341656	0.68410474	0.41769275	0.39910686	0.5634455	0.71080536	0.5270997	0.5287408	0.5785226	0.5766449	0.5799418	0.52722955	0.60547465	0
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking ondansetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking ondansetron as normal. There is no recommendation.', 'Take ondansetron with a reduced dose.', 'Take ondansetron with an increased dose.']	Avoid ondansetron. Take an alternate therapy.	For an individual who is an Ultrarapid Metabolizer (UM) with an activity score of ≥5.0 for CYP2D6, they may metabolize ondansetron more rapidly than normal, potentially leading to reduced efficacy or adverse effects. Monitoring for therapeutic response and considering adjusting the ondansetron dose based on clinical response or considering alternative medications may be warranted in this population to ensure optimal treatment outcomes.	0.48715589919208335	0.6064120937930781	0.4734419763492406	0.6043569464215554	0.4796798	0.5319944	0.47772932	0.54017836	0.7088159	0.41769275	0.39910686	0.5734427	0.66599786	0.5270997	0.5287408	0.5695627	0.52231085	0.5799418	0.52722955	0.5479505	0
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking oxcarbazepine? Give a 2-3 sentence summary.	If patient is oxcarbazepine-naïve, do not use oxcarbazepine.	['Proceed taking oxcarbazepine as normal. There is no recommendation.', 'Take oxcarbazepine with a reduced dose.', 'Take oxcarbazepine with an increased dose.']	Avoid oxcarbazepine. Take an alternate therapy.	For individuals who are HLA-B*15:02 positive, there is an increased risk of developing a severe skin reaction, such as Stevens-Johnson syndrome or toxic epidermal necrolysis, when taking medications like oxcarbazepine. It is recommended to consider alternative medications or perform genetic testing before initiating oxcarbazepine treatment to reduce the risk of these severe skin reactions. Close monitoring for any signs of skin reactions is also crucial if oxcarbazepine therapy is initiated.	0.6084266445955105	0.7135790550383974	0.6881527451258563	0.6247919458877657	0.4727119	0.6514912	0.53940594	0.5026776	0.6255616	0.71380687	0.6159231	0.5608429	0.59178025	0.80327135	0.7270234	0.5397281	0.5845217	0.7186559	0.59483653	0.62143844	0
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking oxcarbazepine? Give a 2-3 sentence summary.	The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used oxcarbazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future.	['Avoid oxcarbazepine. Take an alternate therapy.', 'Take oxcarbazepine with a reduced dose.', 'Take oxcarbazepine with an increased dose.']	Proceed taking oxcarbazepine as normal. There is no recommendation.	For individuals who are HLA-B*15:02 positive, there is an increased risk of developing a severe skin reaction, such as Stevens-Johnson syndrome or toxic epidermal necrolysis, when taking medications like oxcarbazepine. It is recommended to consider alternative medications or perform genetic testing before initiating oxcarbazepine treatment to reduce the risk of these severe skin reactions. Close monitoring for any signs of skin reactions is also crucial if oxcarbazepine therapy is initiated.	0.6373107240092597	0.5043979438756131	0.5344224150315137	0.5644599602035679	0.51720387	0.5658956	0.5124112	0.5079835	0.572529	0.6096384	0.4981693	0.5672849	0.5116524	0.49684122	0.5035804	0.4797421	0.52823347	0.5025414	0.51570123	0.552153	0
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking oxcarbazepine? Give a 2-3 sentence summary.	Use oxcarbazepine per standard dosing guidelines.	['Avoid oxcarbazepine. Take an alternate therapy.', 'Take oxcarbazepine with a reduced dose.', 'Take oxcarbazepine with an increased dose.']	Proceed taking oxcarbazepine as normal. There is no recommendation.	For individuals who are HLA-B*15:02 negative, there is a decreased risk of developing a severe skin reaction, such as Stevens-Johnson syndrome or toxic epidermal necrolysis, when taking oxcarbazepine. However, it is still important to be cautious and monitor for any signs of adverse reactions when initiating oxcarbazepine therapy. Consulting with a healthcare provider before starting the medication is recommended to discuss individual risk factors and potential adverse effects.	0.595780858636261	0.7546955498099462	0.760685780590325	0.601827069125108	0.43865046	0.7262312	0.7635482	0.6071855	0.4830805	0.84319997	0.87197757	0.60804236	0.43699506	0.8297167	0.78971976	0.51858675	0.5679524	0.79110354	0.7943649	0.54653734	0
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking oxcarbazepine? Give a 2-3 sentence summary.	Use oxcarbazepine per standard dosing guidelines.	['Avoid oxcarbazepine. Take an alternate therapy.', 'Take oxcarbazepine with a reduced dose.', 'Take oxcarbazepine with an increased dose.']	Proceed taking oxcarbazepine as normal. There is no recommendation.	For individuals who are HLA-B*15:02 negative, there is a decreased risk of developing a severe skin reaction, such as Stevens-Johnson syndrome or toxic epidermal necrolysis, when taking oxcarbazepine. However, it is still important to be cautious and monitor for any signs of adverse reactions when initiating oxcarbazepine therapy. Consulting with a healthcare provider before starting the medication is recommended to discuss individual risk factors and potential adverse effects.	0.595780858636261	0.7546955498099462	0.760685780590325	0.601827069125108	0.43865046	0.7262312	0.7635482	0.6071855	0.4830805	0.84319997	0.87197757	0.60804236	0.43699506	0.8297167	0.78971976	0.51858675	0.5679524	0.79110354	0.7943649	0.54653734	0
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking pantoprazole? Give a 2-3 sentence summary.	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	['Proceed taking pantoprazole as normal. There is no recommendation.', 'Avoid pantoprazole. Take an alternate therapy.']	Take pantoprazole with an altered dose.	For someone who is an Ultrarapid Metabolizer for CYP2C19, pantoprazole may be metabolized more quickly, resulting in potentially lower drug levels in the body and decreased efficacy. Clinical guidance may involve considering alternative medications or adjusting the pantoprazole dose to ensure adequate therapeutic effect while minimizing the risk of treatment failure due to rapid metabolism. Consulting with a healthcare provider or a pharmacogenomics expert is recommended for personalized treatment recommendations.	0.3654020517977546	0.46036628881789327	0.3805938698243083	0.67746427840022	0.4899391	0.65451384	0.4859116	0.659117	0.4373591	0.6395466	0.53436863	0.60486454	0.4017657	0.51645404	0.42759904	0.5541338	0.41710588	0.5662754	0.36993787	0.7093122	0
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking pantoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking pantoprazole as normal. There is no recommendation.', 'Avoid pantoprazole. Take an alternate therapy.']	Take pantoprazole with an altered dose.	For someone who is a Likely Poor Metabolizer for CYP2C19 and is taking pantoprazole, the recommended clinical guidance is to consider a lower initial dose and close monitoring for potential side effects or reduced efficacy. Adjusting the dose based on individual response may be necessary to optimize therapeutic outcomes while minimizing the risk of adverse effects. Consulting with a healthcare provider or a clinical pharmacist for personalized guidance is recommended.	0.4950807630646939	0.42783515005305905	0.40592745274181374	0.7139769928806003	0.56344014	0.46150437	0.42293596	0.63760364	0.4813107	0.44084656	0.46522775	0.6252583	0.5233816	0.3958696	0.3891765	0.58030856	0.5215068	0.53891414	0.42433175	0.7198723	0
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking pantoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking pantoprazole as normal. There is no recommendation.', 'Avoid pantoprazole. Take an alternate therapy.']	Take pantoprazole with an altered dose.	As an Intermediate Metabolizer for CYP2C19, individuals may have reduced metabolism of pantoprazole leading to higher levels of the drug in the body. This could potentially increase the risk of adverse effects. Close monitoring for pantoprazole efficacy and side effects is recommended, and dose adjustments may be necessary to optimize treatment outcomes. Consulting with a healthcare provider or a pharmacist for personalized recommendations based on individual factors is advisable.	0.37427657279435095	0.42783515005305905	0.40592745274181374	0.7080901477186242	0.43676162	0.46150437	0.42293596	0.6651362	0.40564013	0.44084656	0.46522775	0.61961323	0.4103225	0.3958696	0.3891765	0.5594604	0.50346196	0.53891414	0.42433175	0.70267797	0
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking pantoprazole? Give a 2-3 sentence summary.	No recommendation	['Avoid pantoprazole. Take an alternate therapy.', 'Take pantoprazole with a reduced dose.', 'Take pantoprazole with an increased dose.']	Proceed taking pantoprazole as normal. There is no recommendation.	For individuals who are Indeterminate for CYP2C19 genotype and are prescribed pantoprazole, it is important to monitor for potential drug interactions or adverse effects. Consideration should be given to adjusting the dose based on clinical response and monitoring for any signs of decreased efficacy or increased side effects. Consulting a healthcare provider or pharmacogenomics expert for personalized guidance is recommended.	0.22529471804407622	0.4439879908864724	0.2060539952911775	0.6374667857520945	0.11708944	0.3284786	0.18227132	0.52505493	0.07156489	0.22252685	0.112472035	0.6159337	-0.043874547	0.29856524	0.09517778	0.50733835	0.26455793	0.5326224	0.38784862	0.56750965	0
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking paromomycin as normal. There is no recommendation.', 'Take paromomycin with a reduced dose.', 'Take paromomycin with an increased dose.']	Avoid paromomycin. Take an alternate therapy.	Individuals who are at increased risk of aminoglycoside-induced hearing loss due to MT-RNR1 variants should use caution when taking paromomycin, another aminoglycoside antibiotic. Close monitoring for signs of hearing loss, such as tinnitus or difficulty hearing, is recommended. Healthcare providers may consider alternative antibiotic options when possible to minimize the risk of hearing loss in individuals with MT-RNR1 variants.	0.6869523494438293	0.5106822880239688	0.4285185628870885	0.5849127293759996	0.717236	0.6090968	0.48464417	0.6192759	0.71734947	0.4754906	0.47105178	0.5884622	0.77076167	0.4146247	0.4179776	0.4747106	0.60650724	0.5933152	0.48953977	0.607663	0
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid paromomycin. Take an alternate therapy.', 'Take paromomycin with a reduced dose.', 'Take paromomycin with an increased dose.']	Proceed taking paromomycin as normal. There is no recommendation.	Individuals with normal risk of aminoglycoside-induced hearing loss due to MT-RNR1 gene variants generally do not have specific contraindications to taking aminoglycoside antibiotics like paromomycin. However, caution should still be exercised, and close monitoring for signs of ototoxicity should be considered during treatment with paromomycin, especially in individuals with a family history of hearing problems or other risk factors for hearing loss. Consulting with a healthcare provider or a pharmacist before starting the medication is recommended to discuss the potential risks and benefits based on individual genetic and clinical factors.	0.5825356810073687	0.44548281031033354	0.46271528692336333	0.6085511182996012	0.5455103	0.4691963	0.47202793	0.6190836	0.65590805	0.53912383	0.52893585	0.6386099	0.71908295	0.49476042	0.47414574	0.49270663	0.5480923	0.53017235	0.5722973	0.55717146	0
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid paromomycin. Take an alternate therapy.', 'Take paromomycin with a reduced dose.', 'Take paromomycin with an increased dose.']	Proceed taking paromomycin as normal. There is no recommendation.	For individuals with an uncertain risk of aminoglycoside-induced hearing loss due to MT-RNR1 variations, caution is advised when considering treatment with paromomycin, which is also an aminoglycoside antibiotic. Close monitoring for signs of hearing loss, such as regular audiometric evaluations, may be warranted during treatment to promptly detect and manage any potential adverse effects. Consultation with a healthcare provider experienced in pharmacogenomics and audiology is recommended to discuss personalized risk assessment and appropriate monitoring strategies.	0.635151164884638	0.44548281031033354	0.46271528692336333	0.5941834994917521	0.58412135	0.4691963	0.47202793	0.5178678	0.7013969	0.53912383	0.52893585	0.5282139	0.76463974	0.49476042	0.47414574	0.43591785	0.6772912	0.53017235	0.5722973	0.570794	0
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking paroxetine? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6.	['Proceed taking paroxetine as normal. There is no recommendation.', 'Take paroxetine with a reduced dose.', 'Take paroxetine with an increased dose.']	Avoid paroxetine. Take an alternate therapy.	For individuals who are Ultrarapid Metabolizers of CYP2D6 and have an activity score of ≥6.0, caution should be exercised when taking paroxetine, as these individuals may metabolize the medication more quickly than expected, potentially leading to reduced efficacy or increased side effects. Close monitoring for therapeutic response and adverse effects, as well as consideration of alternative medications or dose adjustments, may be necessary in such individuals. It is crucial to consult with a healthcare provider or a pharmacogenomics specialist for personalized recommendations based on individual factors.	0.48385929271995093	0.4998528205180899	0.34633956705925195	0.600871112290845	0.47592667	0.39904875	0.33855024	0.52162415	0.6445759	0.2325868	0.2382857	0.61462516	0.6125046	0.34230387	0.33780465	0.52772737	0.48122928	0.5248598	0.4494816	0.6182553	0
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking paroxetine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose	['Avoid paroxetine. Take an alternate therapy.', 'Take paroxetine with a reduced dose.', 'Take paroxetine with an increased dose.']	Proceed taking paroxetine as normal. There is no recommendation.	Individuals who are Normal Metabolizers with an activity score of 1.75 for CYP2D6 are considered to have normal metabolism of drugs metabolized by this enzyme. For paroxetine, a medication primarily metabolized by CYP2D6, standard dosing guidelines are typically recommended. Monitoring for therapeutic efficacy and potential adverse effects may be important in this population as with any patient taking paroxetine.	0.36508266126166894	0.45628113748083265	0.4735275356348543	0.5360044168880745	0.36676595	0.3495537	0.3774395	0.43200943	0.32971504	0.375729	0.29313543	0.5335045	0.36430725	0.42626578	0.4125264	0.5625347	0.38809818	0.5126283	0.5601581	0.61694354	1
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking paroxetine? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6.	['Proceed taking paroxetine as normal. There is no recommendation.', 'Take paroxetine with a reduced dose.', 'Take paroxetine with an increased dose.']	Avoid paroxetine. Take an alternate therapy.	For individuals who are Ultrarapid Metabolizers of CYP2D6 and have an activity score of 2.75, they may metabolize paroxetine more quickly than normal, potentially leading to lower drug levels and reduced effectiveness. Clinical guidance may involve monitoring for lack of efficacy or potential side effects due to rapid metabolism and considering dose adjustments or alternative medications that are not primarily metabolized by CYP2D6. Consulting with a healthcare provider or a pharmacist with expertise in pharmacogenomics is recommended for personalized recommendations.	0.5118123005839407	0.4998528205180899	0.34633956705925195	0.5769658152788636	0.4453548	0.39904875	0.33855024	0.47517592	0.6787947	0.2325868	0.2382857	0.58297056	0.6574517	0.34230387	0.33780465	0.5477841	0.5020933	0.5248598	0.4494816	0.6191806	0
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking paroxetine? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6.	['Proceed taking paroxetine as normal. There is no recommendation.', 'Take paroxetine with a reduced dose.', 'Take paroxetine with an increased dose.']	Avoid paroxetine. Take an alternate therapy.	For individuals who are Ultrarapid Metabolizers of CYP2D6 and have an activity score of ≥5.0, caution should be exercised when prescribing paroxetine as they may metabolize the drug more rapidly, potentially leading to reduced efficacy or suboptimal therapeutic outcomes. Close monitoring for both efficacy and side effects is recommended, and dose adjustments may be necessary to achieve the desired clinical response. Consulting with a clinical pharmacogenomics expert or a healthcare provider familiar with pharmacogenetic testing is advisable to guide personalized treatment decisions.	0.4696067818779042	0.4998528205180899	0.34633956705925195	0.5986864681010333	0.4863406	0.39904875	0.33855024	0.5252399	0.63898593	0.2325868	0.2382857	0.5868854	0.61868703	0.34230387	0.33780465	0.557287	0.4871076	0.5248598	0.4494816	0.6493518	0
pegloticase	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking pegloticase? Give a 2-3 sentence summary.	Avoid use	['Proceed taking pegloticase as normal. There is no recommendation.', 'Take pegloticase with a reduced dose.', 'Take pegloticase with an increased dose.']	Avoid pegloticase. Take an alternate therapy.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) may be at an increased risk of hemolysis when taking pegloticase. Therefore, it is recommended to use caution and closely monitor for signs of hemolysis if pegloticase is prescribed for these individuals. Consideration should be given to alternative treatment options for managing gout in individuals with G6PD deficiency.	0.22034638977351587	0.29798209054542835	0.2569559045705651	0.6128440751063069	0.2531248	0.37155733	0.29162398	0.6272067	0.10638996	0.1747964	0.18571635	0.65053296	0.09188223	0.17363565	0.17409736	0.57667017	0.36386338	0.5796388	0.47259387	0.64157665	0
pegloticase	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking pegloticase? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid pegloticase. Take an alternate therapy.', 'Take pegloticase with a reduced dose.', 'Take pegloticase with an increased dose.']	Proceed taking pegloticase as normal. There is no recommendation.	For individuals who are Indeterminate for G6PD and need to take pegloticase, it is recommended to closely monitor for signs and symptoms of hemolysis, as pegloticase can potentially trigger hemolytic reactions in individuals with G6PD deficiency. Consideration should be given to using an alternative medication or adjusting the dosage based on individual patient factors and close monitoring of G6PD levels and hemoglobin levels throughout treatment. Additionally, discussion with a healthcare provider specializing in this area is recommended to ensure safe management of the condition.	0.618902903740943	0.4144346370152838	0.37652409244113483	0.6338227148482121	0.57915413	0.2793679	0.3210735	0.5984779	0.646701	0.37694275	0.33661437	0.7101748	0.6231859	0.39990237	0.32525682	0.61046207	0.57153225	0.42390808	0.4283959	0.54593986	0
pegloticase	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking pegloticase? Give a 2-3 sentence summary.	Avoid use	['Proceed taking pegloticase as normal. There is no recommendation.', 'Take pegloticase with a reduced dose.', 'Take pegloticase with an increased dose.']	Avoid pegloticase. Take an alternate therapy.	For individuals deficient in G6PD (glucose-6-phosphate dehydrogenase) with Central and Northern Sardinian haplotype (CNSHA), caution is advised when considering pegloticase therapy due to the potential risk of hemolysis. Close monitoring of hemoglobin levels and signs of hemolysis is recommended if pegloticase treatment is necessary, as these individuals may be at increased risk of experiencing severe side effects. Consultation with a healthcare provider or a clinical pharmacist with expertise in pharmacogenomics is highly recommended to assess the risks and benefits of pegloticase therapy in this population.	0.2091564776213415	0.29798209054542835	0.2569559045705651	0.6094184350710266	0.23881674	0.37155733	0.29162398	0.57296497	0.070867434	0.1747964	0.18571635	0.5997684	0.098573565	0.17363565	0.17409736	0.5874041	0.41342592	0.5796388	0.47259387	0.64750576	0
pegloticase	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking pegloticase? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid pegloticase. Take an alternate therapy.', 'Take pegloticase with a reduced dose.', 'Take pegloticase with an increased dose.']	Proceed taking pegloticase as normal. There is no recommendation.	For individuals who are normal for G6PD (glucose-6-phosphate dehydrogenase), there is no specific clinical guidance regarding the use of pegloticase as pegloticase is not considered to cause any significant risk or adverse effects related to G6PD status. Regular monitoring for treatment efficacy and potential side effects as per standard guidelines for pegloticase therapy would be recommended in this population.	0.6079947097120496	0.42853417818463013	0.33599287042169923	0.6755965056067397	0.5685461	0.4098072	0.217561	0.7044169	0.4783427	0.28910205	0.16120887	0.6984145	0.4787287	0.2068913	0.09266206	0.61148214	0.6184259	0.43167853	0.32591045	0.60920364	1
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking phenazopyridine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid phenazopyridine. Take an alternate therapy.', 'Take phenazopyridine with a reduced dose.', 'Take phenazopyridine with an increased dose.']	Proceed taking phenazopyridine as normal. There is no recommendation.	Individuals who are deficient in G6PD (glucose-6-phosphate dehydrogenase) with CNSHA (chronic non-spherocytic hemolytic anemia) are at an increased risk of hemolysis when exposed to certain medications like phenazopyridine. It is recommended to avoid the use of phenazopyridine in these individuals due to the potential for severe hemolysis. Alternative medications should be considered to manage symptoms of urinary tract infections or other conditions for which phenazopyridine is prescribed.	0.42734339319382325	0.3539091668975645	0.3927109184153717	0.5331469511638274	0.6248642	0.5002355	0.5164551	0.55831134	0.63006175	0.48254967	0.474049	0.54979366	0.57273644	0.39339694	0.3603239	0.48778415	0.54049635	0.42967528	0.48021817	0.5763582	0
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking phenazopyridine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid phenazopyridine. Take an alternate therapy.', 'Take phenazopyridine with a reduced dose.', 'Take phenazopyridine with an increased dose.']	Proceed taking phenazopyridine as normal. There is no recommendation.	For individuals who are normal for G6PD, there is no specific clinical guidance concerning the use of phenazopyridine. This medication is not known to be metabolized by the G6PD enzyme, so no dose adjustments or special monitoring are typically required in individuals with normal G6PD activity. However, as with any medication, it is important to follow the dosing and safety recommendations provided by healthcare professionals.	0.6363280070244782	0.4287327066912678	0.31568525801773767	0.6621909591968489	0.4863795	0.39865574	0.19810335	0.7260622	0.44045445	0.28774935	0.14585656	0.738169	0.43058425	0.16834332	0.09964835	0.59715974	0.6012684	0.46084315	0.331821	0.6447697	1
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking phenazopyridine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid phenazopyridine. Take an alternate therapy.', 'Take phenazopyridine with a reduced dose.', 'Take phenazopyridine with an increased dose.']	Proceed taking phenazopyridine as normal. There is no recommendation.	Individuals who are G6PD deficient may be at risk for hemolytic anemia when taking phenazopyridine, as this medication can cause oxidative stress that could worsen hemolysis in these individuals. Therefore, caution is advised when prescribing phenazopyridine to individuals with G6PD deficiency, and alternative non-oxidative medications should be considered to manage symptoms such as urinary tract pain. Consulting a healthcare provider or pharmacist for personalized recommendations based on the individual's specific healthcare needs is recommended.	0.6019070050971652	0.48869851183414725	0.3837959319455644	0.5976964932114515	0.5672612	0.5575637	0.35187903	0.54303473	0.63109434	0.49766034	0.3031375	0.59506035	0.6590551	0.44163874	0.33736953	0.5532283	0.5283949	0.5493739	0.41835925	0.572465	0
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking phenazopyridine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid phenazopyridine. Take an alternate therapy.', 'Take phenazopyridine with a reduced dose.', 'Take phenazopyridine with an increased dose.']	Proceed taking phenazopyridine as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) may be at increased risk of hemolytic anemia when exposed to phenazopyridine, as it may trigger oxidative stress leading to red blood cell damage. Therefore, it is generally recommended to avoid phenazopyridine in individuals with G6PD deficiency to prevent serious complications such as hemolysis. Physicians should consider alternative pain management options for individuals with G6PD deficiency.	0.6095132865362802	0.48869851183414725	0.3837959319455644	0.5492812656561828	0.57323724	0.5575637	0.35187903	0.57671624	0.605813	0.49766034	0.3031375	0.56081766	0.60971856	0.44163874	0.33736953	0.54666466	0.5525456	0.5493739	0.41835925	0.5520371	0
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin? Give a 2-3 sentence summary.	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	['Avoid phenytoin. Take an alternate therapy.', 'Take phenytoin with a reduced dose.', 'Take phenytoin with an increased dose.']	Proceed taking phenytoin as normal. There is no recommendation.	For individuals who are HLA-B*15:02 negative, the risk of developing Stevens-Johnson syndrome or toxic epidermal necrolysis when taking phenytoin is significantly lower compared to those who are positive for HLA-B*15:02. Therefore, in the absence of this specific genetic variant, there is reduced concern for severe skin reactions associated with phenytoin use. However, it is still recommended to closely monitor for any signs of adverse reactions while taking phenytoin, as individual responses can vary.	0.7383697132139012	0.5941313711752331	0.5563997669360304	0.5611246787738733	0.6392421	0.6312081	0.5283107	0.5163703	0.72903156	0.62854886	0.5542701	0.53234226	0.70310175	0.5241668	0.5305268	0.47392944	0.77444893	0.52779835	0.50937027	0.5286404	1
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin? Give a 2-3 sentence summary.	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	['Proceed taking phenytoin as normal. There is no recommendation.', 'Avoid phenytoin. Take an alternate therapy.']	Take phenytoin with an altered dose.	Individuals with No HLA-B Result for HLA-B are generally considered to be at average risk for developing phenytoin-induced severe cutaneous adverse reactions (SCARs). Clinical guidance for these individuals may involve standard monitoring for signs and symptoms of adverse reactions while on phenytoin therapy, along with appropriate dosing adjustments based on clinical response. It is still recommended to monitor closely for any signs of adverse reactions when initiating phenytoin therapy in these individuals.	0.6777460059241777	0.5854740858915999	0.5958967520919687	0.49513916358727555	0.58741486	0.5539176	0.6040654	0.3721698	0.59348226	0.5490833	0.6752889	0.35460967	0.65416366	0.54993606	0.53744864	0.37592164	0.71223974	0.55776227	0.5125804	0.5000596	0
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin? Give a 2-3 sentence summary.	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	['Proceed taking phenytoin as normal. There is no recommendation.', 'Avoid phenytoin. Take an alternate therapy.']	Take phenytoin with an altered dose.	Individuals with No HLA-B Result for HLA-B are generally considered to be at average risk for developing phenytoin-induced severe cutaneous adverse reactions (SCARs). Clinical guidance for these individuals may involve standard monitoring for signs and symptoms of adverse reactions while on phenytoin therapy, along with appropriate dosing adjustments based on clinical response. It is still recommended to monitor closely for any signs of adverse reactions when initiating phenytoin therapy in these individuals.	0.6780994351160248	0.5851076454452884	0.5961573440046032	0.49513916358727555	0.5723119	0.54565316	0.5921931	0.3721698	0.5806771	0.5445964	0.6684654	0.35460967	0.64497954	0.55336046	0.53762925	0.37592164	0.7116458	0.55979866	0.51231253	0.5000596	0
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin? Give a 2-3 sentence summary.	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	['Avoid phenytoin. Take an alternate therapy.', 'Take phenytoin with a reduced dose.', 'Take phenytoin with an increased dose.']	Proceed taking phenytoin as normal. There is no recommendation.	For individuals who are HLA-B*15:02 positive, particularly in certain populations such as those of Asian descent, it is recommended to avoid the use of phenytoin due to an increased risk of developing severe cutaneous adverse reactions, specifically Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Alternative antiepileptic medications should be considered in these individuals to prevent these potentially life-threatening reactions. Genetic testing for HLA-B*15:02 prior to initiating phenytoin therapy is recommended in populations with a high prevalence of this allele.	0.6942402493011642	0.5608653544805681	0.5544001017735645	0.5733060184946657	0.53885174	0.59154713	0.52103406	0.59148747	0.5618792	0.64347273	0.5483784	0.53497916	0.5035815	0.5169034	0.5282492	0.4362353	0.48240992	0.48335138	0.4902078	0.5555973	0
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking piroxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid piroxicam. Take an alternate therapy.', 'Take piroxicam with a reduced dose.', 'Take piroxicam with an increased dose.']	Proceed taking piroxicam as normal. There is no recommendation.	Individuals who are Normal Metabolizers with an activity score of 2.0 for CYP2C9 may have normal metabolism of drugs like piroxicam. However, as with all medications, it is important for healthcare providers to monitor for potential adverse reactions or changes in response to treatment. Close monitoring for efficacy and potential side effects is recommended when taking piroxicam in this population.	0.33765309148713757	0.43231982704298505	0.43786295664995545	0.6021311695173963	0.32777482	0.35056245	0.29469594	0.5807866	0.26985976	0.4132601	0.2480439	0.6136586	0.26367792	0.38000882	0.36730972	0.46773505	0.32817253	0.467388	0.4555997	0.6562628	0
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking piroxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid piroxicam. Take an alternate therapy.', 'Take piroxicam with a reduced dose.', 'Take piroxicam with an increased dose.']	Proceed taking piroxicam as normal. There is no recommendation.	For individuals who are Intermediate Metabolizers with CYP2C9 activity score of 1.5, cautious dosing adjustments may be necessary when taking piroxicam, a medication metabolized by CYP2C9. Close monitoring for potential adverse effects or decreased efficacy of piroxicam is recommended to optimize treatment outcomes in this population. It is advisable to consult with a healthcare provider or a pharmacist for personalized dosing recommendations based on individual genotype and clinical factors.	0.3981430817048698	0.43231982704298505	0.43786295664995545	0.6203153289949205	0.466336	0.35056245	0.29469594	0.5139154	0.39961147	0.4132601	0.2480439	0.6034514	0.39623618	0.38000882	0.36730972	0.5444613	0.4806915	0.467388	0.4555997	0.6088966	0
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking piroxicam? Give a 2-3 sentence summary.	No recommendation	['Avoid piroxicam. Take an alternate therapy.', 'Take piroxicam with a reduced dose.', 'Take piroxicam with an increased dose.']	Proceed taking piroxicam as normal. There is no recommendation.	For individuals classified as Indeterminate for CYP2C9 with regards to taking piroxicam, it is recommended to consider alternatives with lower CYP2C9 metabolism dependence or to start with a lower dose of piroxicam and closely monitor for efficacy and adverse effects. Additionally, regular monitoring for drug response and potential side effects can aid in adjusting the dosage as needed for optimal therapeutic outcomes.	0.28373720195177177	0.46262241622174644	0.23498001668003513	0.6415615922116729	0.21816091	0.37049466	0.2272154	0.621079	0.13681465	0.26741773	0.18145466	0.6729586	-0.007613655	0.32825956	0.080221005	0.54021317	0.3131283	0.5253647	0.3766552	0.62820387	0
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking piroxicam? Give a 2-3 sentence summary.	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	['Proceed taking piroxicam as normal. There is no recommendation.', 'Take piroxicam with a reduced dose.', 'Take piroxicam with an increased dose.']	Avoid piroxicam. Take an alternate therapy.	For an Intermediate Metabolizer with an activity score of 1.0 for CYP2C9 taking piroxicam, it is recommended to monitor for potential adverse effects and consider dosage adjustments based on clinical response. This is important as individuals with reduced CYP2C9 activity may be at a higher risk of experiencing drug-related side effects or reduced efficacy when taking medications metabolized by this enzyme. Consultation with a healthcare provider or a pharmacogenomics expert can help determine the most appropriate dosage for optimal therapeutic outcomes.	0.6036709054536655	0.6194366849470393	0.5103363520932606	0.6179175883721358	0.5989396	0.5393946	0.43539992	0.52855647	0.6761248	0.32969302	0.27722454	0.54876196	0.6012501	0.42809734	0.38362703	0.45207918	0.5984243	0.5536652	0.5251735	0.5769116	0
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking pitavastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid pitavastatin. Take an alternate therapy.', 'Take pitavastatin with a reduced dose.', 'Take pitavastatin with an increased dose.']	Proceed taking pitavastatin as normal. There is no recommendation.	Individuals with an increased function variant in SLCO1B1 may have a higher risk of experiencing adverse effects from pitavastatin due to increased drug uptake into the liver. Close monitoring for side effects such as myopathy and liver toxicity may be necessary, and consideration of a lower starting dose of pitavastatin could be appropriate in these individuals. Consulting with a healthcare provider or a pharmacist for personalized recommendations is recommended.	0.34637155328372404	0.3738394401778674	0.3665385020649207	0.5622680797982241	0.4528881	0.29842973	0.37568787	0.52432156	0.40526626	0.44845253	0.33967733	0.6887736	0.32707524	0.3579497	0.31679413	0.51346505	0.45720166	0.4783974	0.569094	0.54635656	0
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking pitavastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid pitavastatin. Take an alternate therapy.', 'Take pitavastatin with a reduced dose.', 'Take pitavastatin with an increased dose.']	Proceed taking pitavastatin as normal. There is no recommendation.	For individuals who are Normal Function for SLCO1B1, there is no specific recommendation to adjust the dose of pitavastatin based on this gene alone. However, it is important to consider other factors such as age, liver function, concurrent medications, and other medical conditions when determining the appropriate dose of pitavastatin to ensure optimal efficacy and safety. Close monitoring for any signs of adverse drug reactions or treatment failure is recommended.	0.409020621214181	0.3738394401778674	0.3665385020649207	0.6793773881353232	0.5440568	0.29842973	0.37568787	0.516346	0.54349834	0.44845253	0.33967733	0.6527118	0.4784831	0.3579497	0.31679413	0.54849356	0.47466797	0.4783974	0.569094	0.6128824	1
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking pitavastatin? Give a 2-3 sentence summary.	No recommendation	['Avoid pitavastatin. Take an alternate therapy.', 'Take pitavastatin with a reduced dose.', 'Take pitavastatin with an increased dose.']	Proceed taking pitavastatin as normal. There is no recommendation.	Individuals who are classified as Indeterminate for SLCO1B1 may have a variable response to pitavastatin due to their genetic makeup. It is recommended to consider personalized dosing based on other clinical factors, such as lipid levels and tolerance to the medication. Close monitoring for any potential side effects or efficacy issues is crucial in individuals with an Indeterminate SLCO1B1 genotype when taking pitavastatin.	0.22821826343092624	0.4630801461764192	0.22187783001761704	0.5426123291816639	0.13122204	0.2974844	0.14459728	0.53104496	0.058242578	0.18318969	0.07401037	0.57313097	-0.06337998	0.26902944	0.061543923	0.3658464	0.25862324	0.49070147	0.3865284	0.5173221	0
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking pitavastatin? Give a 2-3 sentence summary.	Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >1mg. If dose >2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	['Proceed taking pitavastatin as normal. There is no recommendation.', 'Avoid pitavastatin. Take an alternate therapy.']	Take pitavastatin with an altered dose.	For someone with Possible Decreased Function for SLCO1B1 gene, caution should be taken when considering pitavastatin therapy as they may be at an increased risk of experiencing statin-induced myopathy due to impaired transport of statins into the liver. Close monitoring for adverse drug reactions, especially muscle-related symptoms, and consideration of alternative statins or lower doses may be warranted to minimize potential side effects and optimize therapeutic outcomes. Consulting with a healthcare provider or a pharmacogenomics expert for personalized recommendations is recommended.	0.7379496670122724	0.707962598951693	0.6749716719216314	0.6419021402804035	0.6870818	0.6625408	0.60888934	0.56899923	0.701011	0.66534716	0.72140014	0.5785845	0.61129516	0.6414486	0.6054331	0.51365227	0.69155264	0.69705236	0.60709554	0.6631543	0
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking plazomicin as normal. There is no recommendation.', 'Take plazomicin with a reduced dose.', 'Take plazomicin with an increased dose.']	Avoid plazomicin. Take an alternate therapy.	Individuals with an increased risk of aminoglycoside-induced hearing loss due to MT-RNR1 variants should exercise caution when taking plazomicin, another aminoglycoside antibiotic. Close monitoring of hearing function and renal function is recommended before and during treatment with plazomicin in these individuals to minimize the risk of ototoxicity. Consulting a healthcare provider with expertise in pharmacogenomics and ototoxicity is advised for personalized clinical guidance.	0.5833485703971402	0.4472512092312358	0.3727989293258867	0.5882089733334809	0.69074357	0.5412148	0.4360197	0.57222223	0.72136277	0.35951802	0.36452246	0.524307	0.7214386	0.38931897	0.3954724	0.47500545	0.60384667	0.5577428	0.44866768	0.6026178	0
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid plazomicin. Take an alternate therapy.', 'Take plazomicin with a reduced dose.', 'Take plazomicin with an increased dose.']	Proceed taking plazomicin as normal. There is no recommendation.	Individuals with normal risk of aminoglycoside-induced hearing loss related to MT-RNR1 gene variants may still be at a slightly increased risk compared to the general population when taking plazomicin, an aminoglycoside antibiotic. Therefore, caution should be exercised when prescribing plazomicin to these individuals, and close monitoring for hearing loss should be considered during treatment. Pharmacogenomic testing may help identify those at higher risk for adverse effects and guide personalized treatment decisions.	0.5138431624969015	0.3899982173670886	0.3817365061863362	0.5726715795183818	0.5513752	0.42339244	0.42624426	0.50294966	0.6234955	0.4513895	0.44311866	0.4790451	0.70680887	0.48940736	0.4860718	0.46094453	0.57295895	0.45863158	0.50893945	0.52137214	0
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid plazomicin. Take an alternate therapy.', 'Take plazomicin with a reduced dose.', 'Take plazomicin with an increased dose.']	Proceed taking plazomicin as normal. There is no recommendation.	Patients with MT-RNR1 variants may be at an increased risk of aminoglycoside-induced hearing loss. Plazomicin is an aminoglycoside antibiotic, so extra caution should be taken when considering its use in individuals with MT-RNR1 variants. It is essential to consult with a healthcare provider or a genetic counselor to assess the individual's specific risk factors and determine the best course of action to minimize the risk of hearing loss while still providing effective treatment.	0.5078716131850556	0.3899982173670886	0.3817365061863362	0.5042988799020726	0.49384782	0.42339244	0.42624426	0.47338665	0.56012017	0.4513895	0.44311866	0.5401077	0.6410301	0.48940736	0.4860718	0.51103014	0.5636514	0.45863158	0.50893945	0.52744	0
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking pravastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid pravastatin. Take an alternate therapy.', 'Take pravastatin with a reduced dose.', 'Take pravastatin with an increased dose.']	Proceed taking pravastatin as normal. There is no recommendation.	Individuals who are Increased Function for SLCO1B1 may have higher plasma concentrations of pravastatin due to increased uptake into the liver. This could potentially increase the risk of adverse effects, such as myopathy. Therefore, these individuals may benefit from a lower starting dose of pravastatin and close monitoring for any signs of muscle toxicity.	0.3408663142361555	0.3605569898414859	0.3542630150556501	0.5077790460522941	0.37359017	0.31167483	0.37594128	0.47205132	0.36643532	0.44127497	0.3295271	0.56337637	0.34831724	0.3474089	0.3156984	0.49839255	0.37824246	0.49523875	0.5714204	0.48445445	0
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking pravastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid pravastatin. Take an alternate therapy.', 'Take pravastatin with a reduced dose.', 'Take pravastatin with an increased dose.']	Proceed taking pravastatin as normal. There is no recommendation.	For individuals who are Normal Function for SLCO1B1, no dose adjustment is typically required when taking pravastatin, a medication used to lower cholesterol levels. Regular monitoring for any signs of adverse effects or lack of therapeutic response should be conducted per standard practice guidelines.	0.36989217113863654	0.3605569898414859	0.3542630150556501	0.6435278176161187	0.43726853	0.31167483	0.37594128	0.66278845	0.5194055	0.44127497	0.3295271	0.6879935	0.4265673	0.3474089	0.3156984	0.53650546	0.5012195	0.49523875	0.5714204	0.5910456	1
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking pravastatin? Give a 2-3 sentence summary.	No recommendation	['Avoid pravastatin. Take an alternate therapy.', 'Take pravastatin with a reduced dose.', 'Take pravastatin with an increased dose.']	Proceed taking pravastatin as normal. There is no recommendation.	Individuals who are categorized as Indeterminate for SLCO1B1 may have a variable response to pravastatin due to uncertainty in their genetic profile. In this case, it is recommended to monitor closely for potential adverse effects and lipid-lowering response when initiating pravastatin therapy. Consideration of alternative statins with different metabolic pathways may also be warranted in some cases.	0.22593803259217676	0.4604720300723354	0.21207025254258874	0.5180964508253583	0.11876216	0.30104142	0.1422076	0.51714355	0.052655715	0.1877276	0.07142191	0.5945016	-0.0523697	0.28907138	0.06006204	0.44718096	0.32045788	0.5008195	0.40348327	0.5337141	0
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking pravastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.	['Avoid pravastatin. Take an alternate therapy.', 'Take pravastatin with a reduced dose.', 'Take pravastatin with an increased dose.']	Proceed taking pravastatin as normal. There is no recommendation.	For someone who is Possible Decreased Function for SLCO1B1 and considering taking pravastatin, it is recommended to closely monitor for potential adverse effects such as increased risk of statin-induced myopathy. Adjustments in pravastatin dosage or selection of alternative medications may be considered based on individual response and tolerability. Consulting with a healthcare provider or a clinical pharmacist with expertise in pharmacogenomics can help in making informed decisions regarding pravastatin therapy for this individual.	0.7588103174825382	0.620144850658007	0.6545112391949791	0.587575183567754	0.6860832	0.53047866	0.54431134	0.5438873	0.5777003	0.6562759	0.5162477	0.62168777	0.5559876	0.52027243	0.5000932	0.5160556	0.6572119	0.5667448	0.6025362	0.5922754	0
primaquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking primaquine? Give a 2-3 sentence summary.	Avoid primaquine, except in the following cases where established expert consensus guidelines for the treatment of malaria should be followed: (1) Treating Plasmodium vivax or Plasmodium ovale malaria for radical cure of liver-stage infections: 0.75 mg/kg once weekly x8 weeks (WHO) or 45 mg once weekly x8 weeks (CDC) - with close monitoring for hemolysis; (2) Treating Plasmodium falciparum malaria by using primaquine single dose as a gametocytocide at 0.25 mg/kg (WHO) - without need for monitoring for hemolysis.	['Proceed taking primaquine as normal. There is no recommendation.', 'Take primaquine with a reduced dose.', 'Take primaquine with an increased dose.']	Avoid primaquine. Take an alternate therapy.	For individuals who are deficient in the enzyme glucose-6-phosphate dehydrogenase (G6PD), caution is advised when considering treatment with primaquine, as it can cause hemolysis (breakdown of red blood cells) in these individuals. The decision to use primaquine in G6PD-deficient individuals should be made carefully, weighing the risks and benefits, and close monitoring for signs of hemolysis is recommended if the medication is prescribed. It is crucial to consult with a healthcare provider who is knowledgeable about pharmacogenomics before initiating treatment with primaquine in individuals with G6PD deficiency.	0.6816847907152821	0.6726552337278622	0.6680096506396304	0.5538574583196977	0.5882841	0.58287287	0.5400314	0.52343005	0.6432602	0.58089745	0.5449776	0.57452434	0.57135105	0.6139145	0.56615275	0.5866523	0.47006905	0.5496724	0.53993255	0.5510402	0
primaquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking primaquine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid primaquine. Take an alternate therapy.', 'Take primaquine with a reduced dose.', 'Take primaquine with an increased dose.']	Proceed taking primaquine as normal. There is no recommendation.	Individuals who are classified as Indeterminate for G6PD may have reduced enzyme activity, which puts them at risk for developing hemolysis when taking drugs like primaquine. In such cases, it is recommended to consider alternative treatments or closely monitor for signs of hemolysis if primaquine is necessary, especially at higher doses. Consulting a healthcare provider with expertise in pharmacogenomics is advisable to make informed decisions regarding the use of primaquine in individuals with an Indeterminate G6PD status.	0.6448250017521001	0.3957739150872026	0.3357205345318657	0.5373647175069525	0.54359776	0.2341523	0.2933162	0.5874066	0.63635486	0.29548275	0.21225011	0.63103044	0.69983286	0.28192836	0.21875142	0.5102177	0.5561024	0.4019604	0.39547744	0.518943	0
primaquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking primaquine? Give a 2-3 sentence summary.	Avoid primaquine	['Proceed taking primaquine as normal. There is no recommendation.', 'Take primaquine with a reduced dose.', 'Take primaquine with an increased dose.']	Avoid primaquine. Take an alternate therapy.	Individuals who are deficient in G6PD (glucose-6-phosphate dehydrogenase) and are classified as CNSHA (Class II severe enzyme deficiency) are at a higher risk of developing hemolytic anemia when exposed to medications such as primaquine, which can trigger oxidative stress on red blood cells. Therefore, caution must be exercised when considering primaquine therapy in these individuals, and alternative treatment options should be explored to avoid potential adverse effects on the red blood cells. Consulting with a healthcare provider or a pharmacogenomics expert is recommended to determine the most appropriate course of action.	0.538002088836529	0.7941096806073801	0.7327787493016475	0.5160747856855481	0.5676876	0.7907023	0.6753638	0.45683855	0.5906409	0.81679296	0.7111111	0.55952877	0.602757	0.85295165	0.7064869	0.55584383	0.62062526	0.91153246	0.7195818	0.5733908	0
primaquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking primaquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid primaquine. Take an alternate therapy.', 'Take primaquine with a reduced dose.', 'Take primaquine with an increased dose.']	Proceed taking primaquine as normal. There is no recommendation.	For individuals who are normal for G6PD enzyme activity, primaquine can be considered a safe and effective treatment for malaria. Clinical guidance typically includes checking G6PD status before prescribing primaquine, monitoring for signs of hemolysis during treatment, and ensuring appropriate dosing based on guidelines to minimize the risk of adverse effects such as hemolysis.	0.60011458146909	0.44320085399607934	0.320001652324512	0.6215206343858499	0.44800168	0.3753424	0.19332863	0.52959454	0.38495824	0.25333205	0.11490496	0.6405019	0.34890342	0.186888	0.110461764	0.5702015	0.53231287	0.42969733	0.31606653	0.54744446	0
quinine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking quinine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid quinine. Take an alternate therapy.', 'Take quinine with a reduced dose.', 'Take quinine with an increased dose.']	Proceed taking quinine as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) should avoid using quinine due to the risk of hemolysis (destruction of red blood cells) in those with G6PD deficiency. Quinine can trigger hemolytic reactions in these individuals, leading to serious complications. It is important for healthcare providers to be aware of the patient's G6PD status before prescribing quinine to prevent potential harm.	0.6061234598600935	0.4967947110564648	0.37685150025040626	0.5247727385804458	0.56848264	0.53719854	0.3285966	0.665839	0.5860739	0.4374044	0.26512942	0.7012218	0.5636689	0.42400327	0.3297743	0.536078	0.53447205	0.5053088	0.39155784	0.5197742	0
quinine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking quinine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid quinine. Take an alternate therapy.', 'Take quinine with a reduced dose.', 'Take quinine with an increased dose.']	Proceed taking quinine as normal. There is no recommendation.	Individuals who are indeterminate for G6PD deficiency should exercise caution when taking medications that can trigger hemolysis, including quinine. Close monitoring for signs of hemolysis, such as fatigue, jaundice, or dark urine, is recommended. The decision to use quinine in these individuals should be made on a case-by-case basis, weighing the potential benefits against the risk of hemolysis.	0.6152721627264786	0.40342793252349174	0.3370589114570923	0.5636037917918133	0.58492637	0.2657501	0.28618404	0.6141034	0.62020373	0.30287367	0.23640962	0.6506276	0.5591826	0.23715203	0.20171905	0.51719743	0.5185731	0.40367126	0.3890513	0.48021865	0
quinine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking quinine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid quinine. Take an alternate therapy.', 'Take quinine with a reduced dose.', 'Take quinine with an increased dose.']	Proceed taking quinine as normal. There is no recommendation.	Individuals who are Deficient with CNSHA for G6PD (Glucose-6-Phosphate Dehydrogenase) are at an increased risk of hemolytic anemia if exposed to certain medications like quinine. Quinine can trigger hemolysis in individuals with G6PD deficiency, so it is generally recommended to avoid quinine-containing products in these individuals and consider alternative treatments. Consulting with a healthcare provider or pharmacist for personalized guidance based on the individual's specific genetic profile and medical history is recommended.	0.4282467036881245	0.4036725417225148	0.4310828828951392	0.4696148516677185	0.52901286	0.4960569	0.47003403	0.570737	0.5181793	0.43650675	0.4023614	0.5910829	0.45029062	0.3602717	0.32208076	0.48367748	0.5615082	0.4022845	0.46001694	0.5038586	0
quinine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking quinine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid quinine. Take an alternate therapy.', 'Take quinine with a reduced dose.', 'Take quinine with an increased dose.']	Proceed taking quinine as normal. There is no recommendation.	Individuals who are Normal for G6PD are not at an increased risk for quinine-induced hemolysis. They should be able to take quinine as prescribed without any specific concerns related to their G6PD status. It is always advisable to follow healthcare provider guidance and monitor for any signs of adverse reactions while taking quinine.	0.6640908030581963	0.42819000638130583	0.30016950791040203	0.6141077199494023	0.48760462	0.40508378	0.18798845	0.66611326	0.45062393	0.27897647	0.12627245	0.69891244	0.4256308	0.13878319	0.08471268	0.5135549	0.51009655	0.41710633	0.29671517	0.58128035	1
rasburicase	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking rasburicase? Give a 2-3 sentence summary.	Avoid use	['Proceed taking rasburicase as normal. There is no recommendation.', 'Take rasburicase with a reduced dose.', 'Take rasburicase with an increased dose.']	Avoid rasburicase. Take an alternate therapy.	Individuals who are deficient in Glucose-6-Phosphate Dehydrogenase (G6PD) are at an increased risk of developing hemolytic anemia when exposed to rasburicase, a medication used to prevent and treat high uric acid levels in the blood. It is generally recommended to avoid rasburicase in individuals with G6PD deficiency due to the potential for severe hemolysis. Alternative medications or treatments should be considered in such cases.	0.2374392716274982	0.30641063544360625	0.25943499170577683	0.5852670344546135	0.27469078	0.43802193	0.3459865	0.5619538	0.15107974	0.24215324	0.23364854	0.60126126	0.13516802	0.18794441	0.17483377	0.64443046	0.42166072	0.59386873	0.47473112	0.6332366	1
rasburicase	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking rasburicase? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid rasburicase. Take an alternate therapy.', 'Take rasburicase with a reduced dose.', 'Take rasburicase with an increased dose.']	Proceed taking rasburicase as normal. There is no recommendation.	For individuals who are Indeterminate for G6PD, caution is advised when considering the use of rasburicase, as it may potentially cause hemolysis in this population. Prior to initiating rasburicase therapy, consulting with a healthcare provider experienced in managing G6PD deficiency is recommended to weigh the risks and benefits of treatment.	0.5961240339823465	0.39656991086299803	0.33292973587823566	0.6343946450530851	0.49531046	0.33025667	0.32421282	0.5950915	0.5799074	0.3262097	0.31580418	0.5964116	0.6434255	0.3295244	0.28478152	0.5596746	0.53133196	0.3680207	0.37297413	0.44413927	0
rasburicase	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking rasburicase? Give a 2-3 sentence summary.	Avoid use	['Proceed taking rasburicase as normal. There is no recommendation.', 'Take rasburicase with a reduced dose.', 'Take rasburicase with an increased dose.']	Avoid rasburicase. Take an alternate therapy.	Individuals who are deficient with CNSHA (Class III deficient) for the glucose-6-phosphate dehydrogenase (G6PD) enzyme may be at increased risk of hemolysis if administered rasburicase. Therefore, it is generally recommended to avoid the use of rasburicase in patients with G6PD deficiency to prevent potential severe hemolytic reactions. Alternative management strategies should be considered for these individuals.	0.25942506002592264	0.30641063544360625	0.25943499170577683	0.6129422434154561	0.34171554	0.43802193	0.3459865	0.56218606	0.16740808	0.24215324	0.23364854	0.55713266	0.11480813	0.18794441	0.17483377	0.56555676	0.4289452	0.59386873	0.47473112	0.56330055	1
rasburicase	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking rasburicase? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid rasburicase. Take an alternate therapy.', 'Take rasburicase with a reduced dose.', 'Take rasburicase with an increased dose.']	Proceed taking rasburicase as normal. There is no recommendation.	For individuals who are normal for glucose-6-phosphate dehydrogenase (G6PD) deficiency, there is no need for special precautions when taking rasburicase. Rasburicase is an enzyme that is used to prevent and treat high levels of uric acid in the blood, particularly in the setting of oncologic conditions such as leukemia. Monitoring renal function and blood parameters is recommended as part of routine care when using rasburicase, but G6PD status does not typically impact its use in these individuals.	0.5613652924505423	0.43253236665501205	0.3208549059716987	0.6572963027986306	0.5002143	0.43342674	0.25304696	0.6390734	0.46216106	0.28556177	0.18659031	0.64567006	0.3205271	0.1643905	0.07426436	0.5824426	0.4871718	0.3957399	0.30261493	0.51091385	1
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking ribostamycin as normal. There is no recommendation.', 'Take ribostamycin with a reduced dose.', 'Take ribostamycin with an increased dose.']	Avoid ribostamycin. Take an alternate therapy.	Individuals with an increased risk of aminoglycoside-induced hearing loss due to MT-RNR1 variants should exercise caution when taking ribostamycin, as this antibiotic is an aminoglycoside and can potentially cause ototoxicity. Prior to prescribing ribostamycin, clinicians should consider alternative antibiotics or adjust the dosage based on the individual's genotype to minimize the risk of hearing loss associated with aminoglycosides. Regular monitoring for signs of ototoxicity during treatment is also recommended.	0.666950671750674	0.48833956935868106	0.4221317569519207	0.6006681515330998	0.6884811	0.6176445	0.48445666	0.5747496	0.72274184	0.4974237	0.47291005	0.62859434	0.7623984	0.45414892	0.44387367	0.5992613	0.6231226	0.6050108	0.4826611	0.6177821	0
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid ribostamycin. Take an alternate therapy.', 'Take ribostamycin with a reduced dose.', 'Take ribostamycin with an increased dose.']	Proceed taking ribostamycin as normal. There is no recommendation.	For individuals with normal risk of aminoglycoside-induced hearing loss related to the MT-RNR1 gene, there is currently no specific clinical guidance available for taking ribostamycin. However, given the potential risk of aminoglycoside-associated ototoxicity, it is advisable to closely monitor hearing and kidney function during treatment with ribostamycin and consider alternative antibiotics if needed based on individual response and clinical judgment. Consulting with a healthcare provider or genetic counselor for personalized recommendations is recommended.	0.6234195986991324	0.43799749649876824	0.4383074833363336	0.6339944630322416	0.5354349	0.4458685	0.4887046	0.6235896	0.7017476	0.52710116	0.5449565	0.64459795	0.7356939	0.5056631	0.50599897	0.5552063	0.5877296	0.4805947	0.5332294	0.5760476	0
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid ribostamycin. Take an alternate therapy.', 'Take ribostamycin with a reduced dose.', 'Take ribostamycin with an increased dose.']	Proceed taking ribostamycin as normal. There is no recommendation.	For individuals with uncertain risk of aminoglycoside-induced hearing loss due to variations in the MT-RNR1 gene, it is advisable to consider the use of ribostamycin with caution. Due to the potential increased risk of hearing loss associated with aminoglycoside use in individuals with specific genetic variations, close monitoring for hearing function and dosage adjustments may be warranted to minimize the risk. Consulting with a healthcare provider or a pharmacogenomics specialist can help in making informed decisions regarding the use of ribostamycin in such individuals.	0.6174722776040802	0.43799749649876824	0.4383074833363336	0.5383918358011308	0.54224694	0.4458685	0.4887046	0.54426426	0.66077375	0.52710116	0.5449565	0.5990121	0.6808063	0.5056631	0.50599897	0.49339736	0.5986359	0.4805947	0.5332294	0.5083318	0
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Increased Function for SLCO1B1 with regards to taking rosuvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.	['Avoid rosuvastatin. Take an alternate therapy.', 'Take rosuvastatin with a reduced dose.', 'Take rosuvastatin with an increased dose.']	Proceed taking rosuvastatin as normal. There is no recommendation.	For an individual with Normal Function for ABCG2 and Increased Function for SLCO1B1, they may have an increased risk of myopathy when taking rosuvastatin due to the potential for higher systemic exposure to the drug. Close monitoring for symptoms of muscle pain or weakness is important, and consideration of a lower starting dose or alternative statin may be warranted to reduce the risk of adverse effects while still achieving lipid-lowering goals.	0.5283798270991233	0.5865816200693775	0.6182407535591358	0.5372187813435593	0.45798448	0.4243364	0.52305996	0.5061336	0.606695	0.7216861	0.6284959	0.6594234	0.523468	0.52674925	0.5363809	0.54961693	0.5692214	0.66564703	0.7043523	0.5605552	0
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Decreased Function for SLCO1B1 with regards to taking rosuvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.	['Avoid rosuvastatin. Take an alternate therapy.', 'Take rosuvastatin with a reduced dose.', 'Take rosuvastatin with an increased dose.']	Proceed taking rosuvastatin as normal. There is no recommendation.	For someone with Normal Function for ABCG2 and Decreased Function for SLCO1B1, they may be at an increased risk of muscle-related side effects when taking rosuvastatin. It is recommended to closely monitor for signs of muscle pain or weakness and consider dose adjustments or alternative statin medications if side effects occur. Additionally, counseling on lifestyle modifications and regular follow-up with healthcare providers is important to manage and monitor their statin therapy effectively.	0.6351882676966292	0.6027693991621845	0.6433591914629337	0.5433560979241553	0.64389366	0.5140376	0.5700909	0.5682328	0.6025076	0.68006384	0.55727243	0.649509	0.46404782	0.5050037	0.49876928	0.55840075	0.6340261	0.574435	0.6064827	0.5529289	0
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and Normal Function for SLCO1B1 with regards to taking rosuvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.	['Avoid rosuvastatin. Take an alternate therapy.', 'Take rosuvastatin with a reduced dose.', 'Take rosuvastatin with an increased dose.']	Proceed taking rosuvastatin as normal. There is no recommendation.	For a person who has Decreased Function for ABCG2 and Normal Function for SLCO1B1, they may be at increased risk for myopathy when taking rosuvastatin, a commonly prescribed statin. Close monitoring for muscle symptoms and potential dose adjustments may be considered to minimize the risk of adverse effects while still benefiting from the lipid-lowering effects of rosuvastatin. Consulting with a healthcare provider or a pharmacist for personalized guidance is recommended.	0.5656444492029667	0.5865816200693775	0.6182407535591358	0.5632440624498929	0.5129453	0.4243364	0.52305996	0.53533	0.5857226	0.7216861	0.6284959	0.6380193	0.5105757	0.52674925	0.5363809	0.5786454	0.639306	0.66564703	0.7043523	0.57602894	0
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and No Result for SLCO1B1 with regards to taking rosuvastatin? Give a 2-3 sentence summary.	Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific guidelines and specific population guidelines. SLCO1B1 genotype result is not available.	['Avoid rosuvastatin. Take an alternate therapy.', 'Take rosuvastatin with a reduced dose.', 'Take rosuvastatin with an increased dose.']	Proceed taking rosuvastatin as normal. There is no recommendation.	For an individual with Decreased Function for ABCG2 and No Result for SLCO1B1, caution should be exercised when prescribing rosuvastatin due to potential increased risk of side effects or reduced efficacy. Close monitoring for adverse effects and lipid levels is recommended, and consideration of alternative statins or dose adjustments may be necessary. Consulting with a healthcare provider or a pharmacogenomics specialist for personalized guidance is advisable.	0.8137280228850402	0.5743903681949449	0.6018017344721867	0.5700664313526741	0.7755407	0.5871856	0.48963356	0.6321586	0.87850744	0.67801756	0.59198934	0.68325615	0.7566693	0.5029694	0.48327032	0.57322955	0.7940207	0.6010229	0.5738715	0.6132281	0
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is No Result for CYP2B6 and Indeterminate for CYP2C19 with regards to taking sertraline? Give a 2-3 sentence summary.	No recommendation	['Avoid sertraline. Take an alternate therapy.', 'Take sertraline with a reduced dose.', 'Take sertraline with an increased dose.']	Proceed taking sertraline as normal. There is no recommendation.	For individuals with No Result for CYP2B6 and Indeterminate for CYP2C19, prescribing sertraline may require closer monitoring for potential adverse effects or therapeutic response variability. Clinicians may consider starting at a lower dose and titrating based on individual response, as genetic variations in these enzymes may influence sertraline metabolism and efficacy. Regular monitoring for adverse effects and therapeutic response is recommended in such individuals to optimize treatment outcomes.	0.23381841258121921	0.4327824774902563	0.20945409364805853	0.5688495331632886	0.084002	0.3150432	0.16553693	0.5344684	0.020096123	0.17384869	0.10388883	0.62751156	-0.0026231594	0.3057449	0.09174416	0.5473367	0.32629162	0.5215013	0.3970836	0.5991604	0
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and No Result for CYP2C19 with regards to taking sertraline? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid sertraline. Take an alternate therapy.', 'Take sertraline with a reduced dose.', 'Take sertraline with an increased dose.']	Proceed taking sertraline as normal. There is no recommendation.	For an individual who is an Ultrarapid Metabolizer for CYP2B6 and has No Result for CYP2C19, they may metabolize sertraline at a faster rate due to their CYP2B6 status, which could potentially affect the drug's efficacy and side effects. Monitoring for signs of overmedication or inadequate response to sertraline therapy may be necessary, and dosage adjustments may be required based on clinical response. Consulting a healthcare provider or a pharmacist with knowledge of pharmacogenomics is recommended for personalized guidance on sertraline therapy in this specific case.	0.3519389774537515	0.4630028899358478	0.49691091383335034	0.5509573683414506	0.320774	0.38907063	0.42368975	0.5033481	0.30963296	0.48815998	0.40268913	0.6163862	0.34092796	0.44016293	0.4359481	0.499112	0.3825172	0.51360846	0.58839625	0.5785575	0
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking sertraline? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid sertraline. Take an alternate therapy.', 'Take sertraline with a reduced dose.', 'Take sertraline with an increased dose.']	Proceed taking sertraline as normal. There is no recommendation.	For an individual who is Indeterminate for CYP2B6 and an Ultrarapid Metabolizer for CYP2C19 taking sertraline, close monitoring of sertraline efficacy and adverse effects is recommended. CYP2B6 genotype may impact sertraline metabolism, while CYP2C19 Ultrarapid Metabolism may lead to faster clearance of the drug. Individualized dosing adjustments or consideration of alternative treatments may be necessary based on the individual's response to sertraline. Consulting with a healthcare provider or a pharmacist specializing in pharmacogenomics is advised for personalized recommendations.	0.3661296178753102	0.4630028899358478	0.49691091383335034	0.5693603136620354	0.32430345	0.38907063	0.42368975	0.52893394	0.31167984	0.48815998	0.40268913	0.58799815	0.32145944	0.44016293	0.4359481	0.55512965	0.33995908	0.51360846	0.58839625	0.55456597	0
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and No Result for CYP2C19 with regards to taking sertraline? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid sertraline. Take an alternate therapy.', 'Take sertraline with a reduced dose.', 'Take sertraline with an increased dose.']	Proceed taking sertraline as normal. There is no recommendation.	For someone who is a Rapid Metabolizer for CYP2B6, there is a potential for increased metabolism of sertraline, which could lead to lower drug levels and potentially reduced efficacy. Since there is no result for CYP2C19, there may be less impact on sertraline metabolism through this pathway. Close monitoring for efficacy and side effects of sertraline may be warranted in this individual to ensure proper dosing and treatment outcomes.	0.3152722000539058	0.4630028899358478	0.49691091383335034	0.5485524476311006	0.21720678	0.38907063	0.42368975	0.53838706	0.30688483	0.48815998	0.40268913	0.5977681	0.32346573	0.44016293	0.4359481	0.5190691	0.3153506	0.51360846	0.58839625	0.57684314	0
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking sevoflurane? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking sevoflurane as normal. There is no recommendation.', 'Take sevoflurane with a reduced dose.', 'Take sevoflurane with an increased dose.']	Avoid sevoflurane. Take an alternate therapy.	Individuals who are No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S may still have an increased risk of malignant hyperthermia (MH) when exposed to trigger agents such as sevoflurane. Therefore, caution is advised when using sevoflurane in these individuals. Close monitoring for signs of MH and having a clear plan for managing an MH crisis should be in place prior to administering sevoflurane.	0.6660380667841783	0.4577322968908379	0.3950503790050188	0.5086377801158699	0.75797355	0.5242743	0.41952017	0.5907967	0.71986145	0.38997516	0.32202256	0.60852313	0.7223166	0.38056022	0.37776628	0.5238804	0.6678334	0.5110538	0.4875466	0.52532625	0
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking sevoflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking sevoflurane as normal. There is no recommendation.', 'Take sevoflurane with a reduced dose.', 'Take sevoflurane with an increased dose.']	Avoid sevoflurane. Take an alternate therapy.	In individuals with Malignant Hyperthermia Susceptibility (MHS) for RYR1 or CACNA1S gene mutations, it is recommended to avoid triggering agents such as sevoflurane and opt for alternative anesthesia agents. Sevoflurane is known to trigger malignant hyperthermia in susceptible individuals, increasing the risk of a life-threatening reaction. Therefore, individuals with MHS for RYR1 or CACNA1S gene mutations should inform their healthcare providers about their genetic susceptibility to malignant hyperthermia before undergoing any procedures requiring anesthesia.	0.7378313996721225	0.4545663107907299	0.390423410687307	0.5031642466470759	0.7729671	0.5301802	0.4270331	0.6204081	0.7420407	0.4028364	0.3430284	0.49662116	0.7193116	0.40479818	0.40274474	0.38916695	0.58716905	0.5206879	0.4927721	0.5085025	1
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking sevoflurane? Give a 2-3 sentence summary.	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid sevoflurane. Take an alternate therapy.', 'Take sevoflurane with a reduced dose.', 'Take sevoflurane with an increased dose.']	Proceed taking sevoflurane as normal. There is no recommendation.	For someone with Uncertain Susceptibility for RYR1 and No Result for CACNA1S related to sevoflurane, it is important to exercise caution due to the potential risk of malignant hyperthermia (MH), a rare but life-threatening condition triggered by certain medications like sevoflurane. Close monitoring and coordination with healthcare providers experienced in managing MH are recommended. Consideration of alternative anesthetic agents with a lower risk of triggering MH may be advisable in this situation.	0.5908857922107228	0.404625231433635	0.35035865710471553	0.5827634848846617	0.5955684	0.44700626	0.3018782	0.5391937	0.59506816	0.28510997	0.27155432	0.55473435	0.49136078	0.34939775	0.28251505	0.5473906	0.6000506	0.41315067	0.36498272	0.561805	0
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking sevoflurane? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid sevoflurane. Take an alternate therapy.', 'Take sevoflurane with a reduced dose.', 'Take sevoflurane with an increased dose.']	Proceed taking sevoflurane as normal. There is no recommendation.	For an individual with No Result for RYR1 and Uncertain Susceptibility for CACNA1S in relation to sevoflurane, caution is advised. Due to the uncertainty around their genetic profile and potential risk of adverse reactions, it is recommended to consult with a healthcare provider specializing in pharmacogenomics or anesthesiology to determine the most appropriate anesthesia plan, considering alternative medications or monitoring strategies.	0.7538525331261949	0.42048804759396385	0.3688005636801659	0.5727278537938462	0.74755365	0.44580105	0.28976873	0.5305884	0.7507025	0.2849354	0.26839402	0.5570754	0.6985453	0.3944337	0.32558468	0.4958535	0.74856335	0.41290683	0.3670448	0.6049482	0
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking simvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid simvastatin. Take an alternate therapy.', 'Take simvastatin with a reduced dose.', 'Take simvastatin with an increased dose.']	Proceed taking simvastatin as normal. There is no recommendation.	Individuals who are classified as Increased Function for SLCO1B1 may be at an increased risk of experiencing myopathy or myalgia when taking simvastatin. Therefore, it is recommended to consider alternative statin medications or lower doses of simvastatin in these individuals to minimize the risk of adverse effects while still effectively managing their cholesterol levels. Close monitoring for muscle symptoms is also advisable.	0.2728732255258868	0.35520323393516884	0.3625538167552265	0.5221025922242145	0.35511613	0.29368147	0.37379178	0.58514386	0.3154739	0.43996063	0.33405927	0.69485104	0.24982637	0.3681696	0.3272569	0.5474648	0.42347187	0.51872534	0.5893848	0.56107	0
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking simvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid simvastatin. Take an alternate therapy.', 'Take simvastatin with a reduced dose.', 'Take simvastatin with an increased dose.']	Proceed taking simvastatin as normal. There is no recommendation.	For individuals classified as Normal Function for the SLCO1B1 gene, they are not expected to have an increased risk of statin-induced myopathy with simvastatin compared to the general population. Standard dosing guidelines for simvastatin can be followed in this group, without the need for dose adjustment based on SLCO1B1 genotype. However, regular monitoring for any potential side effects or efficacy of simvastatin therapy is still recommended.	0.31824520398713907	0.35520323393516884	0.3625538167552265	0.5975277528611873	0.31287295	0.29368147	0.37379178	0.6409734	0.380907	0.43996063	0.33405927	0.68588513	0.32631037	0.3681696	0.3272569	0.5120158	0.42927077	0.51872534	0.5893848	0.6077015	1
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking simvastatin? Give a 2-3 sentence summary.	No recommendation	['Avoid simvastatin. Take an alternate therapy.', 'Take simvastatin with a reduced dose.', 'Take simvastatin with an increased dose.']	Proceed taking simvastatin as normal. There is no recommendation.	For individuals who are categorized as Indeterminate for SLCO1B1, it means there is uncertainty in predicting how they will metabolize simvastatin. In such cases, it may be prudent to consider alternative statin medications or closely monitor for potential side effects when starting or adjusting the dose of simvastatin. Consulting with a healthcare provider or a pharmacist for personalized recommendations based on individual factors is advisable.	0.2295828910018001	0.4625140376620879	0.2085460208797063	0.5354388584807755	0.12803406	0.2978556	0.14447227	0.51387644	0.09299077	0.19657017	0.08326497	0.6124653	0.018305207	0.31804746	0.080486454	0.4874947	0.28934065	0.52485126	0.40065327	0.571146	0
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking simvastatin? Give a 2-3 sentence summary.	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to <20mg/day.	['Proceed taking simvastatin as normal. There is no recommendation.', 'Take simvastatin with a reduced dose.', 'Take simvastatin with an increased dose.']	Avoid simvastatin. Take an alternate therapy.	For individuals who are categorized as Possible Decreased Function for SLCO1B1 and are prescribed simvastatin, it is recommended to consider dose reduction or alternative statin therapy, as they may be at an increased risk of experiencing statin-related myopathy due to reduced drug uptake. Close monitoring for signs of muscle pain or weakness is also advised, with appropriate adjustments in medication as needed to minimize the risk of adverse effects.	0.6845810421946875	0.7277971588287913	0.6528134150679131	0.5976268325762135	0.7104846	0.73048836	0.6647571	0.6536329	0.7280026	0.81392723	0.7618964	0.7392371	0.56554985	0.5576565	0.56782985	0.6441614	0.58148134	0.66800714	0.5938259	0.6379698	0
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking streptomycin as normal. There is no recommendation.', 'Take streptomycin with a reduced dose.', 'Take streptomycin with an increased dose.']	Avoid streptomycin. Take an alternate therapy.	Individuals with increased risk of aminoglycoside-induced hearing loss due to MT-RNR1 variants should exercise caution when taking streptomycin. It is recommended to closely monitor for signs of hearing impairment and consider alternative antibiotics if possible. Consultation with healthcare providers and pharmacists, as well as monitoring of hearing function during treatment, is important for managing the risk of hearing loss while on streptomycin therapy.	0.6876510523316945	0.5142258212686126	0.4284793099705051	0.5740033691746679	0.69832623	0.6081317	0.48939642	0.5964455	0.7389304	0.5112248	0.48077092	0.64449203	0.7521901	0.41462815	0.4065719	0.53296214	0.6157609	0.5992292	0.5111725	0.5584204	0
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid streptomycin. Take an alternate therapy.', 'Take streptomycin with a reduced dose.', 'Take streptomycin with an increased dose.']	Proceed taking streptomycin as normal. There is no recommendation.	Individuals who are identified as normal risk for aminoglycoside-induced hearing loss based on MT-RNR1 genotyping may still benefit from monitoring for potential side effects when taking streptomycin. While they may have a lower risk compared to those with high-risk genotypes, regular monitoring of auditory function is recommended to promptly identify any signs of hearing loss and adjust treatment if necessary. Additionally, healthcare providers may consider alternative antibiotics or dosage adjustments for individuals with normal-risk genotypes if deemed appropriate based on additional clinical factors.	0.6659839652334357	0.45422819547735455	0.45307174671684985	0.564990922413799	0.5697373	0.45912617	0.49132943	0.5219645	0.67070556	0.5299307	0.5460022	0.6266678	0.7035124	0.47248167	0.4446279	0.45741722	0.5884867	0.53565234	0.5680272	0.4866932	0
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid streptomycin. Take an alternate therapy.', 'Take streptomycin with a reduced dose.', 'Take streptomycin with an increased dose.']	Proceed taking streptomycin as normal. There is no recommendation.	Individuals with uncertain risk of aminoglycoside-induced hearing loss due to MT-RNR1 variants may benefit from pharmacogenomic testing to guide the use of streptomycin. Testing for the presence of MT-RNR1 variants can help identify those at increased risk for this adverse effect, allowing for personalized dosing strategies, closer monitoring, or avoidance of aminoglycoside therapy altogether to minimize the risk of hearing loss. Consulting with a healthcare provider experienced in pharmacogenomics can help determine the most appropriate course of action based on individual risk factors and medication needs.	0.6022588001328182	0.45422819547735455	0.45307174671684985	0.46443837021380213	0.498643	0.45912617	0.49132943	0.39222464	0.60917777	0.5299307	0.5460022	0.5060901	0.6218697	0.47248167	0.4446279	0.38400197	0.60994405	0.53565234	0.5680272	0.44524044	0
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking succinylcholine? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking succinylcholine as normal. There is no recommendation.', 'Take succinylcholine with a reduced dose.', 'Take succinylcholine with an increased dose.']	Avoid succinylcholine. Take an alternate therapy.	For individuals with Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S, caution is advised when considering the use of succinylcholine due to the increased risk of triggering malignant hyperthermia. Consultation with a healthcare provider experienced in managing individuals with susceptibility to malignant hyperthermia is recommended for personalized risk assessment and to develop an appropriate anesthetic plan to minimize the risk of complications.	0.7268114475668909	0.527814087888422	0.48228017872192	0.5477965445979639	0.75439423	0.58536065	0.49024773	0.52939916	0.83249503	0.5190823	0.42098674	0.5572941	0.76153344	0.5455104	0.48073366	0.5017978	0.6721037	0.5365511	0.50722456	0.5432251	0
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking succinylcholine? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking succinylcholine as normal. There is no recommendation.', 'Take succinylcholine with a reduced dose.', 'Take succinylcholine with an increased dose.']	Avoid succinylcholine. Take an alternate therapy.	For individuals with No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S, caution should be exercised when considering the use of succinylcholine due to the increased risk of malignant hyperthermia. Alternative non-triggering agents should be considered for anesthesia induction or muscle relaxation in these individuals. Consultation with a healthcare provider knowledgeable in pharmacogenomics and anesthesia is recommended to determine the safest course of action.	0.7632377285618247	0.5234694651738674	0.4817853108071822	0.6017156178844643	0.8649412	0.57796425	0.49079117	0.6217556	0.83231723	0.4955142	0.39472172	0.5913973	0.82805234	0.5378755	0.46728277	0.5427313	0.7806031	0.5330462	0.50714344	0.5736149	1
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking succinylcholine? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking succinylcholine as normal. There is no recommendation.', 'Take succinylcholine with a reduced dose.', 'Take succinylcholine with an increased dose.']	Avoid succinylcholine. Take an alternate therapy.	Individuals who are Malignant Hyperthermia Susceptibility (MHS) positive for RYR1 and uncertain for CACNA1S should avoid succinylcholine due to the risk of triggering a malignant hyperthermia crisis. An alternative non-triggering muscle relaxant should be considered for anesthesia to reduce the risk of severe adverse reactions. Consultation with a genetics specialist and anesthesiologist is recommended for personalized guidance in this scenario.	0.7728788059727805	0.527814087888422	0.48228017872192	0.5438112473595554	0.8915821	0.58536065	0.49024773	0.5885667	0.8406617	0.5190823	0.42098674	0.49815917	0.78960127	0.5455104	0.48073366	0.50268453	0.7550845	0.5365511	0.50722456	0.59532034	1
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking succinylcholine? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid succinylcholine. Take an alternate therapy.', 'Take succinylcholine with a reduced dose.', 'Take succinylcholine with an increased dose.']	Proceed taking succinylcholine as normal. There is no recommendation.	For an individual with a No Result for RYR1 and Uncertain Susceptibility for CACNA1S related to succinylcholine, caution and close monitoring are recommended when using this medication due to the potential risk of adverse reactions. It is essential to consult with a healthcare provider familiar with pharmacogenomic testing results to determine the most appropriate course of action and to consider alternative medications if needed.	0.6817515445890715	0.4012847013331125	0.3691897245764412	0.5484664985827052	0.6980288	0.49628866	0.31289098	0.5905512	0.7069336	0.33169323	0.3286617	0.58416843	0.66895956	0.42874748	0.34859177	0.53168887	0.70957345	0.41059837	0.34475026	0.5837697	0
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfadiazine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfadiazine. Take an alternate therapy.', 'Take sulfadiazine with a reduced dose.', 'Take sulfadiazine with an increased dose.']	Proceed taking sulfadiazine as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) should not take sulfadiazine due to the risk of hemolysis, a condition where red blood cells are destroyed. Sulfadiazine can trigger hemolysis in patients with G6PD deficiency by causing oxidative stress. Alternative medications should be considered for these individuals to avoid this serious side effect.	0.5873974656301291	0.49409310659631833	0.38567168209215	0.5526326899737093	0.56445104	0.55285794	0.34279808	0.64667696	0.5609353	0.47429895	0.2665436	0.6890193	0.5597508	0.44109833	0.3475649	0.5491376	0.50325036	0.4953315	0.3599021	0.6130234	0
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfadiazine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfadiazine. Take an alternate therapy.', 'Take sulfadiazine with a reduced dose.', 'Take sulfadiazine with an increased dose.']	Proceed taking sulfadiazine as normal. There is no recommendation.	Individuals who are Indeterminate for G6PD deficiency may have enzyme levels that fall within an ambiguous range. Therefore, caution is advised when considering the use of medications like sulfadiazine, which can potentially trigger hemolysis in individuals with G6PD deficiency. Clinical guidance may recommend close monitoring for signs of drug-induced hemolysis and consideration of alternative medications in individuals who are Indeterminate for G6PD deficiency.	0.6729784712782626	0.41211662832204105	0.3489397021930356	0.4783056542579016	0.6109249	0.25197884	0.28623995	0.5315007	0.69395906	0.32540876	0.23879947	0.51792103	0.62729645	0.25633618	0.24435584	0.49643004	0.58681935	0.44424903	0.4111406	0.5402602	0
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfadiazine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid sulfadiazine. Take an alternate therapy.', 'Take sulfadiazine with a reduced dose.', 'Take sulfadiazine with an increased dose.']	Proceed taking sulfadiazine as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) with the CNSHA variant may be at an increased risk of hemolysis when taking sulfadiazine, as sulfadiazine has been associated with hemolytic anemia in G6PD-deficient individuals. Clinical guidance would be to avoid the use of sulfadiazine in individuals with G6PD deficiency, particularly those with the CNSHA variant, and consider alternative treatment options to prevent the risk of hemolysis.	0.41351361305284334	0.3683210736983723	0.41165556589554164	0.5424820204885377	0.52706176	0.48263654	0.4828907	0.6331509	0.48333836	0.4822018	0.42708778	0.61806333	0.47905862	0.4086935	0.37994298	0.50112784	0.44481754	0.4005608	0.4407929	0.52031916	0
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfadiazine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfadiazine. Take an alternate therapy.', 'Take sulfadiazine with a reduced dose.', 'Take sulfadiazine with an increased dose.']	Proceed taking sulfadiazine as normal. There is no recommendation.	For individuals with normal G6PD enzyme activity, there is typically no need to adjust sulfadiazine dosing or avoid its use based on pharmacogenomics. Monitoring for typical drug-related side effects and interactions is recommended. As always, it is important to consult with a healthcare provider for personalized recommendations based on individual medical history and overall health status.	0.662110517004057	0.44098857563454497	0.32580317638210055	0.6188811775713603	0.5402821	0.403317	0.20066725	0.68480337	0.46713218	0.2926803	0.13621284	0.71887904	0.45313334	0.19492838	0.13273613	0.613521	0.49969155	0.4200052	0.2845944	0.64763474	1
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfadimidine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfadimidine. Take an alternate therapy.', 'Take sulfadimidine with a reduced dose.', 'Take sulfadimidine with an increased dose.']	Proceed taking sulfadimidine as normal. There is no recommendation.	For individuals deficient in glucose-6-phosphate dehydrogenase (G6PD), avoiding sulfadimidine (sulfonamide antibiotic) is recommended, as it can cause hemolysis (destruction of red blood cells) leading to a hemolytic crisis. It is important for individuals with G6PD deficiency to communicate their condition to healthcare providers to ensure safe and effective treatment options are chosen. Alternative antibiotics not associated with G6PD-related hemolysis should be considered for these individuals.	0.6272266562627545	0.5366443753840053	0.4172271170802881	0.5914160678514588	0.62509966	0.56382734	0.37480518	0.6146557	0.59017473	0.5065424	0.31411874	0.6042939	0.59117055	0.4707895	0.38082504	0.53314954	0.5489843	0.53090537	0.4009732	0.5226688	0
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfadimidine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfadimidine. Take an alternate therapy.', 'Take sulfadimidine with a reduced dose.', 'Take sulfadimidine with an increased dose.']	Proceed taking sulfadimidine as normal. There is no recommendation.	Individuals who are classified as Indeterminate for G6PD enzyme deficiency should exercise caution when taking sulfadimidine, as this medication may potentially trigger hemolysis in those with underlying G6PD deficiency. Prior to initiating sulfadimidine therapy, healthcare providers should consider the potential risks and benefits of treatment and may opt for an alternative medication in individuals with uncertain G6PD status to prevent adverse reactions. Consulting a genetic counselor or a healthcare provider with expertise in pharmacogenomics can provide more personalized guidance for individuals with an indeterminate G6PD status.	0.6622124406091828	0.4630560778176447	0.3867991396176147	0.6151920423659293	0.5779897	0.2764976	0.34482363	0.6103735	0.71246356	0.38954467	0.34922948	0.61408037	0.7135225	0.2797548	0.26608437	0.5385402	0.57379484	0.45811012	0.41824174	0.54921347	0
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfadimidine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid sulfadimidine. Take an alternate therapy.', 'Take sulfadimidine with a reduced dose.', 'Take sulfadimidine with an increased dose.']	Proceed taking sulfadimidine as normal. There is no recommendation.	Individuals who are deficient in G6PD (glucose-6-phosphate dehydrogenase) with CNSHA (chronic nonspherocytic hemolytic anemia) may be at increased risk for hemolysis (breakdown of red blood cells) when exposed to certain medications, such as sulfadimidine (sulfamethoxazole). It is recommended to avoid the use of sulfonamides, including sulfadimidine, in individuals with G6PD deficiency to prevent hemolytic reactions. Alternative non-sulfonamide antibiotics should be considered for these individuals to avoid potential adverse effects.	0.44735164265144534	0.4209225930462725	0.43827578042200527	0.5384659253543682	0.5747773	0.48220828	0.52227277	0.45605603	0.55429584	0.48777655	0.47218665	0.58260125	0.52767134	0.4433251	0.40773273	0.5251246	0.503424	0.3986235	0.44751632	0.53345793	0
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfadimidine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfadimidine. Take an alternate therapy.', 'Take sulfadimidine with a reduced dose.', 'Take sulfadimidine with an increased dose.']	Proceed taking sulfadimidine as normal. There is no recommendation.	Individuals who are normal for G6PD (glucose-6-phosphate dehydrogenase) enzyme activity can typically safely take sulfadimidine without an increased risk of drug-induced hemolysis. However, as with any medication, it is important to monitor for any signs of adverse reactions and consult with a healthcare provider if any concerns arise during treatment. It is always advisable to follow personalized medical advice based on individual health conditions and considerations.	0.615224365047624	0.47151580356404366	0.34642321593753733	0.6717440672088358	0.48096913	0.41365242	0.22407989	0.6966497	0.4535918	0.32886207	0.1757294	0.7243099	0.46163923	0.22115462	0.15708718	0.642393	0.52192116	0.45304385	0.3298614	0.64202565	1
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfamethoxazole / trimethoprim? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.', 'Take sulfamethoxazole / trimethoprim with a reduced dose.', 'Take sulfamethoxazole / trimethoprim with an increased dose.']	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.	For individuals who are normal for G6PD, sulfamethoxazole/trimethoprim can typically be prescribed as there is no increased risk of hemolysis associated with this medication in this population. However, it is always important to monitor for any signs of adverse effects and discontinue the medication if any concerns arise.	0.6264374235029962	0.4306443638139204	0.3247689733049191	0.6384589063911468	0.53376263	0.41712707	0.20478147	0.72598255	0.48292992	0.30901244	0.14787404	0.73806363	0.42088038	0.16224156	0.09979022	0.6195105	0.52862805	0.4082015	0.28756562	0.6275049	1
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking sulfamethoxazole / trimethoprim? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.', 'Take sulfamethoxazole / trimethoprim with a reduced dose.', 'Take sulfamethoxazole / trimethoprim with an increased dose.']	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.	Individuals who are G6PD deficient are at risk of developing hemolysis (breakdown of red blood cells) when exposed to sulfamethoxazole/trimethoprim due to oxidative stress. Therefore, it is generally recommended to avoid sulfamethoxazole/trimethoprim in individuals who are G6PD deficient to prevent this serious side effect. Alternative antibiotics should be considered for these individuals to avoid potential harm.	0.6278489177592836	0.4705058638684977	0.37906068861041886	0.5288316963146004	0.6498221	0.5506341	0.3296366	0.60020745	0.6473843	0.46586427	0.25076166	0.632938	0.5928738	0.40578195	0.30630967	0.58274996	0.54166776	0.466226	0.33565807	0.6082601	0
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfamethoxazole / trimethoprim? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.', 'Take sulfamethoxazole / trimethoprim with a reduced dose.', 'Take sulfamethoxazole / trimethoprim with an increased dose.']	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.	Individuals deficient for G6PD (Glucose-6-Phosphate Dehydrogenase) are at risk for hemolytic anemia when exposed to sulfamethoxazole/trimethoprim. It is recommended to avoid this medication in individuals with G6PD deficiency to prevent severe adverse effects. Alternative antibiotics should be considered under the guidance of a healthcare provider to ensure safe and effective treatment.	0.6567624279935939	0.4705058638684977	0.37906068861041886	0.5378068929102799	0.6041186	0.5506341	0.3296366	0.6170522	0.5902692	0.46586427	0.25076166	0.62137276	0.6131898	0.40578195	0.30630967	0.5268572	0.5387097	0.466226	0.33565807	0.6334342	0
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfamethoxazole / trimethoprim? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.', 'Take sulfamethoxazole / trimethoprim with a reduced dose.', 'Take sulfamethoxazole / trimethoprim with an increased dose.']	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.	Individuals who are classified as Indeterminate for G6PD deficiency may have reduced enzyme activity, but the clinical significance is unclear. For these individuals, the decision to use sulfamethoxazole/trimethoprim should be made on a case-by-case basis, considering the potential risks and benefits. Close monitoring for signs of hemolysis should be conducted if the medication is prescribed.	0.6903286402879558	0.4036652776421411	0.3479839129552009	0.5436652575760316	0.65360767	0.24292305	0.27221867	0.53796196	0.7620747	0.315268	0.23093794	0.5982145	0.7037814	0.2193713	0.19654308	0.5267988	0.6338631	0.43268222	0.36607432	0.5882982	0
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfanilamide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfanilamide. Take an alternate therapy.', 'Take sulfanilamide with a reduced dose.', 'Take sulfanilamide with an increased dose.']	Proceed taking sulfanilamide as normal. There is no recommendation.	Individuals who are normal for G6PD (glucose-6-phosphate dehydrogenase) do not have an increased risk of hemolysis when taking sulfanilamide. Therefore, for these individuals, sulfanilamide can typically be used safely without the need for dose adjustment or special monitoring based on G6PD status. It is important to always consult with a healthcare provider before starting any new medication to ensure it is appropriate for your individual health needs.	0.6391243499407313	0.4343700432793431	0.2947795499277937	0.621784855198928	0.5689146	0.4056054	0.21576686	0.67710644	0.4999817	0.29410857	0.13966405	0.6756441	0.4344112	0.19536656	0.1379577	0.592255	0.61273366	0.437908	0.3261619	0.5916756	1
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfanilamide? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfanilamide. Take an alternate therapy.', 'Take sulfanilamide with a reduced dose.', 'Take sulfanilamide with an increased dose.']	Proceed taking sulfanilamide as normal. There is no recommendation.	Individuals who are indeterminate for glucose-6-phosphate dehydrogenase (G6PD) deficiency may have reduced enzyme activity and are at risk of hemolysis when exposed to medications like sulfanilamide that can trigger oxidative stress. It is recommended to exercise caution and consider alternative medications if possible in individuals with indeterminate G6PD status to avoid potential hemolytic reactions. Consulting with a healthcare provider or a pharmacogenomics specialist for personalized guidance is advisable.	0.699288213386654	0.4182746565908878	0.33729696844813817	0.4629667733957508	0.5758348	0.22919756	0.28116187	0.5387662	0.6689556	0.29972067	0.2222008	0.56859946	0.6903546	0.25603768	0.24801755	0.4176437	0.5855418	0.44852558	0.44223008	0.5497685	0
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfanilamide? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid sulfanilamide. Take an alternate therapy.', 'Take sulfanilamide with a reduced dose.', 'Take sulfanilamide with an increased dose.']	Proceed taking sulfanilamide as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) with Class I enzyme activity (CNSHA) are at an increased risk of hemolytic anemia when exposed to certain medications, including sulfanilamide. It is recommended to avoid sulfanilamide in these individuals and consider alternative medications that do not pose a risk of hemolysis. Close monitoring of blood counts is advised if sulfanilamide use is deemed necessary under the guidance of a healthcare provider.	0.43822905839936466	0.4041840488988126	0.42074429790244183	0.5291273085497598	0.57377774	0.49054238	0.5201581	0.567703	0.5629814	0.49501613	0.45352992	0.60404134	0.49597326	0.39184275	0.36526337	0.5294241	0.5830781	0.39136568	0.46028605	0.6007868	0
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfanilamide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfanilamide. Take an alternate therapy.', 'Take sulfanilamide with a reduced dose.', 'Take sulfanilamide with an increased dose.']	Proceed taking sulfanilamide as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) are at risk of hemolytic anemia when exposed to certain medications, including sulfanilamide. Therefore, it is recommended to avoid drugs like sulfanilamide in individuals with G6PD deficiency to prevent the risk of severe adverse reactions such as hemolysis. Consulting a healthcare provider for alternative treatment options is advisable for individuals with G6PD deficiency.	0.633163233452114	0.5001107078985911	0.37375390210550646	0.48632516242835	0.6159823	0.5555609	0.36481413	0.5845575	0.62782747	0.47597387	0.26766637	0.56582654	0.61495566	0.44162732	0.36039737	0.5100021	0.55385584	0.506491	0.3976718	0.5930506	0
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfasalazine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfasalazine. Take an alternate therapy.', 'Take sulfasalazine with a reduced dose.', 'Take sulfasalazine with an increased dose.']	Proceed taking sulfasalazine as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) are at an increased risk of hemolysis when taking sulfasalazine due to the oxidative stress it can cause. Therefore, it is generally recommended to avoid sulfasalazine in individuals with G6PD deficiency or to closely monitor for signs of hemolysis if its use is necessary. Alternative medications that do not pose a risk of hemolysis should be considered in these individuals.	0.583470208971417	0.454761608173271	0.34050768287039546	0.5155328779379288	0.5803323	0.5211813	0.31954464	0.5966537	0.5634874	0.4119653	0.20937975	0.6205114	0.5238517	0.4059127	0.31599593	0.59245944	0.51437503	0.47757736	0.35316658	0.5660566	0
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfasalazine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfasalazine. Take an alternate therapy.', 'Take sulfasalazine with a reduced dose.', 'Take sulfasalazine with an increased dose.']	Proceed taking sulfasalazine as normal. There is no recommendation.	For individuals who are Indeterminate for G6PD deficiency, caution is advised when considering the use of sulfasalazine due to its potential to cause hemolytic anemia in G6PD-deficient individuals. Consultation with a healthcare provider, particularly a genetic counselor or a specialist in pharmacogenomics, is recommended to determine the appropriateness of using sulfasalazine in this population and to closely monitor for any signs of hemolysis if the medication is prescribed.	0.609487907079933	0.3616340990132798	0.30436571600079243	0.5319593184806164	0.5848414	0.2402507	0.27568257	0.53039515	0.6504378	0.27466792	0.19229496	0.55896	0.5666284	0.21604878	0.2027477	0.53661984	0.52937454	0.4199025	0.3860419	0.55396163	0
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfasalazine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid sulfasalazine. Take an alternate therapy.', 'Take sulfasalazine with a reduced dose.', 'Take sulfasalazine with an increased dose.']	Proceed taking sulfasalazine as normal. There is no recommendation.	For an individual with CNSHA (Class II) deficiency in the G6PD gene, caution is advised when considering the use of sulfasalazine. Sulfasalazine has been associated with hemolytic anemia in individuals with G6PD deficiency due to its potential to induce oxidative stress. Monitoring for signs of hemolysis and adjusting therapy as necessary is recommended in this population. Consulting with a healthcare provider, such as a pharmacist or genetic counselor, can help in determining the appropriateness of sulfasalazine use and exploring alternative treatment options if needed.	0.4279712052190211	0.37233782366052026	0.4072278126853995	0.5066506238358323	0.564528	0.4658889	0.47853336	0.491949	0.5015179	0.43297738	0.37736353	0.5483122	0.4559147	0.4247376	0.38877144	0.50420797	0.50316423	0.41632393	0.46072897	0.51473224	1
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfasalazine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfasalazine. Take an alternate therapy.', 'Take sulfasalazine with a reduced dose.', 'Take sulfasalazine with an increased dose.']	Proceed taking sulfasalazine as normal. There is no recommendation.	For individuals who are normal for G6PD (glucose-6-phosphate dehydrogenase) deficiency, there are no specific recommendations against taking sulfasalazine. However, as with any medication, it is important to monitor for potential side effects and consult with a healthcare provider if any concerning symptoms arise while taking sulfasalazine. Additionally, regular monitoring of blood counts may be advisable during treatment with sulfasalazine in case of any adverse effects.	0.5757737898031657	0.38913060984950526	0.26991477255176216	0.6847974607129664	0.54927945	0.38723877	0.19100542	0.6453838	0.53211766	0.25948122	0.105310656	0.6285192	0.425494	0.16246423	0.09714504	0.6432877	0.5079599	0.4087324	0.28224456	0.6203698	1
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfisoxazole? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfisoxazole. Take an alternate therapy.', 'Take sulfisoxazole with a reduced dose.', 'Take sulfisoxazole with an increased dose.']	Proceed taking sulfisoxazole as normal. There is no recommendation.	Individuals who are deficient in the enzyme glucose-6-phosphate dehydrogenase (G6PD) may be at increased risk of hemolysis when taking sulfisoxazole. Therefore, it is generally recommended to avoid the use of sulfisoxazole in individuals with G6PD deficiency to prevent serious adverse effects such as hemolytic anemia. Alternative non-sulfonamide antibiotics should be considered for these individuals.	0.5723365554841527	0.4776053441656646	0.3572792340137502	0.5606909858680732	0.58448577	0.521006	0.31720397	0.6380924	0.57077205	0.41421908	0.21777071	0.6394806	0.53535414	0.41013876	0.30259517	0.55763227	0.5127393	0.47607094	0.35071957	0.5596926	0
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfisoxazole? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfisoxazole. Take an alternate therapy.', 'Take sulfisoxazole with a reduced dose.', 'Take sulfisoxazole with an increased dose.']	Proceed taking sulfisoxazole as normal. There is no recommendation.	Individuals who are classified as Indeterminate for G6PD status should use caution when taking medications that can cause hemolysis, like sulfisoxazole. It is recommended to consider alternative medications or dose adjustments and closely monitor for signs of hemolysis, such as unexplained anemia, jaundice, or dark urine. Consultation with a healthcare provider or a pharmacist who is knowledgeable in pharmacogenomics is recommended for personalized guidance.	0.6576512451548578	0.37962200061456314	0.30808743873921896	0.5049706045335676	0.5229151	0.21456246	0.2426911	0.5459519	0.62475294	0.24887781	0.16867976	0.5027867	0.6298835	0.23579325	0.20944287	0.47632506	0.5697039	0.43196598	0.4036893	0.5482142	0
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfisoxazole? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid sulfisoxazole. Take an alternate therapy.', 'Take sulfisoxazole with a reduced dose.', 'Take sulfisoxazole with an increased dose.']	Proceed taking sulfisoxazole as normal. There is no recommendation.	Individuals who are deficient in G6PD with CNSHA (chronic nonspherocytic hemolytic anemia) should avoid sulfisoxazole due to the risk of hemolysis. Sulfisoxazole is known to trigger hemolytic episodes in individuals with G6PD deficiency. Alternative antibiotic options should be considered for these individuals to prevent hemolysis and related complications.	0.4135564640066144	0.37925551666284074	0.41648910957060004	0.5170951510636529	0.6097547	0.46666807	0.4705049	0.63049334	0.5630719	0.4460879	0.38614416	0.6325497	0.516328	0.45544776	0.40924263	0.5166548	0.4981619	0.3974429	0.45411095	0.5564607	0
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfisoxazole? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfisoxazole. Take an alternate therapy.', 'Take sulfisoxazole with a reduced dose.', 'Take sulfisoxazole with an increased dose.']	Proceed taking sulfisoxazole as normal. There is no recommendation.	For individuals who are normal for G6PD (Glucose-6-Phosphate Dehydrogenase) enzyme activity, there is typically no specific contraindication for taking sulfisoxazole. However, as with any medication, it is important to follow standard dosing guidelines, be aware of potential side effects, and consult with a healthcare provider if there are any concerns about drug interactions or individual risk factors.	0.6080478212216979	0.419649122489722	0.2882677919284511	0.677091854603945	0.5097183	0.38482702	0.18866698	0.68046755	0.48955578	0.26523647	0.11324816	0.68671364	0.3784619	0.16146298	0.09198319	0.6234073	0.520415	0.41952357	0.29587677	0.63954085	1
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for CYP3A5 with regards to taking tacrolimus? Give a 2-3 sentence summary.	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.	['Proceed taking tacrolimus as normal. There is no recommendation.', 'Avoid tacrolimus. Take an alternate therapy.']	Take tacrolimus with an altered dose.	Individuals who are Possible Intermediate Metabolizers for CYP3A5 may have decreased metabolism of tacrolimus, potentially leading to increased drug levels and higher risk of adverse effects. Close monitoring of tacrolimus levels and adjusting dosage based on therapeutic drug monitoring is recommended to ensure safety and efficacy of tacrolimus therapy in these individuals. Consulting with a healthcare provider or a clinical pharmacist with expertise in pharmacogenomics is also advised for personalized dosing recommendations.	0.4706174556604219	0.4616834447000675	0.4362495880492575	0.6939357389284404	0.5262824	0.5866446	0.4795239	0.61218184	0.4244131	0.49911952	0.47183117	0.5622654	0.44804972	0.5063754	0.40307587	0.5472865	0.48249552	0.48400515	0.31489778	0.6948172	0
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Indeterminate for CYP3A5 with regards to taking tacrolimus? Give a 2-3 sentence summary.	No recommendation	['Avoid tacrolimus. Take an alternate therapy.', 'Take tacrolimus with a reduced dose.', 'Take tacrolimus with an increased dose.']	Proceed taking tacrolimus as normal. There is no recommendation.	For individuals who are Indeterminate for CYP3A5 genotype, there is limited evidence to guide dosing adjustments for tacrolimus. In such cases, healthcare providers may consider monitoring tacrolimus serum levels closely and adjusting the dosage based on clinical response and drug concentration monitoring. Close observation for signs of tacrolimus toxicity or insufficient immunosuppression is recommended in these individuals.	0.24644546282928778	0.4431192666617696	0.1962160416717064	0.6532026913048524	0.20665887	0.3410242	0.20064467	0.56620216	0.12537622	0.24524479	0.14249896	0.68376666	-0.05813447	0.32175273	0.09869818	0.5272452	0.24835888	0.5299339	0.40260872	0.5526382	0
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP3A5 with regards to taking tacrolimus? Give a 2-3 sentence summary.	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.	['Proceed taking tacrolimus as normal. There is no recommendation.', 'Avoid tacrolimus. Take an alternate therapy.']	Take tacrolimus with an altered dose.	For individuals who are Intermediate Metabolizers for CYP3A5 and are prescribed tacrolimus, it is recommended to closely monitor tacrolimus blood levels and adjust the dosage as needed to achieve therapeutic levels while minimizing the risk of toxicity. The dosage may need to be individualized based on clinical response and tolerance to reach the desired therapeutic effect. Regular monitoring of drug levels and potential adverse effects is essential in this population to ensure safe and effective therapy.	0.5063127521258762	0.4616834447000675	0.4362495880492575	0.7052874717913588	0.623245	0.5866446	0.4795239	0.5876392	0.5481438	0.49911952	0.47183117	0.57401836	0.4897192	0.5063754	0.40307587	0.54982865	0.49562123	0.48400515	0.31489778	0.67565584	0
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Normal Metabolizer for CYP3A5 with regards to taking tacrolimus? Give a 2-3 sentence summary.	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.	['Proceed taking tacrolimus as normal. There is no recommendation.', 'Avoid tacrolimus. Take an alternate therapy.']	Take tacrolimus with an altered dose.	As a Normal Metabolizer for CYP3A5, individuals are not expected to have significant variations in the metabolism of tacrolimus. Standard dosing recommendations for tacrolimus can be followed for Normal Metabolizers of CYP3A5 without the need for dose adjustments based solely on CYP3A5 metabolism status. Close monitoring of tacrolimus levels and clinical response is still recommended to ensure optimal outcomes.	0.4402735461176907	0.4616834447000675	0.4362495880492575	0.6484756435727143	0.45113918	0.5866446	0.4795239	0.50456864	0.47414222	0.49911952	0.47183117	0.5261397	0.4679818	0.5063754	0.40307587	0.49548292	0.4417904	0.48400515	0.31489778	0.6051733	0
tafenoquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking tafenoquine? Give a 2-3 sentence summary.	Avoid use	['Proceed taking tafenoquine as normal. There is no recommendation.', 'Take tafenoquine with a reduced dose.', 'Take tafenoquine with an increased dose.']	Avoid tafenoquine. Take an alternate therapy.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) are at increased risk of hemolysis when taking tafenoquine. Clinical guidance recommends testing for G6PD deficiency before starting tafenoquine therapy, and avoiding its use in individuals with known G6PD deficiency. If tafenoquine is still considered necessary, close monitoring for signs of hemolysis is recommended, along with appropriate management if hemolysis occurs.	0.2081011883740746	0.28266737706399203	0.2424079324782934	0.5891907091937036	0.23812993	0.36137226	0.2774274	0.57196623	0.11907792	0.15206675	0.16466653	0.61901027	0.111688904	0.19780403	0.19426876	0.571934	0.3154224	0.53825694	0.44704333	0.5125961	1
tafenoquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking tafenoquine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid tafenoquine. Take an alternate therapy.', 'Take tafenoquine with a reduced dose.', 'Take tafenoquine with an increased dose.']	Proceed taking tafenoquine as normal. There is no recommendation.	Individuals who are Indeterminate for G6PD enzyme deficiency should be cautious when considering taking tafenoquine due to the risk of hemolysis. Close monitoring of G6PD levels and clinical symptoms is important if tafenoquine therapy is being considered in these individuals. Consultation with a healthcare provider knowledgeable in pharmacogenomics is recommended to assess the individual's risk and determine the appropriate course of action.	0.6322245179706142	0.393089109099031	0.33422251347699206	0.6073079587693595	0.649378	0.19516173	0.21879297	0.52780324	0.699194	0.17707741	0.10083932	0.52627116	0.63054204	0.18699531	0.14543094	0.5171129	0.58676195	0.430844	0.4059942	0.51095575	0
tafenoquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking tafenoquine? Give a 2-3 sentence summary.	Avoid use	['Proceed taking tafenoquine as normal. There is no recommendation.', 'Take tafenoquine with a reduced dose.', 'Take tafenoquine with an increased dose.']	Avoid tafenoquine. Take an alternate therapy.	Individuals who are G6PD deficient with CNSHA (central nervous system hemolytic anemia) are at increased risk of hemolysis when exposed to tafenoquine. Therefore, caution is advised when considering tafenoquine as a treatment option for these individuals. Close monitoring for signs of hemolysis and appropriate management if hemolysis occurs are essential when using tafenoquine in G6PD deficient individuals with CNSHA.	0.1769038464235199	0.28266737706399203	0.2424079324782934	0.5676382933270281	0.28792125	0.36137226	0.2774274	0.59444547	0.14330848	0.15206675	0.16466653	0.5916769	0.08655019	0.19780403	0.19426876	0.5456061	0.3306563	0.53825694	0.44704333	0.49982017	0
tafenoquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking tafenoquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid tafenoquine. Take an alternate therapy.', 'Take tafenoquine with a reduced dose.', 'Take tafenoquine with an increased dose.']	Proceed taking tafenoquine as normal. There is no recommendation.	Patients who are Normal for G6PD can generally take tafenoquine without an increased risk of hemolytic anemia compared to the general population. However, it is still recommended to screen all patients for G6PD deficiency before starting tafenoquine and to monitor for signs of hemolysis following treatment with tafenoquine.	0.5766815199797422	0.42259606475035444	0.3047555703188695	0.63994414520116	0.50796795	0.39961833	0.2058283	0.6175826	0.48720616	0.26932788	0.11702481	0.6194694	0.42958942	0.13655831	0.06740723	0.54901797	0.5076875	0.42233628	0.30055097	0.5291502	0
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking tamoxifen? Give a 2-3 sentence summary.	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	['Proceed taking tamoxifen as normal. There is no recommendation.', 'Take tamoxifen with a reduced dose.', 'Take tamoxifen with an increased dose.']	Avoid tamoxifen. Take an alternate therapy.	For individuals who are Normal Metabolizers and have an activity score of 2.0 for CYP2D6, they are less likely to experience reduced tamoxifen effectiveness compared to poor metabolizers. However, they may still have a moderate risk of reduced tamoxifen response. Close monitoring for therapeutic effects and potential side effects of tamoxifen is recommended, and healthcare providers may consider adjusting the dose or considering alternative treatments if necessary.	0.6315047116128295	0.6741140690515157	0.664771565113239	0.5252919830914555	0.58135784	0.7435186	0.6722197	0.5026192	0.6815961	0.7313675	0.6874338	0.5658998	0.7025422	0.7392635	0.6696129	0.49044335	0.70046777	0.79819125	0.77450246	0.60369027	0
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking tamoxifen? Give a 2-3 sentence summary.	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	['Proceed taking tamoxifen as normal. There is no recommendation.', 'Take tamoxifen with a reduced dose.', 'Take tamoxifen with an increased dose.']	Avoid tamoxifen. Take an alternate therapy.	Individuals who are Ultrarapid Metabolizers (UMs) of CYP2D6 may have lower concentrations of the active metabolite of tamoxifen, reducing its effectiveness in treating hormone receptor-positive breast cancer. The activity score of 2.5 indicates an increased function of the CYP2D6 enzyme, which could further decrease tamoxifen efficacy. Alternative treatment options or increased monitoring may be considered for individuals with this genotype to ensure optimal therapeutic outcomes. Consulting with a healthcare provider or genetic counselor experienced in pharmacogenomics is recommended for personalized recommendations.	0.6412165215427348	0.6741140690515157	0.664771565113239	0.5489617607772286	0.5883894	0.7435186	0.6722197	0.48080373	0.63691	0.7313675	0.6874338	0.50497603	0.62719554	0.7392635	0.6696129	0.4435953	0.7478921	0.79819125	0.77450246	0.6630904	0
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking tamoxifen? Give a 2-3 sentence summary.	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	['Proceed taking tamoxifen as normal. There is no recommendation.', 'Take tamoxifen with a reduced dose.', 'Take tamoxifen with an increased dose.']	Avoid tamoxifen. Take an alternate therapy.	For individuals who are Ultrarapid Metabolizers with an activity score of ≥3.25 for CYP2D6, the clinical guidance regarding taking tamoxifen may suggest monitoring closely for therapeutic efficacy and potential toxicity. Due to the potential for reduced tamoxifen efficacy in this population, alternative treatment options or adjusting the tamoxifen dosage may be considered to achieve optimal treatment outcomes while minimizing the risk of toxicity. Consulting with a healthcare provider or a pharmacogenomics expert for personalized recommendations is advisable in this case.	0.6974055806838978	0.6741140690515157	0.664771565113239	0.6067828671429977	0.7404517	0.7435186	0.6722197	0.586237	0.7283706	0.7313675	0.6874338	0.5924811	0.7090748	0.7392635	0.6696129	0.5141469	0.7677719	0.79819125	0.77450246	0.6870735	0
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking tamoxifen? Give a 2-3 sentence summary.	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	['Proceed taking tamoxifen as normal. There is no recommendation.', 'Take tamoxifen with a reduced dose.', 'Take tamoxifen with an increased dose.']	Avoid tamoxifen. Take an alternate therapy.	Individuals who are Normal Metabolizers with an activity score of 1.75 for CYP2D6 are considered to have normal enzyme function. For patients taking tamoxifen, which is a prodrug that requires metabolism by CYP2D6 to its active form, these individuals are predicted to respond appropriately to standard dosing of tamoxifen. Close monitoring for therapeutic response and possible adverse effects is recommended in all patients, regardless of their CYP2D6 genotype.	0.6255733925246882	0.6741140690515157	0.664771565113239	0.4669365335975112	0.5018989	0.7435186	0.6722197	0.33756185	0.6608027	0.7313675	0.6874338	0.45473915	0.59117573	0.7392635	0.6696129	0.40509018	0.69375664	0.79819125	0.77450246	0.5515606	1
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking tenoxicam? Give a 2-3 sentence summary.	No recommendation	['Avoid tenoxicam. Take an alternate therapy.', 'Take tenoxicam with a reduced dose.', 'Take tenoxicam with an increased dose.']	Proceed taking tenoxicam as normal. There is no recommendation.	For individuals who are Indeterminate for CYP2C9 status, caution is advised when taking tenoxicam, a nonsteroidal anti-inflammatory drug (NSAID) metabolized by CYP2C9. Consideration of potential risks and benefits, as well as close monitoring for adverse effects and therapeutic response, is recommended when prescribing tenoxicam to individuals with an indeterminate CYP2C9 status. Consulting with a healthcare provider or a pharmacist specializing in pharmacogenomics may be beneficial to make informed treatment decisions.	0.27521556939031333	0.45549037908208784	0.24614018057835055	0.6382584759440706	0.17828439	0.28179795	0.14689119	0.60838234	0.06826336	0.14983788	0.071839415	0.57328707	0.027270172	0.34113693	0.11707452	0.5576929	0.35544127	0.55544454	0.41888833	0.65117645	0
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking tenoxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid tenoxicam. Take an alternate therapy.', 'Take tenoxicam with a reduced dose.', 'Take tenoxicam with an increased dose.']	Proceed taking tenoxicam as normal. There is no recommendation.	For a Normal Metabolizer with an activity score of 2.0 for CYP2C9, caution should be exercised when taking tenoxicam, as this medication is primarily metabolized by CYP2C9 enzyme. Since the activity score is within the normal range, standard dosing may be appropriate, but close monitoring for potential increased drug levels and side effects is recommended. Consulting a healthcare provider for personalized dosing recommendations based on genetic information is advisable.	0.36284983239136115	0.43137110084097624	0.43317168704404146	0.6510708560310894	0.36042184	0.37811524	0.3729335	0.5207332	0.37105533	0.4783564	0.3365829	0.5905609	0.36683986	0.39204037	0.40393975	0.6204229	0.40927497	0.48403755	0.46221796	0.6352115	0
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking tenoxicam? Give a 2-3 sentence summary.	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	['Proceed taking tenoxicam as normal. There is no recommendation.', 'Take tenoxicam with a reduced dose.', 'Take tenoxicam with an increased dose.']	Avoid tenoxicam. Take an alternate therapy.	For individuals who are Poor Metabolizers of CYP2C9 and have an activity score of 0.0, it is recommended to avoid medications metabolized by this enzyme, such as tenoxicam. Due to impaired metabolism, these individuals may be at an increased risk of experiencing adverse effects or reduced efficacy of tenoxicam. Alternative medications that do not rely on the CYP2C9 pathway for metabolism should be considered for this population.	0.6346992849360445	0.5851060746176674	0.484081942471341	0.5949149964170021	0.69724154	0.6312463	0.5491793	0.6304712	0.7246146	0.44854802	0.41460106	0.57513815	0.6170381	0.35341328	0.3262374	0.5656935	0.66709465	0.5569536	0.52573466	0.6404111	1
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking tenoxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid tenoxicam. Take an alternate therapy.', 'Take tenoxicam with a reduced dose.', 'Take tenoxicam with an increased dose.']	Proceed taking tenoxicam as normal. There is no recommendation.	As an Intermediate Metabolizer with an activity score of 1.5 for CYP2C9, individuals may have a reduced ability to metabolize tenoxicam, a drug primarily metabolized by CYP2C9. It is recommended to monitor for potential adverse effects and consider reducing the dose of tenoxicam to minimize the risk of toxicity in these individuals. Consulting with a healthcare provider or a pharmacogenomics specialist for personalized dosing recommendations is advisable.	0.3839604219106539	0.43137110084097624	0.43317168704404146	0.5986778787656384	0.43041924	0.37811524	0.3729335	0.46736273	0.36578208	0.4783564	0.3365829	0.5299665	0.4032386	0.39204037	0.40393975	0.5685507	0.44747153	0.48403755	0.46221796	0.59397924	0
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking thioguanine? Give a 2-3 sentence summary.	Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).	['Proceed taking thioguanine as normal. There is no recommendation.', 'Avoid thioguanine. Take an alternate therapy.']	Take thioguanine with an altered dose.	For individuals who are Normal Metabolizers for TPMT and Poor Metabolizers for NUDT15, considering the variability in drug metabolism pathways, caution is warranted when prescribing thioguanine due to the increased risk of severe myelosuppression. Close monitoring for adverse effects and frequent monitoring of blood counts are recommended to ensure safe and effective treatment with thioguanine. Alternative therapeutic options with different metabolic pathways may also be considered in these individuals.	0.7392507245684373	0.6743777498658091	0.6739901993629687	0.6793749735039109	0.56076527	0.58721167	0.5339574	0.50970316	0.6654481	0.57932216	0.6469989	0.508729	0.57199764	0.5916697	0.5719942	0.53628737	0.65026784	0.64058524	0.5567079	0.67671835	0
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking thioguanine? Give a 2-3 sentence summary.	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	['Proceed taking thioguanine as normal. There is no recommendation.', 'Avoid thioguanine. Take an alternate therapy.']	Take thioguanine with an altered dose.	For an individual who is a Possible Intermediate Metabolizer for TPMT and a Normal Metabolizer for NUDT15, caution is advised when considering the use of thioguanine. Close monitoring for signs of toxicity and adjusting the dose based on clinical response and tolerance may be necessary to minimize the risk of adverse effects. Consultation with a healthcare provider experienced in pharmacogenomics and personalized medicine is recommended to guide dosing decisions.	0.6924556264969892	0.6942473925877668	0.6671470331959455	0.6611582977257808	0.56900555	0.5512906	0.5244281	0.56187135	0.6186775	0.5617464	0.63988155	0.5586566	0.50179666	0.5995758	0.5753321	0.54684454	0.6027395	0.618008	0.5470049	0.6774604	0
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking thioguanine? Give a 2-3 sentence summary.	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	['Proceed taking thioguanine as normal. There is no recommendation.', 'Avoid thioguanine. Take an alternate therapy.']	Take thioguanine with an altered dose.	For a person who is a Normal Metabolizer for TPMT and an Intermediate Metabolizer for NUDT15, the clinical guidance for taking thioguanine would involve adjusting the dose of the medication based on this genotype information. Close monitoring for potential adverse effects such as myelosuppression would also be recommended during treatment with thioguanine in this individual. Consulting with a healthcare provider or a pharmacogenomics expert is crucial for optimizing the therapeutic outcomes and minimizing risks with thioguanine use in this patient.	0.7481231455568103	0.6942473925877668	0.6671470331959455	0.7079827015514376	0.6220104	0.5512906	0.5244281	0.5590795	0.6418203	0.5617464	0.63988155	0.51004595	0.60293007	0.5995758	0.5753321	0.5716191	0.61008346	0.618008	0.5470049	0.65056807	0
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking thioguanine? Give a 2-3 sentence summary.	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	['Proceed taking thioguanine as normal. There is no recommendation.', 'Avoid thioguanine. Take an alternate therapy.']	Take thioguanine with an altered dose.	For an individual who is an Intermediate Metabolizer for TPMT and a Possible Intermediate Metabolizer for NUDT15, they are at an increased risk of developing thiopurine-induced myelosuppression when taking thioguanine. Therefore, it is recommended to consider dose reduction, close monitoring for myelosuppression, and utilizing alternative medications if available. Consultation with a healthcare provider or a pharmacogenomics specialist is advisable to determine the best course of action for the individual based on their genetic profile and clinical condition.	0.734874724723573	0.6942473925877668	0.6671470331959455	0.6548259055233134	0.56799465	0.5512906	0.5244281	0.5387899	0.6398235	0.5617464	0.63988155	0.5133108	0.5640373	0.5995758	0.5753321	0.49612737	0.64939994	0.618008	0.5470049	0.64749783	0
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking tobramycin as normal. There is no recommendation.', 'Take tobramycin with a reduced dose.', 'Take tobramycin with an increased dose.']	Avoid tobramycin. Take an alternate therapy.	Individuals with increased risk of aminoglycoside-induced hearing loss due to MT-RNR1 genetic variations may benefit from alternate antibiotic options or reduced dosages of tobramycin. Close monitoring for symptoms of hearing loss is recommended, and healthcare providers may consider audiologic assessments to detect early signs of ototoxicity. Shared decision-making between healthcare providers and patients is crucial to weigh the benefits of tobramycin against the potential risks of hearing loss in this population.	0.7077021906803578	0.5476688334099847	0.4323345697345123	0.558618056600757	0.706301	0.59542096	0.4749798	0.5732519	0.7422494	0.48701894	0.47801688	0.60978836	0.73737735	0.40880623	0.39415637	0.5347921	0.6268381	0.62957263	0.51017684	0.56927466	0
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid tobramycin. Take an alternate therapy.', 'Take tobramycin with a reduced dose.', 'Take tobramycin with an increased dose.']	Proceed taking tobramycin as normal. There is no recommendation.	Individuals who are at normal risk of aminoglycoside-induced hearing loss for MT-RNR1 may need standard monitoring for signs of hearing loss and kidney damage if prescribed tobramycin. It is advisable to follow recommended dosages and monitor renal function regularly. Any signs of hearing loss should be promptly reported to the healthcare provider for further evaluation and management.	0.667287977404004	0.46278889384433863	0.4613069044437061	0.5792716048616087	0.59786034	0.46600628	0.4814185	0.5548318	0.65748	0.54020387	0.53728217	0.6398638	0.65654886	0.46048653	0.4700062	0.55391556	0.60007495	0.5228594	0.55286264	0.5115266	1
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid tobramycin. Take an alternate therapy.', 'Take tobramycin with a reduced dose.', 'Take tobramycin with an increased dose.']	Proceed taking tobramycin as normal. There is no recommendation.	For individuals with uncertainty in the risk of aminoglycoside-induced hearing loss due to MT-RNR1 variations and considering tobramycin therapy, a cautious approach is advisable. Close monitoring of auditory function before and during tobramycin treatment, alongside consideration of alternative antibiotics or dose adjustments, may be warranted to mitigate the potential risk of hearing loss in this population. Consulting with a healthcare provider specializing in pharmacogenomics or otolaryngology can help tailor the treatment plan based on individual risk factors and genetic profile.	0.6712472559067265	0.46278889384433863	0.4613069044437061	0.5589954995353472	0.60572267	0.46600628	0.4814185	0.5505521	0.6722523	0.54020387	0.53728217	0.546563	0.7360778	0.46048653	0.4700062	0.456674	0.6555903	0.5228594	0.55286264	0.5039545	0
tolbutamide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking tolbutamide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid tolbutamide. Take an alternate therapy.', 'Take tolbutamide with a reduced dose.', 'Take tolbutamide with an increased dose.']	Proceed taking tolbutamide as normal. There is no recommendation.	Individuals who are normal for G6PD do not have an increased risk of hemolytic anemia when taking tolbutamide. Therefore, no specific dose adjustments or monitoring are recommended for patients who are G6PD normal when prescribed tolbutamide. It is still important to monitor for any signs of adverse effects or drug interactions while using this medication.	0.6537097357339435	0.3978715225371441	0.26623399455833563	0.5917259369995317	0.45394546	0.39871144	0.21813262	0.6431112	0.41325974	0.2890023	0.15585126	0.67278266	0.44485596	0.18447715	0.1237425	0.5271622	0.53029025	0.43831187	0.3309244	0.52839833	1
tolbutamide	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking tolbutamide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid tolbutamide. Take an alternate therapy.', 'Take tolbutamide with a reduced dose.', 'Take tolbutamide with an increased dose.']	Proceed taking tolbutamide as normal. There is no recommendation.	Individuals who are G6PD deficient may be at an increased risk of hemolytic anemia when taking tolbutamide, as the drug can potentially induce oxidative stress in red blood cells. Therefore, it is important for healthcare providers to consider alternative medications or closely monitor patients for signs of hemolysis if tolbutamide is deemed necessary. Genetic testing for G6PD deficiency prior to initiating tolbutamide can help guide treatment decisions and minimize the risk of adverse effects.	0.6367829146053715	0.4795004323743753	0.3477702332090405	0.5310098243836678	0.58592016	0.5720664	0.41603467	0.542671	0.61504185	0.51813716	0.37049937	0.5497483	0.6211669	0.43208045	0.3473115	0.4234388	0.545538	0.5191674	0.40989113	0.4807562	0
tolbutamide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking tolbutamide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid tolbutamide. Take an alternate therapy.', 'Take tolbutamide with a reduced dose.', 'Take tolbutamide with an increased dose.']	Proceed taking tolbutamide as normal. There is no recommendation.	Individuals who are deficient in Glucose-6-Phosphate Dehydrogenase (G6PD) may experience hemolysis (breakdown of red blood cells) when exposed to certain drugs like tolbutamide. Clinical guidance would recommend avoiding tolbutamide in individuals with G6PD deficiency due to the potential risk of hemolytic anemia. An alternative medication that does not pose a risk of hemolysis should be considered in these individuals.	0.6380740942117972	0.4795004323743753	0.3477702332090405	0.4561937092955851	0.5985764	0.5720664	0.41603467	0.597978	0.5992726	0.51813716	0.37049937	0.5649039	0.54818386	0.43208045	0.3473115	0.45723405	0.5476987	0.5191674	0.40989113	0.4980142	0
tolbutamide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking tolbutamide? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid tolbutamide. Take an alternate therapy.', 'Take tolbutamide with a reduced dose.', 'Take tolbutamide with an increased dose.']	Proceed taking tolbutamide as normal. There is no recommendation.	Individuals who are Indeterminate for G6PD status should exercise caution when taking tolbutamide, as this medication can potentially lead to hemolytic anemia in individuals with G6PD deficiency. Close monitoring for any signs of anemia or hemolysis is recommended, and alternative medications that do not carry the same risk should be considered if possible. Consulting with a healthcare provider or a pharmacogenomics specialist for personalized guidance is advisable in this situation.	0.6425073963898876	0.3674451738801272	0.29136042505834625	0.5542450664283879	0.52539456	0.26330706	0.3401234	0.6508179	0.6283175	0.34107542	0.32032183	0.6893616	0.6241971	0.24749395	0.24025297	0.57980204	0.53503746	0.43693367	0.41461125	0.5338402	0
toluidine blue	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking toluidine blue? Give a 2-3 sentence summary.	Avoid use	['Proceed taking toluidine blue as normal. There is no recommendation.', 'Take toluidine blue with a reduced dose.', 'Take toluidine blue with an increased dose.']	Avoid toluidine blue. Take an alternate therapy.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) should avoid toluidine blue due to the risk of hemolysis, a condition where red blood cells are destroyed, leading to anemia. Toluidine blue can trigger oxidative stress in G6PD-deficient individuals, potentially causing severe complications. Therefore, it is crucial to consider alternative treatment options for individuals with G6PD deficiency to avoid adverse reactions.	0.2186043484279348	0.2980446336423948	0.2584023072366985	0.5941595011219433	0.32245636	0.37050304	0.28443608	0.6491438	0.15719534	0.14705415	0.16725342	0.6611077	0.15194969	0.18024425	0.18333058	0.59556	0.48826692	0.6264256	0.53623605	0.6761908	1
toluidine blue	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking toluidine blue? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid toluidine blue. Take an alternate therapy.', 'Take toluidine blue with a reduced dose.', 'Take toluidine blue with an increased dose.']	Proceed taking toluidine blue as normal. There is no recommendation.	Individuals who are Indeterminate for G6PD deficiency may have reduced enzyme activity, potentially putting them at risk for drug-induced hemolysis. As toluidine blue can oxidize hemoglobin and lead to hemolysis in individuals with G6PD deficiency, caution should be exercised when considering its use in individuals with an Indeterminate G6PD status. Consulting with a healthcare provider or a pharmacogenomics specialist for personalized recommendations based on the individual's G6PD enzyme activity levels would be prudent to ensure safe use of toluidine blue.	0.6866626889120394	0.38046713247243874	0.3319291540459879	0.5251463885980656	0.5467119	0.25050306	0.29103774	0.5569763	0.6403027	0.29739705	0.25317505	0.636812	0.6044026	0.17507719	0.15172201	0.59902054	0.5185734	0.44400343	0.41728577	0.5548899	0
toluidine blue	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking toluidine blue? Give a 2-3 sentence summary.	Avoid use	['Proceed taking toluidine blue as normal. There is no recommendation.', 'Take toluidine blue with a reduced dose.', 'Take toluidine blue with an increased dose.']	Avoid toluidine blue. Take an alternate therapy.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) are at an increased risk of hemolytic anemia when exposed to oxidizing agents such as toluidine blue. CNSHA (Central Nervous System Hemorrhage with Amyloidosis) is a rare genetic disorder associated with G6PD deficiency. Therefore, individuals with both conditions should avoid exposure to toluidine blue to prevent the risk of hemolytic reactions and associated complications.	0.16537651521619967	0.2980446336423948	0.2584023072366985	0.44776261861917976	0.16458786	0.37050304	0.28443608	0.5110656	0.10208863	0.14705415	0.16725342	0.5617103	0.1378859	0.18024425	0.18333058	0.55337405	0.4333157	0.6264256	0.53623605	0.62260723	1
toluidine blue	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking toluidine blue? Give a 2-3 sentence summary.	No reason to avoid ased on G6PD status	['Avoid toluidine blue. Take an alternate therapy.', 'Take toluidine blue with a reduced dose.', 'Take toluidine blue with an increased dose.']	Proceed taking toluidine blue as normal. There is no recommendation.	Individuals who are normal for G6PD enzyme function are generally not at an increased risk for hemolysis when taking toluidine blue. However, caution should still be exercised as toluidine blue can potentially cause oxidative stress and hemolytic effects in susceptible individuals. Monitoring for signs of hemolysis and discontinuing the medication if any symptoms arise is recommended.	0.5688065536825959	0.3832973724406889	0.27439065600628215	0.6027076408756586	0.40363	0.3332946	0.17082961	0.66915077	0.33802107	0.20651574	0.10903177	0.7140356	0.24275325	0.1498567	0.09597397	0.6431466	0.3898296	0.39933273	0.30317935	0.579402	0
tramadol	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking tramadol? Give a 2-3 sentence summary.	Use tramadol label recommended age- or weight-specific dosing.	['Avoid tramadol. Take an alternate therapy.', 'Take tramadol with a reduced dose.', 'Take tramadol with an increased dose.']	Proceed taking tramadol as normal. There is no recommendation.	For individuals who are normal metabolizers with an activity score of 2.25 for CYP2D6, they are likely to metabolize tramadol at an expected rate. This means standard dosing and monitoring guidelines for tramadol can be followed without the need for significant dose adjustments based on CYP2D6 metabolism status.	0.5213113204409956	0.6038994949920677	0.6141755963826413	0.5644317034242242	0.52971214	0.5441053	0.60032505	0.50949407	0.55509	0.7159648	0.6857438	0.54291624	0.5812031	0.717866	0.6263256	0.52947026	0.549186	0.649606	0.6656346	0.58053017	1
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking tramadol? Give a 2-3 sentence summary.	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.	['Proceed taking tramadol as normal. There is no recommendation.', 'Take tramadol with a reduced dose.', 'Take tramadol with an increased dose.']	Avoid tramadol. Take an alternate therapy.	For individuals who are Ultrarapid Metabolizers of CYP2D6 and have an activity score of 2.75, there is an increased risk of faster metabolism of tramadol into its active metabolite, potentially leading to excessive opioid effects such as respiratory depression, overdose, or toxicity. It is recommended to consider alternative pain management strategies, such as alternative medications or dose adjustments, under the guidance of a healthcare provider familiar with pharmacogenomic testing to minimize potential adverse effects.	0.6147769966981578	0.65166882131708	0.6042582884576166	0.5609708734978042	0.6175134	0.7926296	0.6635241	0.54990375	0.68721014	0.8252405	0.69806117	0.64674217	0.67227614	0.70845723	0.6453412	0.6366699	0.7000725	0.8070759	0.6973669	0.684417	1
tramadol	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking tramadol? Give a 2-3 sentence summary.	No recommendation	['Avoid tramadol. Take an alternate therapy.', 'Take tramadol with a reduced dose.', 'Take tramadol with an increased dose.']	Proceed taking tramadol as normal. There is no recommendation.	For individuals who are categorized as Indeterminate for CYP2D6 metabolizer status and are prescribed tramadol, it is recommended to closely monitor for signs of drug efficacy and adverse effects. Due to the potential for variability in tramadol metabolism, personalized dosing adjustments may be necessary based on individual response and tolerability. Consultation with a healthcare provider experienced in pharmacogenomics can help guide treatment decisions for optimal therapeutic outcomes.	0.21688944014458175	0.4600213841923948	0.19723027660599546	0.5641488783172952	0.14575367	0.29108873	0.1541182	0.5082754	0.04853401	0.15144742	0.060811922	0.5393456	-0.014807008	0.3331763	0.09190323	0.5081942	0.3169566	0.51242226	0.40023413	0.55833143	0
tramadol	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking tramadol? Give a 2-3 sentence summary.	Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.	['Avoid tramadol. Take an alternate therapy.', 'Take tramadol with a reduced dose.', 'Take tramadol with an increased dose.']	Proceed taking tramadol as normal. There is no recommendation.	For an individual who is an Intermediate Metabolizer with a CYP2D6 activity score of 0.5, caution is advised when taking tramadol due to the potential for reduced drug metabolism leading to altered drug efficacy and potential for increased risk of adverse effects such as sedation or respiratory depression. Monitoring for signs of opioid toxicity and adjusting the tramadol dosage or considering alternative medications may be necessary to ensure safe and effective treatment in this individual.	0.5694480761026216	0.587250480160361	0.5907024537820077	0.5385469268989694	0.5093755	0.6682551	0.6443482	0.5354314	0.5497966	0.73243827	0.67626715	0.63521945	0.6403528	0.6370095	0.54356027	0.64048505	0.50071555	0.5737987	0.5163027	0.55438226	0
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine? Give a 2-3 sentence summary.	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking trimipramine as normal. There is no recommendation.', 'Take trimipramine with a reduced dose.', 'Take trimipramine with an increased dose.']	Avoid trimipramine. Take an alternate therapy.	For an individual with Intermediate Metabolizer status for CYP2D6 and Rapid Metabolizer status for CYP2C19 regarding trimipramine, considering trimipramine is primarily metabolized by CYP2D6, the individual may have reduced metabolism and potentially higher plasma levels of trimipramine leading to an increased risk of side effects. Monitoring for trimipramine efficacy and side effects may be necessary, with dosage adjustments based on clinical response and tolerability. Consulting with a healthcare provider or pharmacist experienced in pharmacogenomics is recommended to personalize the treatment plan.	0.803295774161823	0.7205071124789763	0.6967962886416269	0.6159029512742438	0.66624796	0.6132038	0.5084726	0.46190852	0.81451565	0.6125775	0.5228842	0.60746014	0.8177717	0.60412467	0.5893733	0.6053135	0.7504553	0.67121416	0.63971174	0.5908465	0
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine? Give a 2-3 sentence summary.	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking trimipramine as normal. There is no recommendation.', 'Take trimipramine with a reduced dose.', 'Take trimipramine with an increased dose.']	Avoid trimipramine. Take an alternate therapy.	Individuals who are Intermediate Metabolizers for CYP2D6 and Poor Metabolizers for CYP2C19 may experience altered metabolism of trimipramine, potentially leading to increased risk of side effects or decreased efficacy. Close monitoring for adverse effects and therapeutic drug monitoring may be necessary to optimize treatment outcomes. Consideration of alternative medications with different metabolic pathways may also be warranted in these individuals.	0.7259063719818986	0.7771476589904226	0.7680207899772258	0.6413669080936738	0.67037004	0.6677426	0.55407435	0.61094874	0.6691028	0.665936	0.58458394	0.6506156	0.559901	0.62257713	0.5840695	0.5960939	0.6229519	0.67260283	0.58920425	0.6651809	0
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine? Give a 2-3 sentence summary.	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking trimipramine as normal. There is no recommendation.', 'Take trimipramine with a reduced dose.', 'Take trimipramine with an increased dose.']	Avoid trimipramine. Take an alternate therapy.	Given that the individual is classified as a Rapid Metabolizer for CYP2C19 and has a No Result for CYP2D6, the guidance would be to monitor for potential increased metabolism of trimipramine due to the CYP2C19 Rapid Metabolizer status. Since CYP2D6 status is unknown, consideration should be given to potential variability in response to trimipramine based on CYP2D6 metabolism. Close monitoring for efficacy and adverse effects is recommended to adjust the dose as needed based on individual response.	0.6519493036489465	0.5792876271934558	0.5271472954129592	0.59764925566052	0.6673419	0.52675956	0.43399516	0.42209688	0.62927705	0.44597912	0.3908305	0.6482961	0.5825577	0.52155083	0.50305074	0.5277584	0.5750529	0.59707296	0.51390237	0.5728704	0
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid trimipramine. Take an alternate therapy.', 'Take trimipramine with a reduced dose.', 'Take trimipramine with an increased dose.']	Proceed taking trimipramine as normal. There is no recommendation.	For an individual who is a Normal Metabolizer with an activity score of 1.5 for CYP2D6 and has No Result for CYP2C19, when considering trimipramine therapy, significant variability in drug metabolism and response may be expected. Close monitoring for potential side effects and efficacy is recommended, as dose adjustments may be necessary based on individual response and tolerance to trimipramine. Consulting with a healthcare provider who is knowledgeable in pharmacogenomics is advisable to optimize treatment outcomes.	0.42868912717837787	0.4863876319797294	0.4991228368314869	0.6730719054858706	0.3198079	0.34320813	0.4081172	0.5077294	0.2833082	0.47519058	0.3911542	0.6166531	0.3273763	0.47008038	0.4813083	0.5367567	0.4954546	0.54109067	0.5978351	0.6579363	0
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking tropisetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking tropisetron as normal. There is no recommendation.', 'Take tropisetron with a reduced dose.', 'Take tropisetron with an increased dose.']	Avoid tropisetron. Take an alternate therapy.	For an individual who is an Ultrarapid Metabolizer with an activity score of ≥6.0 for CYP2D6 and considering taking tropisetron, caution is advised. Tropisetron is a substrate of CYP2D6, and in Ultrarapid Metabolizers, there is a potential for increased metabolism of tropisetron, leading to reduced efficacy. Close monitoring for efficacy and potential side effects is recommended, and an alternative medication or dose adjustment may be considered based on individual response. Consulting with a healthcare provider or pharmacist experienced in pharmacogenomics is recommended for personalized guidance.	0.5409654864265531	0.5835268545103266	0.47303160652976484	0.6617954604600514	0.54358596	0.47649994	0.4419063	0.56412745	0.74081415	0.36477804	0.40524304	0.58276814	0.67208856	0.46304816	0.50664824	0.5505637	0.58824795	0.6042384	0.56028277	0.6377758	0
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking tropisetron? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid tropisetron. Take an alternate therapy.', 'Take tropisetron with a reduced dose.', 'Take tropisetron with an increased dose.']	Proceed taking tropisetron as normal. There is no recommendation.	For individuals who are Normal Metabolizers with a CYP2D6 activity score of 1.75, it is recommended to use standard dosing guidelines for tropisetron. Tropisetron is primarily metabolized by CYP2D6, so individuals with normal metabolism of this enzyme are expected to metabolize tropisetron normally and therefore standard dosing is appropriate. Monitoring for efficacy and any potential side effects is recommended.	0.4272742970290789	0.516534548537015	0.5169334524902284	0.6626835130231227	0.43843248	0.41645208	0.5192625	0.545923	0.43234232	0.5008607	0.4915854	0.6800488	0.37708977	0.49092492	0.50587296	0.6121938	0.38145968	0.46484816	0.56466436	0.6022352	1
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking tropisetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking tropisetron as normal. There is no recommendation.', 'Take tropisetron with a reduced dose.', 'Take tropisetron with an increased dose.']	Avoid tropisetron. Take an alternate therapy.	As an Ultrarapid Metabolizer with an activity score of 2.75 for CYP2D6, individuals may metabolize tropisetron at a faster rate compared to normal metabolizers. This could result in reduced drug efficacy due to increased metabolism. Monitoring for therapeutic response may be necessary, and dosage adjustments or alternative medications may be considered based on clinical response and potential drug interactions. Consulting with a healthcare provider or a pharmacist for personalized recommendations is recommended.	0.5021905485789587	0.5835268545103266	0.47303160652976484	0.6229333646985002	0.4996959	0.47649994	0.4419063	0.52452487	0.7370762	0.36477804	0.40524304	0.6035434	0.7255329	0.46304816	0.50664824	0.56827044	0.58853954	0.6042384	0.56028277	0.622206	0
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking tropisetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking tropisetron as normal. There is no recommendation.', 'Take tropisetron with a reduced dose.', 'Take tropisetron with an increased dose.']	Avoid tropisetron. Take an alternate therapy.	Individuals who are Ultrarapid Metabolizers with an activity score ≥5.0 for CYP2D6 may have increased metabolism of tropisetron, potentially leading to reduced effectiveness of the medication. Clinical guidance would typically involve monitoring for therapeutic response and potential need for dose adjustment or alternative medication selection based on individual response and symptom control. Consulting with a healthcare provider or a pharmacogenomic specialist can help in tailoring the treatment plan for optimal outcomes.	0.5395086133981369	0.5835268545103266	0.47303160652976484	0.6287519655280682	0.51226735	0.47649994	0.4419063	0.56254965	0.7220601	0.36477804	0.40524304	0.5955329	0.68852895	0.46304816	0.50664824	0.5978297	0.5768883	0.6042384	0.56028277	0.6764655	0
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking venlafaxine? Give a 2-3 sentence summary.	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	['Avoid venlafaxine. Take an alternate therapy.', 'Take venlafaxine with a reduced dose.', 'Take venlafaxine with an increased dose.']	Proceed taking venlafaxine as normal. There is no recommendation.	For Ultrarapid Metabolizers with a CYP2D6 activity score of ≥3.5, venlafaxine may be metabolized more quickly, potentially leading to reduced drug levels and efficacy. Close monitoring for symptoms of inadequate response or side effects is recommended, and dose adjustments may be necessary to achieve optimal therapeutic outcomes. Consulting with a healthcare provider experienced in pharmacogenomics can help personalize treatment based on individual genetic factors.	0.6333678196142083	0.644248746656721	0.5854100535380422	0.5593252173649327	0.31423002	0.5338721	0.3698864	0.4811724	0.6703374	0.6544883	0.5178928	0.52947944	0.6082085	0.6193784	0.52694565	0.4714506	0.5719897	0.66103476	0.52958214	0.6191766	0
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking venlafaxine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid venlafaxine. Take an alternate therapy.', 'Take venlafaxine with a reduced dose.', 'Take venlafaxine with an increased dose.']	Proceed taking venlafaxine as normal. There is no recommendation.	For an individual who is a Normal Metabolizer with an activity score of 1.75 for CYP2D6 and is considering taking venlafaxine, the general recommendation would be to follow standard dosing guidelines for venlafaxine. It is unlikely that significant dose adjustments are needed based on CYP2D6 status alone, as Normal Metabolizers typically have normal enzyme function and should respond to standard dosing regimens. However, close monitoring for efficacy and side effects is always advised when starting a new medication.	0.44078008382633405	0.4708254935308498	0.4944210664684275	0.6696761917059086	0.4001163	0.39294913	0.43581223	0.58417606	0.39832184	0.50705934	0.40087855	0.6273073	0.39234045	0.47035256	0.49559298	0.5638606	0.39590877	0.545141	0.5885901	0.6106775	1
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking venlafaxine? Give a 2-3 sentence summary.	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	['Avoid venlafaxine. Take an alternate therapy.', 'Take venlafaxine with a reduced dose.', 'Take venlafaxine with an increased dose.']	Proceed taking venlafaxine as normal. There is no recommendation.	Individuals who are classified as Ultrarapid Metabolizers (UMs) of CYP2D6 are likely to metabolize drugs such as venlafaxine at a faster rate, leading to potential subtherapeutic levels and reduced efficacy. In this case, it is recommended to consider increasing the dose of venlafaxine or choosing an alternative medication that is not primarily metabolized by CYP2D6 to achieve the desired therapeutic effect. Close monitoring for both efficacy and potential adverse effects is also crucial in these individuals.	0.5648784321333107	0.644248746656721	0.5854100535380422	0.5391001737566377	0.3343883	0.5338721	0.3698864	0.5010849	0.5964572	0.6544883	0.5178928	0.5296437	0.47747365	0.6193784	0.52694565	0.42944238	0.5009258	0.66103476	0.52958214	0.5830528	0
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking venlafaxine? Give a 2-3 sentence summary.	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	['Avoid venlafaxine. Take an alternate therapy.', 'Take venlafaxine with a reduced dose.', 'Take venlafaxine with an increased dose.']	Proceed taking venlafaxine as normal. There is no recommendation.	Individuals who are Ultrarapid Metabolizers for CYP2D6 may metabolize venlafaxine more rapidly, potentially leading to decreased drug efficacy. In this case, close monitoring for therapeutic response and possible dose adjustments may be necessary to ensure optimal treatment outcomes. Consulting with a healthcare provider or a pharmacogenomics expert for personalized dosing recommendations is recommended.	0.618040413377044	0.644248746656721	0.5854100535380422	0.5757620817982061	0.37510425	0.5338721	0.3698864	0.46898675	0.66595495	0.6544883	0.5178928	0.55828136	0.5228611	0.6193784	0.52694565	0.46494237	0.5230836	0.66103476	0.52958214	0.59809995	0
vitamin c	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking vitamin c? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid vitamin c. Take an alternate therapy.', 'Take vitamin c with a reduced dose.', 'Take vitamin c with an increased dose.']	Proceed taking vitamin c as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) enzyme should be cautious when taking high doses of vitamin C (ascorbic acid), particularly in the form of supplements or intravenous administration. High doses of vitamin C can potentially trigger oxidative stress and hemolysis in individuals with G6PD deficiency. It is advisable for G6PD-deficient individuals to consult with a healthcare provider before taking vitamin C supplements to prevent any adverse effects related to their condition.	0.6240211783825729	0.4530491447979341	0.3086773055509428	0.4869754121932256	0.5068082	0.49443772	0.2869438	0.5906739	0.54204255	0.3930725	0.2049738	0.62459606	0.588151	0.42404598	0.3162838	0.54259235	0.5252059	0.46612504	0.38801512	0.53177804	0
vitamin c	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking vitamin c? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid vitamin c. Take an alternate therapy.', 'Take vitamin c with a reduced dose.', 'Take vitamin c with an increased dose.']	Proceed taking vitamin c as normal. There is no recommendation.	For individuals with an Indeterminate G6PD status, caution is advised when taking vitamin C supplements due to a theoretical risk of hemolysis. It is recommended to consult with a healthcare provider or a genetic counselor for personalized guidance on the safe use of vitamin C and potential monitoring measures to prevent adverse effects.	0.6076689371650104	0.3463488797369956	0.25406358202995927	0.5337781177082606	0.49021506	0.19731872	0.21267378	0.6339109	0.53067166	0.22739428	0.17187023	0.6512344	0.476436	0.18388677	0.15508582	0.60780114	0.50073844	0.35586616	0.36363068	0.58146536	0
vitamin c	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking vitamin c? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid vitamin c. Take an alternate therapy.', 'Take vitamin c with a reduced dose.', 'Take vitamin c with an increased dose.']	Proceed taking vitamin c as normal. There is no recommendation.	Individuals who are deficient in G6PD (glucose-6-phosphate dehydrogenase) with CNSHA (Class III G6PD variant) may have an increased risk of hemolysis when taking high doses of vitamin C. Clinical guidance would recommend avoiding high-dose vitamin C supplements or excessive consumption of vitamin C-rich foods in order to prevent hemolytic episodes in individuals with this genetic variant. It is important for individuals with G6PD deficiency to consult with their healthcare provider or a genetic counselor for personalized recommendations.	0.43306536803541995	0.3512040468873965	0.38163011984965345	0.46321344471241743	0.5316491	0.4344965	0.43427587	0.5954401	0.47902113	0.3810941	0.37049732	0.5666709	0.40880305	0.28539318	0.24695516	0.5079788	0.45306596	0.38313934	0.43508217	0.5538766	0
vitamin c	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking vitamin c? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid vitamin c. Take an alternate therapy.', 'Take vitamin c with a reduced dose.', 'Take vitamin c with an increased dose.']	Proceed taking vitamin c as normal. There is no recommendation.	For individuals who are normal for G6PD, there is no specific clinical guidance against taking vitamin C. Vitamin C is generally safe for these individuals and can be taken as recommended for overall health benefits. However, individuals should consult with their healthcare provider before starting any new supplements, including vitamin C, to ensure it is appropriate for their individual health status and needs.	0.6345346081019578	0.3859070158334298	0.23369164048637306	0.6461065875679963	0.43290734	0.33424133	0.14917247	0.67973983	0.43652523	0.21868818	0.08659527	0.70839953	0.5032306	0.16924903	0.10133482	0.5997458	0.59677786	0.3842258	0.29911327	0.5744498	1
vitamin k	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking vitamin k? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid vitamin k. Take an alternate therapy.', 'Take vitamin k with a reduced dose.', 'Take vitamin k with an increased dose.']	Proceed taking vitamin k as normal. There is no recommendation.	For individuals deficient in Glucose-6-Phosphate Dehydrogenase (G6PD), caution is advised when taking vitamin K supplements as high doses of vitamin K can potentially trigger hemolysis in those with G6PD deficiency. It is recommended to consult with a healthcare provider before starting vitamin K supplements to ensure safety and optimal management of G6PD deficiency. Monitoring for signs of hemolysis such as fatigue, dark urine, and jaundice is also important.	0.6004909468496795	0.47501739067051013	0.33179988189873705	0.572091800431939	0.5582499	0.5270561	0.32932243	0.61814356	0.5746185	0.43850276	0.254809	0.6554474	0.51371574	0.4333759	0.34540677	0.5871456	0.4887849	0.47779936	0.3998872	0.50354296	0
vitamin k	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking vitamin k? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid vitamin k. Take an alternate therapy.', 'Take vitamin k with a reduced dose.', 'Take vitamin k with an increased dose.']	Proceed taking vitamin k as normal. There is no recommendation.	For individuals with an indeterminate status for G6PD deficiency, caution is advised when it comes to taking Vitamin K supplements or medications that contain Vitamin K. It is recommended to consult with a healthcare provider or a pharmacist to determine the best course of action based on the specific medication or supplement and the individual's health status. Monitoring for any signs or symptoms of hemolysis is also important in such cases.	0.608114887895054	0.36048308470507007	0.2647857721506815	0.5698641653845731	0.56901366	0.2332723	0.25797138	0.65713984	0.6300734	0.29695123	0.23800881	0.67695785	0.56767106	0.21016854	0.19161749	0.59173226	0.53527683	0.34533143	0.3607073	0.54050255	0
vitamin k	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking vitamin k? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid vitamin k. Take an alternate therapy.', 'Take vitamin k with a reduced dose.', 'Take vitamin k with an increased dose.']	Proceed taking vitamin k as normal. There is no recommendation.	For individuals deficient in G6PD (Glucose-6-phosphate dehydrogenase) with CNSHA (Class 2 No Significant Hemolysis or Anemia), caution is advised when taking Vitamin K. G6PD deficiency can lead to hemolysis triggered by oxidative stress, and Vitamin K has been shown to induce oxidative stress in this population. Therefore, it is recommended to consult with a healthcare provider before taking Vitamin K supplements to ensure safe administration.	0.44182403299333517	0.3777663797910543	0.4139123206713564	0.5336813438103459	0.45380113	0.43144685	0.4303917	0.5962152	0.4149431	0.38260683	0.35706958	0.6433375	0.39571851	0.30072802	0.2888585	0.5921827	0.44849256	0.3988476	0.46758947	0.556889	0
vitamin k	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking vitamin k? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid vitamin k. Take an alternate therapy.', 'Take vitamin k with a reduced dose.', 'Take vitamin k with an increased dose.']	Proceed taking vitamin k as normal. There is no recommendation.	For individuals who are Normal for G6PD, there are typically no specific concerns regarding taking vitamin K. However, it is always best to consult with a healthcare provider or a pharmacist before starting any new supplement to ensure it is safe and appropriate for you based on your individual health status and any other medications you may be taking.	0.6122928191514613	0.40275047664842	0.2574267683750323	0.6512003239498823	0.435847	0.36030218	0.16898845	0.68728983	0.43650898	0.24453539	0.101157606	0.74306077	0.46560478	0.16376248	0.10161227	0.64220804	0.56423265	0.3848919	0.29952303	0.57805055	1
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking voriconazole? Give a 2-3 sentence summary.	No recommendation	['Avoid voriconazole. Take an alternate therapy.', 'Take voriconazole with a reduced dose.', 'Take voriconazole with an increased dose.']	Proceed taking voriconazole as normal. There is no recommendation.	For individuals who are Indeterminate for CYP2C19 and are prescribed voriconazole, it is recommended to consider alternative antifungal medications or adjust the voriconazole dose based on therapeutic drug monitoring to ensure optimal efficacy and safety. Close monitoring for drug interactions and adverse effects is crucial in these individuals due to the potential for altered drug metabolism. Consulting with a healthcare provider or a pharmacogenomics expert is advised to individualize treatment decisions.	0.25119506589804086	0.4455232856732073	0.21188961765860967	0.6344171621030726	0.14530994	0.3322561	0.17737858	0.5885606	0.07878205	0.2217329	0.11324045	0.64711523	-0.051837176	0.2889275	0.06293388	0.50863945	0.28826505	0.50118655	0.36249557	0.58826196	0
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking voriconazole? Give a 2-3 sentence summary.	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole.	['Proceed taking voriconazole as normal. There is no recommendation.', 'Take voriconazole with a reduced dose.', 'Take voriconazole with an increased dose.']	Avoid voriconazole. Take an alternate therapy.	Individuals who are Ultrarapid Metabolizers for CYP2C19 may require higher doses of voriconazole due to their increased metabolism of the drug. Close monitoring of therapeutic drug levels and potential side effects is recommended to ensure optimal efficacy and safety of treatment. Genetic testing for CYP2C19 status may help guide dosing adjustments for voriconazole in Ultrarapid Metabolizers.	0.6245852206476891	0.7363010412312784	0.571944090432645	0.6000040838120829	0.52470875	0.69853616	0.58659106	0.600752	0.7820294	0.7335008	0.6654613	0.63918525	0.6383233	0.62062955	0.5397119	0.48534405	0.6762961	0.6731476	0.59010226	0.5280884	0
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking voriconazole? Give a 2-3 sentence summary.	Initiate therapy with recommended standard of care dosing	['Avoid voriconazole. Take an alternate therapy.', 'Take voriconazole with a reduced dose.', 'Take voriconazole with an increased dose.']	Proceed taking voriconazole as normal. There is no recommendation.	As an Intermediate Metabolizer for CYP2C19, individuals may have reduced metabolism of voriconazole, potentially leading to increased levels and risk of adverse effects. Clinical guidance for these individuals may include starting with a lower dose of voriconazole, monitoring drug levels, and adjusting the dose based on therapeutic drug monitoring to optimize efficacy and minimize toxicity. Close monitoring and individualized dosing are recommended to ensure safe and effective treatment with voriconazole in Intermediate Metabolizers for CYP2C19.	0.4463278653231491	0.4988635947310312	0.4739205566232929	0.5984666896769772	0.5017011	0.4721097	0.49840656	0.5878089	0.44440117	0.53591084	0.45065174	0.6769853	0.34721234	0.40004098	0.33257806	0.5391209	0.52593964	0.49174157	0.51202404	0.5530638	0
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking voriconazole? Give a 2-3 sentence summary.	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.	['Proceed taking voriconazole as normal. There is no recommendation.', 'Take voriconazole with a reduced dose.', 'Take voriconazole with an increased dose.']	Avoid voriconazole. Take an alternate therapy.	For individuals who are Poor Metabolizers for CYP2C19, they are at an increased risk of experiencing higher voriconazole concentrations due to reduced metabolism of the drug. This could lead to an increased risk of voriconazole-associated toxicities, such as neurotoxicity and hepatotoxicity. Therefore, dose reduction or alternative antifungal therapy may be warranted in this population to minimize potential adverse effects. Consulting with a healthcare provider or a clinical pharmacist with expertise in pharmacogenomics is recommended for personalized dosing recommendations.	0.7918590855528689	0.7293043454782862	0.6248677398839856	0.639690799891909	0.5339474	0.71913785	0.6085643	0.52345914	0.8003209	0.6723702	0.6184731	0.60868984	0.7581543	0.601125	0.539354	0.51304865	0.710556	0.6367206	0.56936795	0.6612629	1
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking vortioxetine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid vortioxetine. Take an alternate therapy.', 'Take vortioxetine with a reduced dose.', 'Take vortioxetine with an increased dose.']	Proceed taking vortioxetine as normal. There is no recommendation.	Individuals who are Intermediate Metabolizers with a CYP2D6 activity score of 0.75 may have reduced metabolism of vortioxetine, potentially leading to higher drug levels and an increased risk of adverse effects. It is recommended to consider reducing the dose of vortioxetine in these individuals and closely monitor for side effects or therapeutic response to optimize treatment outcomes. Consulting with a healthcare provider or pharmacist knowledgeable in pharmacogenomics can help guide personalized dosing and management strategies.	0.4332331862986141	0.5076852353817526	0.5230715940737068	0.5779658257808851	0.3333722	0.40537333	0.44112	0.57541263	0.34428495	0.512008	0.43013254	0.6511866	0.39278954	0.5017084	0.5267878	0.59244424	0.48144513	0.5229069	0.6068345	0.5886351	0
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking vortioxetine? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.	['Proceed taking vortioxetine as normal. There is no recommendation.', 'Take vortioxetine with a reduced dose.', 'Take vortioxetine with an increased dose.']	Avoid vortioxetine. Take an alternate therapy.	For individuals who are Ultrarapid Metabolizers with an activity score of ≥3.0 for CYP2D6, caution should be exercised when taking vortioxetine as this may lead to reduced efficacy due to possible increased metabolism of the drug. Close monitoring for therapeutic response and possible side effects may be necessary. Adjusting the dosage of vortioxetine or considering alternative medications with less dependence on CYP2D6 metabolism may be recommended.	0.7935723848664525	0.7034353195833725	0.6783166653460384	0.6389676047556424	0.7713504	0.61908376	0.55448776	0.61254215	0.8242259	0.6243583	0.5784005	0.6941405	0.7747484	0.660748	0.63511544	0.56865156	0.7390804	0.61376745	0.5884796	0.6575677	0
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking vortioxetine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid vortioxetine. Take an alternate therapy.', 'Take vortioxetine with a reduced dose.', 'Take vortioxetine with an increased dose.']	Proceed taking vortioxetine as normal. There is no recommendation.	Individuals who are classified as Intermediate Metabolizers (IM) for CYP2D6 may have reduced metabolism of drugs like vortioxetine, which could lead to higher drug levels and an increased risk of adverse effects. A CYP2D6 activity score of 1.0 suggests reduced activity of this enzyme. Therefore, for individuals with this phenotype, it may be advisable to consider lower starting doses of vortioxetine and closely monitor for potential side effects or drug interactions. Consulting with a healthcare provider or a pharmacist with expertise in pharmacogenomics would be beneficial to optimize treatment outcomes.	0.41343497410976426	0.5076852353817526	0.5230715940737068	0.5250487538241897	0.28811306	0.40537333	0.44112	0.49937433	0.32703066	0.512008	0.43013254	0.59731406	0.3391475	0.5017084	0.5267878	0.46321523	0.455819	0.5229069	0.6068345	0.58301413	0
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking vortioxetine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid vortioxetine. Take an alternate therapy.', 'Take vortioxetine with a reduced dose.', 'Take vortioxetine with an increased dose.']	Proceed taking vortioxetine as normal. There is no recommendation.	For an individual who is an Intermediate Metabolizer with a CYP2D6 activity score of 0.5, caution is advised when taking vortioxetine. Vortioxetine is primarily metabolized by CYP2D6, and reduced enzyme activity can lead to higher blood levels of the medication, potentially increasing the risk of side effects. Close monitoring for adverse reactions and adjusting the vortioxetine dosage may be necessary in this population. Consulting with a healthcare provider experienced in pharmacogenomics is recommended for personalized dosing guidance.	0.40563275037663266	0.5076852353817526	0.5230715940737068	0.5934414019660086	0.31557125	0.40537333	0.44112	0.6148119	0.350299	0.512008	0.43013254	0.6702749	0.36848596	0.5017084	0.5267878	0.62368125	0.4239198	0.5229069	0.6068345	0.588742	0
